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B rea st Cancer
W.J. Temple, MD, FACS, FRCSC
Director o f Surgery, Tom Baker Cancer Centre, Calgary, Alta. Member, Editorial Board,
Canadian Journal o f Surgery

he study by Peloquin and col
leagues in the April 1991 issue
of this journal (pages 151 to 156),
describing 1520 consecutive pa
tients with breast cancer treated at
the Hopital Notre-Dame in Montreal
between 1960 and 1980, covers a
time of treatment revolution. Dur
ing the study period surgical man
agement evolved from Halstedian
concepts, advocating radical en bloc
surgery and radical radiotherapy, to
the present-day understanding of
the biology of the disease, which
demonstrates that limited surgery,
limited radiotherapy and an empha
sis on systemic therapy gives supe
rior results. This is acknowledged
by the authors and is shown by
their findings that 20% of their
patients, most likely in the last 5
years of their series, received breast
conservation treatment. It is notable
that a Canadian group of surgeons,
including Drs. Margolese, Shibata
and Poisson and their colleagues,
deserve much of the credit for this
change. Their beliefs in the process
of clinical trials and their support of
the National Surgical Adjuvant
Breast Project (NSABP) Protocol
B-06 contributed to the success of a
most difficult clinical experiment.1
This trial confirmed and extended
the observations of the Milan trial,2
convincing surgeons that a rational
basis for treating breast cancer re
quires excision of the tumour with
only 1 cm of healthy surrounding

T

* - For prescribing information see page 204

tissue, with radiotherapy only to
the breast and axillary dissection
for staging, provided the cosmetic
result is satisfactory. What is sur
prising and unexplained, however,
is that 60% to 70% of women in the
United States and Canada are still
treated by total mastectomy and
lymph-node dissection.
Although the NSABP Protocol
B-06 limited local excision to pe
ripheral lesions and those less than
4 cm in diameter, there is no bio
logic reason not to include central
lesions or larger lesions as long as
the patient prefers the cosmetic and
functional result over one that
would be provided with total mas
tectomy and reconstruction.
This study by Peloquin and col
leagues stops short of documenting
the changes seen in the last 5 years,
which have resulted from the accep
tance of breast screening mammog
raphy. In Canada, this was signifi
cantly influenced by the conduct of
the National Breast Screening
Study of 90 000 Canadian women,
a trial that I predict will be an
important study. Although the re
sults have not been published the
study did cause women to request
and obtain mammograms more fre
quently. With routine mammogra
phy, the infrequent rate of in-situ
disease seen in Peloquin's study
may rise as high as 25%, the size of
lesion detected will drop from great
er than 2 cm in 80% of women to

less than 1 cm in 50%, and the
incidence of stage I disease will rise
from 20% to 80%. In particular, the
detection of smaller lesions will en
courage the practice of organ-spar
ing surgery. The study of Peloquin
and colleagues also largely predates
the era of routine systemic adjuvant
chemotherapy and hormonal thera
py, which is now standard in preand postmenopausal women with
lymph-node involvement.
Although treatment results are
considered in Peloquin’s study, per
haps through the most controver
sial period of breast cancer therapy,
the next 20 years offers equally
exciting prospects — three of
which are currently being actively
studied. Needle aspiration of mammographically detected lesions may
supplant biopsy of abnormal lesions
seen on mammography. Neoadju
vant chemotherapy coupled with ra
diotherapy may reduce the need and
scope of surgery.3 Prevention
studies, particularly of high-risk pa
tients, with diet and hormonal treat
ments such as tamoxifen promise to
reduce the incidence of this disease.
Most Canadian surgeons can partic
ipate by encouraging their patients
to be randomized into these studies,
usually coordinated at the regional
cancer centre.
Despite our enthusiasm for new
knowledge, we must be vigilant in
documenting local recurrence, long
term local regional control and
CJS, VOL. 34, NO. 3, JU N E 1991
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quality of life associated with these
changes in therapy. Peloquin and
colleagues are to be congratulated
for establishing this standard of
documentation in their institution
and providing this complete re
port on one of the larger institu
tional series reported to date.
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SESAP VI Question / Question SESAP VI

Item 38
During colonoscopy, the polyp diagrammed above was removed by snare and fulguration from the sigmoid colon
of a 72-year-old woman with a history of myocardial infarction. The pathologist identifies it as a
well-differentiated adenocarcinoma involving the head of the polyp, with no apparent vascular or lymphatic
invasion.
Management should now include
(A) limited segmental colectomy
(B) no further treatment
(C) sigmoid colectomy
(D) colotomy with excision of the base of the polyp
(E) repeat colonoscopy and cauterization of the base of the polyp
For the incomplete statement above select the one completion that is best of the five given.
For the critique of Item 38 see page 291.
(Reproduced by permission from SESAP VI Syllabus; Surgical Education and Self-Assessment Program No. 6.
For enrolment in the Surgical Education and Self-Assessment No. 6, please apply to the American College of
Surgeons, 55 East Erie St., Chicago, IL 60611.)
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Retrospective Reviews
Richard G. Margolese, MD, FRCSC
Herbert Black professor o f surgical oncology, M cG ill University. Director, Department o f
Oncology, Sir Mortimer B. Davis Jewish General Hospital, Montreal, PQ

the use of the retro
Historically,
spective review (RR) was im
portant in evaluating therapies and
evolving new ideas, particularly for
those who had large clinical experi
ences. It was an important tool in
the early development of surgery.
These reviews were thoughtfully
prepared and carefully analysed, so
the advances made in the science of
surgery were not surprising. How
ever, we also know from the history
of the last 30 or 40 years that the
RR was not useful in solving many
more subtle questions, especially
the controversy over surgery for
primary breast cancer. Prominent
researchers, such as Haagensen and
Urban, served more to confuse the
issue and to delay progress because
they opposed consideration or test
ing of more conservative proce
dures. Two decades of controversy
were finally resolved by the success
ful application of the prospective
randomized clinical trial (RCT),
which seems to have returned us
toward building a consensus on the
management of primary breast can
cer.
In the April 1991 issue of this
journal (pages 151 to 156), the
experience at the Hopital NotreDame in Montreal between 1960
and 1980 was reviewed by Peloquin
and colleagues. Although the re
view gave these authors some in
sight into the generalities of their
patient population, it also illustrat
ed quite clearly some of the differ
ences between the RR and the RCT.

One problem is the unavoidable
choice of a time interval, which is
different for the RR than the RCT.
To obtain adequate time for follow
up, the authors cut off entry into
their study in 1980. In a welldesigned clinical trial with appropri
ate sample size and control group,
results can often be obtained after
only a few years of follow-up. The
National Surgical Adjuvant Breast
Project (NSABP), Protocol B-04,
published its initial results 4 years
after accrual was completed. Analy
sis at 5 years, 10 years,1 and recent
ly at 15 years (Fisher and associ
ates: Unpublished data, 1990)
showed that the initial report was
accurate, and the conclusions re
mained unchanged.
It is also apparent that the RR
cannot compensate for rapid
changes in surgical practice. Less
than 3% of the tumours in the
series of Peloquin and colleagues
were detected by mammography,
and only 20% were stage I tumours.
Modern series have more than 50%
of cases in stage I, reflecting impor
tant changes in clinical presenta
tion. One-third of the patients in
Peloquin’s review underwent a Halsted radical mastectomy, a proce
dure that is now rarely performed
but was common in the first part of
the study. Sixty percent of the
patients had radiotherapy, but many
of these had regional lymph-node
irradiation following radical or mod
ified radical surgery; others had
breast irradiation after breast-con

serving surgery. With this 20-year
time span the changing practices
blur distinctions about treatments,
so that no conclusions about the
usefulness or appropriateness of
surgery or radiotherapy can be
drawn.
Problems of the RR are clearly
illustrated by the finding of Pelo
quin and colleagues that patients
who underwent the McWhirter pro
cedure (simple mastectomy with
postoperative radiotherapy) did very
poorly. The NSABP Protocol B-04,
however, shows that patients who
had this very same treatment did
just as well as those who had the
Halsted radical mastectomy.1 Which
result is more believable, the pro
spective trial with sound methodol
ogy, appropriate quality control,
data verification and long-term fol
low-up or the retrospective review
with its uncertainties? By compar
ing the outcome from the random
ized trial with these conflicting re
sults, we can accept the conclusions
from Protocol B-04 with more con
fidence than we could accept the
suggestion from the RR that the
McWhirter procedure is inadequate.
Therefore, why publish the RR find
ings? What are we to do with the
observations from it, in the face of
Protocol B-04 results and other
confirmatory studies? Should we
disregard the RR, or allow it to
challenge current surgical practice?
Even if we take into account the
problems of selection bias, the use
of multiple comparisons in an undiCJS, VOL. 34, NO. 3, JUNE 1991
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rected search, uncertainties about
choice of treatment in relation to
clinical features and questions
about timeliness, fundamental ques
tions about the RR still remain.
How do we interpret the results
from a 20-year retrospective collec
tion, which included an operation
accepted in its time as appropriate,
but now universally abandoned?
What does it teach us about the
selection of patients for adjuvant
therapies or about prognostic fea
tures that have also changed in the
interim?
The RCT is recognized to have
some inherent defects. Among these
defects are ethical considerations,
complex design and difficulty adapt
ing some questions to the design.
The historical database (HDB) has
been suggested as an alternative.
This is claimed to be preferable to a
straight series of patients from an
institution’s experience because it is
designed to be large and representa
tive, in the hope of achieving the
same balance found in the random
ized control trials.2 However, it is
not immune to the problems of
changing diagnostic procedures or
changes in the patient population
and cannot control selection factors
of which the statistician may be
unaware. Moreover, the HDB in
cludes all patients, but an RR or
RCT might select one class of pa
tients for different treatments. To
day, estrogen-receptor protein lev
els are determined, but in the his
torical group they were not avail
able. Thus, the method of choosing
treatments today is different, and
the patient groups are obviously
not comparable. Many other such
confounding factors exist — the
use of mammography, changing
patterns in the use of birth control
pills and so on.
Advances such as the use of
penicillin for bacterial endocarditis
or vitamin B12 for pernicious ane
mia do not need the RCT, but
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today’s conditions — cancer, heart
disease, arthritis — do not yield to
simple solutions, and incremental
gains must be ascertained by valid
and reproducible methodologies.
An internal RR can determine if
current cases are managed accord
ing to current perceptions of what
is correct treatment, but it cannot
contribute to the evaluations of new
therapies. How should a meaningful
difference on RR be interpreted?
Should it be dismissed as anachro
nistic or spurious, or accepted as
important? If considered important,
how should the decision be made in
the face of other information from
modern prospective trials? In short,
what do we do with the results of

an RR? Peloquin and colleagues
conclude that further improvement
in the treatment of breast cancer
will probably be obtained by RCTs.
If their RR pushes others in that
direction, it will have served a pur
pose.
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A Historical Account
of Ulcerative Colitis

the other. The rectum was also the seat
of a few small, red, prominent tumours.

CALCEROUS
COLON

To the editors. The first description
of ulcerative colitis was reportedly
by Samuel Wilks in 1859.1 The
following case reported from the
Hotel Dieu in 18242 is not only the
first report of ulcerative colitis but
also the first observation of the
important relationship between this
disease and carcinoma of the colon.
It represents an important contribu
tion to the history of ulcerative
colitis.

B.N. Nathan, MB, FRCS, FRCS(Edin)
Surgical registrar
Department of Surgery
Mayday University Hospital
Croydon, Surrey
CRO 8XJ
UK

This preparation, which was exhibited
by Mr. Erasmus Wilson, showed a num
ber of calcerous concretions within the
intestine. The descending colon present
ed a multilocular appearance, being
divided in its interior by a number of
valvular partitions placed near to each
other, and extending for about two
thirds across the area of the intestine.
Projecting from the sides of the colon,
in the intervals of the septa, were small
coecal pouches, in each of which was
situated one of the concretions referred
to. The number of pouches and concre
tions amounted to nearly thirty.2

In another woman, who had offered no
fixed symptoms, and to whom very little
attention was paid, a cancer of the
rectum was discovered after death. It
was very easy to perceive that this
disease had arisen from chronic inflam
mation of this intestine; indeed, the
progress of alteration of the mucous
membrane could be traced from the
descending colon, where it was of a
reddish brown colour, and thick, to the
rectum, where it had the characters
proper to the mucous tissue covering
schirrhus; the three membranes of the
intestine were completely changed, and
it was impossible to isolate the one from
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Who First Described Colonic
Diverticula?
To the editors. It is traditionally
accepted that colonic diverticula
were first described by Cruveilhier
in 1846.1 It was, however, Sir Eras
mus Wilson (1809-1884) who,
apart from bringing Cleopatra’s
Needle to London and being one of
the founders of dermatology, was
the first to note the presence of
diverticula in a specimen that he
examined in 1840:
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B.N. Nathan, MB, FRCS, FRCS(Edin)
Surgical registrar
Department of Surgery
Mayday University Hospital
Croydon. Surrey
CRO 8XJ
UK
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K in k in the Internal Carotid Artery
Normand Miller, MD, FRCS;* Herbert Dardik, MD, FACS

inking of the internal carotid
artery has been found in 10%
to 16% of cerebral arteriograms12
and may be associated with or be
the cause of cerebrovascular symp
toms. A lower incidence (3%) of
kinking has been noted during op
erations on the carotid system.3

K

Endarterectomy accentuates the an
gulation of a pre-existing kink in
the internal carotid artery and can
cause distortion,4 which may be the
result of development of redundant
media and adventitia. After veinpatch closure of an endarterectomy
extending into a slightly tortuous

internal carotid artery, a kink at the
origin of the posterior wall of the
internal carotid artery may become
obvious (Fig. la).
Although standard kinks are gen
erally treated by resection and reim
plantation, we describe a technique
of posterior-wall plication to repair

FIG. 1. (a) Completion arteriogram shows kink at origin of
internal carotid artery (arrow) after endarterectomy and veinpatch angioplasty, (b) Correction of kink after plication of
posterior wall.

From the Vascular Surgical Service, Englewood Hospital, Englewood,
NJ
*Sir Mortimer B. Davis Jewish General Hospital, Montreal, Que.
Accepted for publication May 22, 1990
Reprint requests to: Dr. Herbert Dardik, 375 Engle St., Englewood, NJ,
07631

FIG. 2. Technique of plication of posterior wall of internal
carotid artery: arteriotomy is made in vein patch (1), and
running suture, beginning either in centre or at one end, is
placed to bring media above and below redundancy into
apposition, thereby excluding intervening tissue into extravascular plane (2). Vein patch is closed primarily (3).
CJS, VOL. 34, NO. 3, JUNE 1991
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kinks that are noted after endar
terectomy and vein-patch angioplas
ty. The procedure is simple, rapid
and reliable.

its redundant portion with a 7-0
polypropylene running suture (Fig.
2). The vein-patch arteriotomy is
then closed primarily. Adequacy of
the repair is confirmed by comple
tion arteriography (Fig. lb).

Technique
Through a longitudinal arteriotomy in the vein patch, the posterior
wall of the internal carotid artery is
plicated by everting and excluding
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A COLOR ATLAS OF ENDOVASCU
LAR SURGERY. Rodney A. White and
Geoffrey H. White. 157 pp. Illust. J.B.
Lippincott Company, Philadelphia.
1990. $129.50 (US). ISBN 0 -3 9 7 58328-1

This is a superb book for anyone inter
ested in the rapidly developing field of
endovascular surgery. The authors are
among the leaders in developing these
techniques and their experience is wide
ly recognized as one of the largest in
the world. The atlas is compact, and the
subject matter is presented largely as
illustrations and diagrams with explana
tory text. In three, very brief introduc
tory chapters, atherosclerotic lesions,
their distribution and techniques to gain
intraluminal access to them are dis
cussed. Detailed chapters on balloon
angioplasty, atherectomy devices and
lasers make up the bulk of the text.
The subjects of angioscopy, angioscopic surgery, intravascular stenting and
imaging techniques (including intravas
cular ultrasonography) fill out the vol
ume.
The text is brief but informative, and
the illustrations and photographs are of
high quality. In particular, the different
catheters and devices employed in en
dovascular surgery are clearly described
by photographs. Descriptions of most
techniques are in the form of case
studies, which illustrate the appropriate
206
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lesion to be treated by endovascular
techniques, the indications for employ
ing them and the potential complica
tions.
Physicians and surgeons looking for
an overview of the subject will be
pleased with this atlas. Enthusiasts and
sceptics alike will find, on the whole, a
balanced view between its covers.
C. Wm. Cole, MD, FRCSC
Chief
Division of Vascular Surgery
Ottawa Civic Hospital
Ottawa, ON
K1Y 4E9

SURGICAL ENDOCRINOLOGY: CLI
NICAL SYNDROMES. 2nd ed. Edited
by Stanley R. Friesen and Norman W.
Thompson. 474 pp. Illust. J.B. Lippin
cott Co., Philadelphia. 1990. $79.50
(US). ISBN 0-3 9 7 -5 0 8 6 1 -1

“It is the greatest major contribution to
surgical endocrinology and illustrates
how fast the subject is advancing,”
states Richard B. Welbourn in his fore
word to this second edition of Surgical
Endocrinology. The authors, two highly
respected, knowledgeable and authori
tative surgical endocrinologists, along
with 37 superbly qualified contributors,
have written a lucid and comprehensive
text on the pathophysiology, diagnosis

and management of an increasingly
broad spectrum of endocrinopathies.
The first edition in 1978 had three
goals: “the unification of basic and
clinical concepts, the simplification of
diagnostic criteria and the presentation
of therapeutic options in surgical man
agement.” In this second edition, con
cepts have been updated and new infor
mation has been compiled on the hu
moral agents (amines, polypeptides and
steroids) as well as techniques of diag
nosis, tumour localization and thera
peutic options. Emphasis is placed on
the multipotential of individual cells, for
example, secretion of both peptides and
amines, and the emerging interrelations
between brain and gut neuroendo
crinology. Endocrine tumours may also
be multipotential as a reflection or
manifestation of an endocrine syn
drome, thereby justifying a search for
other endocrine abnormalities.
This book is divided into two sec
tions: new advances in diagnosis and
management followed by clinical syn
dromes. The section on new advances
includes chapters on concepts of clinical
neuroendocrinology, genesis of the neu
roendocrine system, hormones, neuro
transmitters and other humoral markers
of endocrine tumours, cytochemical
identification of neuroendocrine tu-

continued on page 229
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Care of the Gut in the Surgical Intensive
Care Unit: Fact or Fashion?
Oren K. Steinmetz, MD; Jonathan L. Meakins, MD, DSc, FRCSC, FACS
The traditional approach to the care of the gastrointestinal tract in the intensive
care unit has been one of neglect. However, recent evidence has linked enteric flora
to the generation of clinical sepsis in the absence of other infectious foci. The role of
the bowel as an efficient barrier to the invasion of its own flora is addressed in this
paper.
A variety of insults disrupt the integrity of the barrier function of the gut,
allowing the entry of bowel organisms or endotoxins, or both, into the portal and
systemic circulatory systems. In animal and early clinical studies, a number of
interventions, aimed at altering the enteric flora and enhancing the bowel’s barrier
function, have been shown to modulate the host's resistance to different insults and
may even improve clinical outcome. Such interventions include maintenance of
enteral feeding, glutamine supplementation of hyperalimentation solutions and
selective bacterial decontamination of the bowel.

On a toujours neglige, a l’unite des soins intensifs, le soin du tractus gastrointesti
nal. Des preuves recentes etablissent toutefois un lien entre la flore intestinale et la
septicemie clinique en l’absence d’autres foyers d’infection. Ce document decrit le
role de l’intestin comme barriere efficace a l’invasion de la flore intestinale.
Toutes sortes degressions perturbent l’integrite du role de barriere que joue
l’intestin et permettent l’entree des organismes intestinaux, des endotoxines, ou des
deux, dans les systemes circulatoires general et porte. Au cours d’etudes sur les
animaux et des premieres etudes cliniques, on a demontre que certaines interven
tions qui visent a modifier la flore intestinale et a renforcer le role de barriere que
joue l’intestin ont un effet sur la resistance de l’hote a diverses agressions et
peuvent meme ameliorer Tissue clinique. Ces interventions comprennent le maintien
de l’alimentation enterique, [’administration de supplements glutaminiques et de
solutions de suralimentation, et la decontamination bacterienne selective de
l’intestin.

he multiple-system organ fail
ure (MSOF) syndrome was first
recognized as a distinct entity in the
mid-1970s by Baue.1 Patients mani
fest various combinations of cardio
vascular, respiratory, renal, hemato-

T

logic, hepatic and neurologic dys
function and failure. Since then the
syndrome has been increasingly rec
ognized as a final common pathway
in the critically ill patient and due
to a variety of causes. Multiple

From the Department o f Surgery, McGill University, Montreal
Accepted for publication May 3, 1990
Address reprint requests to: Dr. J.L. Meakins, Department o f Surgery, Royal Victoria Hospital,
687 Pine Ave. W, Montreal, PQ H3A 1A1

trauma, severe burns, hemorrhagic
shock and sepsis have all been
associated with the development of
MSOF.2 Epidemiologic studies have
shown3 that the MSOF syndrome
develops in approximately 15% of
patients admitted to the intensive
care unit, and despite major ad
vances in the supportive care of
failing organ systems the death rate
remains high. Important risk fac
tors for death due to MSOF are age,
neurologic failure and the number
and duration of failed organ sys
tems. Single organ failure for more
than 3 three days is associated with
a death rate of about 40%, whereas
for triple organ failure for longer
than 3 days the death rate ap
proaches 100%.

The Trigger for MultipleSystem Organ Failure
The pathogenesis of the syn
drome is unknown. However, risk
factors for the development of
MSOF are advanced age, increased
severity of illness (as measured by
scales such as the APACHE score)
and the presence of sepsis at the
time the patient is admitted to the
intensive care unit.3 Indeed most
patients who suffer from MSOF
show signs of the septic state in
cluding fever, confusion, hyperdy
namic circulation, transient hypo
tension, fluid retention, erosive gas
tritis, ileus and leukocytosis or leuCJS, VOL. 34, NO. 3, JUNE 1991
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kopenia.24 Although the syndrome
can develop in patients after a vari
ety of different stresses, infection
was thought to be the common
denominator in most cases. Studies
showed the presence of untreated
or undetected infectious foci in
many patients who died from
MSOF, and aggressive localization
and treatment of infectious foci,
including blind laparotomy, was ad
vocated.5-9 Autopsy series have not
uniformly demonstrated the pres
ence of untreated infectious foci in
patients who die with MSOF,10 and
it may be that the development of
better imaging techniques and more
aggressive treatment of infection
have led to a lower incidence of
occult infection in these patients.
Published series,1112 showing a very
low yield and extremely high death
rate after blind laparotomy in pa
tients with multiple organ failure,
have made this practice seem less
relevant.
The term nonbacterial clinical
sepsis is used when a patient has
overt signs and symptoms of sepsis,
but no identifiable infectious focus,
and sterile blood cultures.4 In the
intensive care unit these patients
have the same prognosis as patients
who have sepsis with an identifiable
focus of infection. The septic state
can be produced in experimental
animals in the absence of infection
by injecting endotoxin.13 Similarly,
mediators produced by the host,
such as tumour necrosis factor/cachectin (TNF), interleukin-1, interleukin-2 and prostaglandins, have
been shown to produce the clinical
manifestations of this syndrome.14_
16 In humans a transient clinical
picture similar to the septic state,
with fever, tachycardia, a hyperdy
namic circulation, water retention,
bilirubinemia and a decrease in
renal and respiratory function, has
also been seen in patients receiving
interleukin-2 and lymphokineactivated killer cell therapy for
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metastatic cancer.17 When human
recombinant TNF was administered
to rats in quantities similar to those
produced endogenously in response
to endotoxin, hypotension, metabol
ic acidosis, hemoconcentration and
death occurred within hours. When
the tissues of these animals were
examined, diffuse pulmonary in
flammation and hemorrhage, hem
orrhagic lesions of the gut and
acute tubular necrosis were seen.18
When endotoxin was administered
to primates, its effects could be
markedly blunted by passively im
munizing the animals with antibod
ies against TNF.19 It appears that
the inflammatory response and the
organ damage seen after endotoxin
infusion are the results of mediators
produced by the host in the absence
of infection.
Since it is evident that MSOF can
develop in the absence of overt or
occult infection, what is the trigger
for the initiation and perpetuation
of the MSOF syndrome? Could this
same trigger be responsible for the
septic state?
It has been suggested that the
trigger of the MSOF syndrome
might be bacterial products such as
endotoxin whose effects are mediat
ed by lymphokines or monokines,
and that the source of this endotox
in is the largest reservoir of bacteria
and bacterial products in the body,
namely, the gut.16 The idea that the
contents of the gut could pose a
threat to the individual is not new;
in fact “autointoxication” or the
production of illness by absorption
of toxins from the gut, was a
common belief at the turn of the
century.20 At the time, vigorous
purging with cathartics and enemas
was the mainstay of treatment for
many medical conditions. It was in
a series of experiments in the 1950s
that Fine and colleagues21 identified
a toxin in the serum of animals in
hemorrhagic shock unresponsive to
transfusion. This toxin was identi

fied as bacterial endotoxin and was
thought to arise from the gut.
In this review we examine the
normal gut defences, their role in
containing bacteria and endotoxins
within the gut lumen, their alter
ations in the surgical intensive care
unit (SICU) and some therapeutic
concepts.

The Gut Defences
The Normal Flora
The gastrointestinal tract con
tains the largest collection of bacte
ria and toxins in the body. Normally
the stomach and the upper small
bowel are sterile or sparsely inhabit
ed by Lactobacillus and some gram
positive species. The colon contains
many hundred microbial species, in
cluding sporulating and nonsporulating anaerobes (102 to 1012
organisms per gram), Enterobacteriaceae (106 to 1010 organisms
per gram), Proteus, Enterococcus,
Lactobacillus and Pseudomonas (up
to 108 organisms per gram).22 En
dotoxin is a lipopolysaccharide
component of the wall of gram
negative bacteria. Owing to its re
lease by both living and dead bacte
ria endotoxin is present in high
concentration within the lumen of
the bowel, especially in the distal
bowel.23
The enteric flora are clearly
necessary for the normal digestion
of nutrients. In addition, they pro
vide a biologic environment hostile
to the noncommensal microflora. If
these normal inhabitants were able
to pass through the gut walls the
consequences would be dire, so at
the same time that the gut forms a
suitable environment for the culti
vation of its flora, a complex barrier
is in place to prevent invasion of the
gut bacteria into the host. This
barrier comprises chemical and en-
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zymatic, physical and immunologic
components (Table I).
The Barrier
Chemical and enzymatic. There
is a direct correlation between the
gastric pH and the bacterial content
of the stomach. Since a pH of less
than 4.5 is low enough to kill most
bacteria, the stomach is normally a
sterile milieu because of the action
of gastric acid. Pepsinogen is acti
vated to pepsin at pH less than 4.5
and probably has further inhibitory
action on microbes and their tox
ins.24 Other substances, such as
salivary lysozyme and lactoferrin,
inhibit the growth of sensitive or
ganisms, and coordinated gut motil
ity is essential to control bacterial
numbers.25
Mucin is secreted throughout the
gastrointestinal tract. Besides func
tioning as a lubricant, it forms a
matrix that binds nonspecifically to
bacteria and their toxins and proba
Table I. Gastrointestinal Defence
Mechanisms
Chemical and enzymatic
Gastric acid
Salivary lysozyme
Healthy enterocyte
Lactoferrin
Mucous secretion
Bile salts
Physical
Healthy enterocyte
Tight junctions
Enterocyte regeneration
Immunologic
Submucosal
Neutrophils
Macrophages
Lymphocytes
Eosinophils
Mast cells
Peyer’s patches
Mesenteric lymph nodes
Secretory immunoglobulin A
Salivary
Bile
Intestinal
Hepatic Kupffer cell bed
Factors that maintain homeostasis
Enteral stimulation
Splanchnic blood flow
Balanced enteric flora
Coordinated motility

bly prevents their interaction with
the enterocyte. It is also hypothe
sized26 that mucin helps protect the
enterocyte surface from the action
of gastric acid by creating a pH
gradient with secreted bicarbonate.
Bile salts also may be capable of
binding bacterial endotoxins within
the lumen of the bowel.
Physical. The bowel mucosal
membrane, principally the healthy
enterocyte and the tight junctions
between them, forms a physical
barrier.27 Essential for the mainte
nance of this barrier is the orderly
pattern of regeneration, migration,
maturation and sloughing of enterocytes in the mucosa.
Immunologic: local. The mucosa
and submucosa are rich in macro
phages, lymphocytes, neutrophils,
eosinophils and mast cells. The Pey
er’s patches of the terminal ileum
are strategically located to sample
the antigenic load of the intestinal
contents. Activated B-lymphocytes
from the Peyer’s patches and the
mesenteric lymph nodes migrate to
the systemic circulation by way of
the thoracic duct. En route they
differentiate into secretory immuno
globulin A (IgA)-producing plasma
cells. These plasma cells selectively
relocate themselves along mucosal
surfaces and secrete antibodies into
saliva, bile and the succus entericus. Immunoglobulin A acts by
binding to bacteria in the bowel and
results in bacteriolysis and preven
tion of bacterial adherence to the
mucosal surface. Various toxins
and virions are also precipitated and
inactivated by IgA.25
Immunologic: systemic. Bacteria
and endotoxin, which pass through
the gut wall into the portal circula
tion, must pass through the Kupffer-cell bed of the liver, the largest
collection of macrophages in the
body. These cells are in a position
to sample antigens present in portal
blood and mediate the immune re
sponse to these antigens. Marshall,

Christou and Meakins28 showed
that the character of the small
bowel flora had an effect on system
ic immune responsiveness. The delayed-type hypersensitivity response
to subcutaneously injected antigens
was depressed by colonizing the
small bowel with gram-negative
bacteria28 or by injecting these bac
teria into the portal circulation.29 In
other experiments Kupffer cells in
coculture with hepatocytes that
were exposed to bacterial endotoxin
were found to inhibit hepatocyte
protein synthesis.3031 When the
Kupffer cells for coculture were
obtained from rats whose small
bowel had been colonized with Es
cherichia coli, endotoxin exposure
resulted in enhanced suppression of
hepatocyte protein synthesis. Kupf
fer cells from these same rats also
produced significantly more interleukin-1 and prostaglandin E2 when
exposed to endotoxin.32 In these
experiments the gut flora were also
shown to affect the immune re
sponse indirectly through its influ
ence on the Kupffer cell. This type
of mechanism may be responsible
for the state of impaired cell-mediat
ed and humoral immunity seen in
patients after trauma and sepsis.33-34
The Kupffer cell probably acts by
producing mediators that control
the immune response to antigens
originating from the gastrointesti
nal tract. We shall review clinical
and experimental evidence showing
that bacteria and bacterial toxins
can gain access to mesenteric
lymph nodes, the portal circulation
and often the systemic circulation
when the intestinal defence mecha
nisms are impaired. Severe impair
ment of the gut barrier may result
in uncontrolled or continuous re
lease of antigenic material from the
gut and overstimulation of the
Kupffer cell bed. Such a state of
continuous antigenic stimulation
could result in a generalized uncon
trolled immune response and possiCJS, VOL. 34. NO. 3, JUNE 1991
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bly the organ damage seen in the
MSOF syndrome.

Bacterial Translocation and
Endotoxemia of Gut Origin
The study of translocation of
bacteria or bacterial products has
burgeoned in recent years. At surgi
cal scientific meetings, much data
from a variety of experimental set
tings have been presented to show
that the phenomenon exists. But
does it have clinical significance?
Clinical Evidence
Impairment of the intact gut bar
rier would result in translocation of
bacteria and toxins into the system
ic circulation. Indeed, bacterial
translocation or endotoxemia is
documented in a number of clinical
states. Viable bacteria have been
isolated from the mesenteric lymph
nodes of patients who have under
gone laparotomy for conditions
such as simple small-bowel obstruc
tion,35 Crohn’s disease36 and colo
rectal cancer.37 Endotoxin has been
found in the portal blood of patients
with obstructive jaundice,38 and sys
temic endotoxemia has been found
in patients with heat stroke.39 Caridis and colleagues40 reported sys
temic endotoxemia in a variety of
septic and nonseptic conditions. In
patients with an identifiable infec
tion, endotoxemia resolved after
clearance of the infection. Endotox
emia in the absence of infection was
associated with a high death rate,
hepatic dysfunction, gastrointesti
nal bleeding, shock and pneumoni
tis. These authors hypothesized
that the endotoxemia was of gut
origin, and that the appearance of
endotoxin in the systemic circula
tion was due to inadequate clear
ance by the hepatic reticuloendothe
lial system.
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There are defined clinical settings
in which enteric flora translocate
from the gastrointestinal tract to
produce substantial morbidity and
mortality. Bacteremia of enteric ori
gin is one of the leading causes of
death in leukopenic patients after
cancer chemotherapy. In a study of
neutropenic patients with bacter
emia due to Enterobacteriaceae and
Pseudomonas sp. Tancrede and Andremont41 found that in 45 (82%) of
55 cases the bacteremic organism
was also the dominant fecal strain.
Recurrent systemic infection with
enteric organisms is one of the
limiting factors to the success of
hollow viscera organ transplanta
tion. In these patients, as with
neutropenic patients, the bacterem
ic organism can be isolated in stool
cultures. This problem is illustrated
by the case of a 3V2-year-old girl
who survived 193 days after receiv
ing transplantation of stomach, du
odenum, small and large bowel,
pancreas and liver.42 During the
first 12 days after transplantion she
suffered six bacteremias due to
gram-negative organisms. After the
initiation of a regimen of oral and
enteral tobramycin, amphotericin B
and polymyxin E for selective de
contamination of the gut, she had
39 bacteremias due to gram-positive
organisms and 6 due to Candida.
The bacteremic organism was in the
stool in 81% of the cases. The
antibiotic regimen therefore
changed the nature of the enteric
flora but did not prevent recurrent
sepsis from an impaired gut.
Different stresses such as burns,
heart failure, sepsis and hypoten
sion produce erosive and necrotic
lesions of the intestinal mucosa in
animals.43 The clinical syndromes of
cardiogenic and hemorrhagic shock
cause splanchnic low-flow states
and are associated with systemic
bacteremia in humans. In one
study, blood cultures were taken
from patients within 12 hours of

resuscitation from cardiac arrest.44
Thirteen patients had one or more
positive blood cultures, and 12 of
these had fetid diarrhea from which
the bacteremic organism could be
isolated. All 12 patients with both
bacteremia and diarrhea died. The
only four who survived had neither
bacteremia nor diarrhea. In a study
of trauma patients, Rush and asso
ciates45 were able to detect bacter
emia and endotoxemia in patients
who presented with hemorrhagic
shock. The clinical importance of
these findings is unclear, but the
detection of bacteremia in these
patients correlated with the degree
of hypotension.
Animal Studies
Bacterial translocation to mesen
teric lymph nodes, peritoneum, vis
cera and the systemic circulation
has been clearly demonstrated.
Hemorrhagic shock,46-50 endotox
emia,51 peritonitis,52’53 surface
burns54 and heat stress55 can all
cause bacterial translocation from
the gut in experimental models.
Zymosan injected into the peritone
um of rats has caused peritonitis
associated with translocation of
bacteria into the peritoneum, with
systemic signs of severe illness.
Rats became lethargic, anorectic,
had liquid stools, hyperventilated
and lost hemorrhagic fluid from
their noses and conjunctiva. Germfree rats had a rate of positive
peritoneal cultures and a death rate
that were 10% of those of normally
raised laboratory rats.52 Other fac
tors, such as change and over
growth of the enteric flora54’56 and
protein malnutrition,57 have in
creased the rate of translocation in
response to other stimuli. The exact
mechanism of bacterial transloca
tion is not known, but a role for
reperfusion injury,49 the macro
phage58 and the effect of endotox
in59 and vasoactive amines20 on in-
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creasing intestinal permeability
have all been proposed.
Clinical and experimental evi
dence support the view that translo
cation of bacteria and endotoxemia
from the gut occurs when there is a
breakdown of the gut barrier (Table
IJ35-42,44-57.60,6i)
js evjdent that
both stressors, such as endotox
emia, trauma and burns, and sup
portive measures, such as antibiot
ics, fasting and parenteral nutrition,
can affect the state of the gut
barrier and therefore the rate of
translocation. The clinical data sug
gest that translocation can be clini
cally relevant.

The Gut as a Target Organ
In patients with full-blown or
impending MSOF the emphasis of
treatment has been on aggressive
control of sources of ongoing in
flammation and infection and the
correction of recognized perfusion
deficits. Supportive care for failing
Table II. Conditions for Which There Is
Clinical or Experimental Evidence for
Bacterial Translocation or Endotoxemia of
Gut Origin
Condition

Shock
Cardiogenic
Hemorrhagic
Burns
Infection or endotoxemia
Altered immunity:
neutropenia
Peritonitis
Crohn’s disease
Small-bowel obstruction
Colorectal carcinoma
Hollow-organ
transplantation
Starvation
Malnutrition
Total parenteral nutrition
versus lack of enteral
stimulation
Bacterial
overgrowth/antibiotics
Spontaneous bacterial
peritonitis
Heat stroke
Obstructive jaundice

Reference number

44
45-50
55
51
41
52,53
36
35
37
42
57
57
60
54,56
61
39,40,55
38

organ systems and nutritional ther
apy is increasingly effective. Similar
to the lungs, the heart and the
kidneys, the gut is now recognized
as a target organ in the critically ill
patient. Acute acalculous cholecys
titis,62 stress ulceration of the stom
ach,63 jaundice, ileus and diarrhea64
all occur in patients in the intensive
care unit who have extraintestinal
illness. Although acalculous chole
cystitis is relatively rare, ileus oc
curs very frequently in this group of
patients. In one group of patients
admitted to the intensive care unit
because of respiratory failure, an
ileus requiring nasogastric decom
pression developed in 50% of them,
together with a variety of other gut
complications.64 Less obvious than
the rate of ileus and stress alter
ation is the state of the intestinal
barrier function in the critically ill
patient. Laparotomy in the patient
with MSOF characteristically re
veals a flaccid, edematous and
boggy bowel. The barrier function
of this bowel would undoubtedly be
impaired.
Starvation alone has been shown,
in several animal models, to result
in thinning of the bowel mucosa,
especially that of the small bowel. If
mice are starved for 3 to 4 days, the
weight loss of the small bowel is
greatly out of proportion to that of
the whole body. Epithelial cell re
newal is decreased, and normal dif
ferentiation and migration are im
paired.65 These changes in the mu
cosa can be detected in rats after
very short periods of starvation. In
one study significant loss in gut
weight, DNA content and DNA rep
lication could be detected after
overnight fasting.66 Starvation also
causes increased mucosal perme
ability to macromolecular pro
teins.67 The effects of fasting on the
bowel are not due simply to a lack
of calories, since similar findings
are seen in parenterally fed ani
mals.68 When compared with isocal

oric enterally fed rats, parenterally
fed rats show substantial weight
loss of the stomach, small bowel
and pancreas. Other organs, such
as the kidneys, spleen and testes,
maintain their weight in parenteral
ly fed rats. Parenterally fed rats also
have impaired epithelial cell prolif
eration and migration, disaccharidase activity and markedly lower
serum gastrin levels.6970
Immune function also seems to
be impaired by parenteral nutrition.
Alverdy, Chi and Sheldon71 demon
strated depressed S-IgA levels in
the secretions of parenterally fed
rats. Parenterally fed animals had
significantly lower levels of IgA in
bile when compared with rats fed
the same solution orally and rats
fed solid food. Both enteric bacteri
al overgrowth and translocation of
bacteria to mesenteric lymph nodes
were also greater in parenterally fed
rats.60 It appears as if enteral stimu
lation or the presence of nutrients
within the gut lumen is essential for
maintaining mucosal integrity as
well as some of the immunologic
functions of the gut.

Care of the Gut in the Surgical
Intensive Care Unit: Enhancing
Gut-Barrier Function?
Care of the gastrointestinal tract
is hindered by the lack of accurate
parameters of gut function that can
be monitored to gauge the effective
ness of treatment. Clinical signs
such as ileus and diarrhea, and
laboratory measurements such as
bilirubin and liver enzyme levels are
nonspecific measures of gut func
tion. Because of our inability to
judge effectively the state of gas
trointestinal homeostasis we have
treated the gut as a “black box.”
We have largely ignored the state of
the intestinal barrier and perhaps
we have been missing the more
central role that the gut has in the
CJS, VOL. 34, NO. 3, JUNE 1991
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pathogenesis of the septic state and
MSOF.16-72
Supportive care of the gut has
consisted mostly of the administra
tion of antacids and nasogastric
decompression to prevent gastric
stress ulceration, and fasting and
total parenteral nutrition to “ keep
the bowel at rest.” Until recently
there has been little effort to imple
ment measures that may actually
maintain the homeostasis and per
haps improve the barrier functions
of the gut.

leagues75 mechanically ventilated
patients treated with sucralfate had
markedly greater gastric acidity,
lower gastric colonization and lower
airway colonization with gram
negative bacteria. The patients
treated with antacids had twice the
rate of pneumonia (p = 0.11) and
1.6 times the death rate (p = 0.07)
of the sucralfate-treated group. By
preserving gastric acidity sucralfate
may preserve part of the gut’s barri
er function.

Prophylaxis o f Stress Ulcers

Liberal use of multiple or broadspectrum antibiotics results in over
growth of resistant organisms. Ex
perimentally it is evident that the
make up of the enteric flora affects
the rate of bacterial transloca
tion5456 and the state of immunocompetence.28 32 Intentional
sterilization of the gut has been
used to treat many conditions in the
laboratory as well as clinically. For
example, in primates subjected to
heat stress,55 endotoxemia can be
eliminated, and tolerance to heat
stress can be improved by prior
sterilization of the gut with oral
nonabsorbable antibiotics. Regi
mens employing both oral and par
enteral antibiotics have met with
some success in lowering septic
morbidity after severe burns76 and
in reducing the rate of spontaneous
bacterial peritonitis in cirrhotics
presenting with variceal bleeding.61
However, when selective bacterial
decontamination is applied to a
more general intensive care unit
population the results are less con
vincing.77

Recently we have seen that extraintestinal septic morbidity in the
critically ill patient may be altered
by special care of the gastrointesti
nal tract. The stomach is the site of
stress ulceration in the patient in
the intensive care unit.63 Superficial
erosions of the gastric mucosa
occur in these patients with a vari
ety of different underlying illnesses
and can cause serious hemorrhage.
Prophylaxis for stress ulceration
has traditionally been with alkalinization of the stomach with local
administration of antacids or intra
venous histamine type-2 blockers.
Alkalinization of the stomach seems
to be effective in preventing upper
intestinal bleeding in these patients,
but it is not clear whether it pre
vents overall morbidity and mortali
ty.73 One effect of such treatment is
colonization of the stomach with
gram-negative bacteria, and Du
Moulin and associates74 showed
that gastric colonization with gram
negative bacilli due to antacid ther
apy is associated with upper-airway
colonization with these same organ
isms and pneumonia.
An alternative to gastric alkalin
ization is treatment with cytoprotective agents, such as sucralfate,
which do not affect gastric acidity.
In a comparison of sucralfate and
antacid therapy by Driks and col
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Antibiotics

Nutritional Support
Nutritional support of the criti
cally ill, catabolic patient is manda
tory and must be aggressive. Key
determinants of effective nutritional
therapy include the quantity and
nature of calories needed and the

route of delivery. The first two
subjects are beyond the scope of
this review, but we shall address the
third.
The choice between enteral or
parenteral nutrition in the critically
ill patient is often a difficult one.
The adage “if the gut works, use
it” is commonly followed, and this
recommendation is often justified
by financial reasons alone. In
studies comparing the delivery of
enteral to parenteral nutrition little
nutritional evidence was found to
favour one over the other, except
the lower insulin requirements seen
in enterally fed patients.78 Not all
patients in the surgical intensive
care unit have adequate gut func
tion to tolerate enteral feeding, and
in some patients, particularly postoperatively, enteral feeding may be
avoided due to concern over intoler
ance.79’80 Parenteral nutrition is a
more efficient route for the delivery
of large caloric requirements in pa
tients who require frequent discon
tinuation of enteral feeding due to
intolerance. Diarrhea is associated
with enteral feeding in mechanically
ventilated patients.81 However, diar
rhea, nausea and vomiting, cramps
and distension are common in the
intensive care unit whether patients
are fed enterally or parenterally.82
At least one study has shown that
adequate enteral calories can be
delivered to the majority of patients
in the intensive care unit after lapa
rotomy for blunt abdominal trau
ma.83
Parenteral nutrition. Parenteral
nutrition has certainly revolution
ized surgical practice, particularly
in dealing with the severely injured
patient, the burned patient and the
postoperative patient. Total paren
teral nutrition (TPN) has enabled us
to provide, safely, large caloric
loads to patients unable to tolerate
enteral nutrition.
Now established, the precise role
of parenteral nutrition in the surgi-

CARE OF THE GUT

cal intensive care unit is being ques
tioned with respect to its influence
on gut-barrier function. The experi
mental data reviewed suggest that
maintaining animals on TPN results
in mucosal wasting and immunolog
ic dysfunction.6068’71 It is not clear
whether this effect is due to a lack
of enteral stimulation or a lack of
adequate specific nutrients for the
enterocyte.
Recently it has been shown that
supplementing standard TPN solu
tions with 2% glutamine, the prima
ry fuel of the enterocyte,72 results in
enhanced cellularity of both small
bowel84 and colonic mucosa.85 Fur
thermore, bile S-IgA levels are high
er, and translocation rates are low
er.86 The effect of glutamine supple
mentation in humans, the practicali
ty of its delivery and clinical rele
vance remain to be established.
Enteral nutrition. Enteral stimu
lation may be necessary for normal
gut homeostasis and maintenance
of gut-barrier function. Bounous,
Cronin and Gurd87 observed an as
sociation between dietary manipula
tion and the systemic sequelae of
shock, and Border and associates88
found an association between the
delivery of adequate amounts of
enteral protein and a favourable
outcome after blunt trauma. Indeed,
it is suggested that enteral feeding,
by enhancing the gut barrier, can
blunt the host response to stress.
The results of animal experiments
are somewhat contradictory. Mochizuki and colleagues89 showed a
reduction in post-burn hypermeta
bolism in guinea pigs by early en
teral feeding, but other investiga
tors could not demonstrate such
effects in rats.90
The effect of enteral and paren
teral nutrition on septic morbidity
after laparotomy for abdominal
trauma was compared in recent clin
ical studies by Moore and col
leagues.9192 Patients randomized to
receive enteral nutrition by way of

needle-catheter jejunostomy suf
fered lower infectious morbidity
than the parenterally fed patients.
More clinical research is needed
before clear conclusions can be
drawn in this area.
Clearly there can be no fixed
rules about how to chose between
enteral and parenteral nutrition;
both have major roles to play in
maintaining and restoring body
composition. Clinical judgement
must be used in each case. The
increasing importance of the gut as
a target organ in hypermetabolic
states suggests the importance of
its care and suggests that enteral
nutrition should be used whenever
possible. If full caloric requirements
cannot be filled by enteral feeding
alone parenteral nutrition can be
used to make up the difference until
full enteral feeding is tolerated.
Other Measures
There are a variety of other sim
ple measures that may be imple
mented to care for the gut in the
critically ill patient. The speed of
resuscitation, its adequacy, the
maintenance of blood volume, oxy
gen delivery and all the supportive
measures that apply to heart, liver,
lung and kidney will have a compa
rable effect upon preservation of
gut function. Attention to the state
of hydration of the patient and
judicious use of vasopressors help
to maintain splanchnic perfusion.
Substances such as lactulose and
bile salts, which may act by binding
endotoxins38 or regulating bacterial
numbers, may have a role in select
ed patient groups, but little direct
evidence in support of these mea
sures is presently available.
Summary
There is increasing evidence that
bacteria and bacterial products from
the gut are capable of triggering

the release of mediators from the
reticuloendothelial system.1314 Tu
mour necrosis factor, interleukin-1,
interleukin-2 and prostaglandins
have all been implicated in the
“septic” condition.14-17’19 Tumour
necrosis factor, in particular, has
been shown to produce organ dam
age similar to that seen in the
MSOF syndrome.18 The complex
array of defences that is in place to
contain the enteric flora and pre
vent its access to the portal and
systemic circulation has been out
lined. Clinical and experimental evi
dence presented indicates that a
breakdown in the gut barrier to its
own flora will result in bacterial
translocation and endotoxemia. A
number of stress factors such as
bacterial overgrowth,54-56 shock,45-50
endotoxem ia,51 perito n itis,52 53
burns54 and immunosuppression41
clearly cause translocation.
Traditionally our approach to the
care of the gut in the critically ill
patient has been supportive. Com
plications such as nausea, vomiting,
ileus and diarrhea are treated as
they arise. It is becoming evident
that the gastrointestinal tract is not
simply a bystander organ in these
patients and may be more pivotal in
the genesis and perpetuation of the
septic state and perhaps the MSOF
syndrome.1672 Direct intervention to
maintain the homeostasis of the
gastrointestinal tract or enhance
the barrier function of the gut has
an influence on the extraintestinal
infectious morbidity in these pa
tients. Cytoprotective agents to
maintain gastric acidity,75 selective
bacterial decontamination of the
gut flora,55-61 glutamine supple
mented TPN solutions to support
the enterocyte86 and enteral stimu
lation by enteral feeding9192 have all
been advocated. The final clinical
significance of each of these inter
ventions and the ultimate roles that
each will play in day-to-day clinical
practice is not yet known and needs
CJS, VOL. 34. NO. 3, JUNE 1991

213

STEINMETZ AND MEAKINS

further study. However, these inter
ventions have shown us that active
treatment o f the gastrointestinal
tract in the critically ill patient is
possible and should not be neglect
ed.
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Now surgery for Dukes’ C
colon cancer is only half the picture.

ErgamisoF + 5-FXJ.
The first adjuvant therapy proven to
reduce recurrence by 41%.
LEVAMISOLE AND FLUOROURACIL FOR ADJUVANT THERAPY OF
RESECTED COLON CARCINOMA
A b stract Twelve hundred ninety-six patients w ith resected
colon cancer tha t either was locally invasive [Stage B2] or
had regional nodal involvement (Stage C] were randomly
assigned to observation or to treatment for one year w ith
levamisole combined w ith fluorouracil. Patients w ith Stage
C disease could also be randomly assigned to treatment
w ith levamisole alone. The median follow-up tim e at this
w ritin g is 3 years (range, 2 to 5%].
Among the patients w ith Stage C disease, therapy w ith
levamisole plus fluorouracil reduced the risk of cancer
recurrence by 41 percent (P < 0.0001]. The overall death
rate was reduced by 33 percent (P ~ 0.006}. Treatment
w ith levamisole alone had no detectable effect. The results
in the patients w ith Stage B2 disease were equivocal and

too preliminary to allow firm conclusions. Toxic effects of
levamisole alone were infrequent, usually consisting of
mild nausea with occasional dermatitis or leukopenia,
and those of levamisole plus fluorouracil were essentially
the same as those of fluorouracil alone—i.e., nausea,
vomiting, stomatitis, diarrhea, dermatitis, and leukopenia.
These reactions were usually not severe and did not greatly
impede patients’ compliance w ith the ir regimen.
We conclude that adjuvant therapy w ith levamisole and
fluorouracil should be standard treatment for Stage C
colon carcinoma. Since most patients in our study were
treated by community oncologists, this approach should
be readily adaptable to conventional m edical practice.
(N Engl J Med 1990; 322:352-8.}'

THERAPY SHOULD BE INITIATED WITHIN 5 WEEKS OF SURGERY.
NEW

ERGAMISOL

■

LEVAMISOLE HQ B S

in combination with 5-fluorouracil

Now a reason to refer patients
JANSSEN
after surgery
PHARMACEUTICA
Mississauga, Ontario

CANADIAN ASSOCIATION OF GENERAL SURGEONS
ASSOCIATION CANADIENNE DES CHIRURGIENS GENERAUX

Presidential Address, 1990. Should
General Surgery Be Redefined?
Jean Couture, MD, FRCSC
The definition of general surgery, adopted by the Canadian Association of General
Surgeons in 1983, has raised the expectations of the general surgical community. It
was thought, at the time, that a definition that took into account the broad aspects
of the specialty would make general surgeons more aware of their role in clinical
and teaching activities, counteract the negative effects of subspecialization and
prevent further fragmentation. Because of the many changes that have taken place
in the 1980s, the author considered that a review of that definition was justified.
To address this issue, the author has attempted to answer the following two
questions: What are general surgeons doing in 1990? To what extent are they
trained to do what they are supposed to do, according to the definition of general
surgery?
Data were obtained from la Regie de 1’assurance-maladie du Quebec in order to
answer to the first question; with respect to the second, a questionnaire was sent to
the chairmen of the 16 Canadian departments of surgery.
The results of the study indicate that the definition of general surgery has not
kept up with the times and should be revised. The author suggests that a modified
definition should include primary and secondary components of the specialty in
order to allow some flexibility. In the event that such a change seems appropriate,
head and neck surgery should be only a secondary component of general surgery.

La definition de la chirurgie generale, adoptee par l’Association canadienne des
chirurgiens generaux en 1983, a suscite beaucoup d’espoir parmi les chirurgiens.
On esperait alors que cette definition qui est tres large et comprend tous les aspects
de la specialite aurait pour effet de sensibiliser davantage les chirurgiens generaux a
l’importance de leurs activites diniques et d’enseiqnement, controlerait les effets
negatifs de la sur-specialisation et previendrait possiblement la fragmentation de la
specialite. Compte tenu des changements importants survenus au cours des annees
1980, l’auteur a pense qu’une revision de la definition etait peut etre justifiee.
Pour discuter de ce probleme, l’auteur a essaye de repondre aux deux questions
suivantes. Quelle est 1’activite des chirurgiens generaux en 1990? Jusqu’a quel
point les chirurgiens generaux refoivent-ils une formation qui est conforme a la
definition de la chirurgie generale? Des statistiques ont ete, obtenues de la Regie de
l’assurance-maladie du Quebec afin de repondre a la premiere question: en ce qui
concerne le second point, un questionnaire a ete adresse aux directeurs des 16
departements de chirurgie au Canada.
Les resultats de l’etude indiquent que la definition de la chirurgie generale n ’est
plus appropriee et devrait etre revisee. L’auteur suggere qu’on devrait inclure, dans
une definition revisee, les secteurs primaires et secondaires de la specialite, ce qui
permettrait une plus grande flexibilite. Si un tel changement parait souhaitable, la
chirurgie tete et cou devrait devenir un secteur secondaire de la chirurgie generale.

* -

For prescribing information see page 270

or the majority of general sur
geons the need to redefine gen
eral surgery is not obvious. The
current definition, endorsed by
many surgical organizations includ
ing the Canadian Association of
General Surgeons (CAGS), has been
widely accepted and has not been
questioned by anyone in the general
surgical community. General sur
geons thought that a definition that
took into account the broad aspects
of general surgery could prevent
further fragmentation, by establish
ing guidelines encompassing its
total field of endeavour.
The CAGS has shown leadership
in this regard by including, at its
annual meeting, sessions in endos
copy, trauma, head and neck sur
gery, colorectal surgery and critical
care management. It should also be
noted that the CAGS, through its
committee on education, has been
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very active in the promotion of
guidelines that take into account
the scope of general surgery and
the needs of its subspecialties.
Many past presidents have ex
pressed hope that these measures
would counteract the negative ef
fects of subspecialization and pre
vent further erosion of the special
tyWe should now ask ourselves
how successful these measures
have been? Is the definition of gen
eral surgery, as agreed upon in
1983, still appropriate in 1990? To
what extent do the activities of
today’s general surgeons corre
spond to this definition?
In order to answer these ques
tions, I thought it was necessary to
define as accurately as possible the
professional activities of general
surgeons relating to both patient
care and the teaching and training
of surgeons in our medical schools.

Activities Relating to Patient
Care
The Quebec Health Insurance
Board provided me with extensive
data on the evolution of the prac
tice of general surgery over the past
10 years. I requested similar data
from the Ontario Ministry of
Health, but they could not be made
available. However, from previous
studies I could only postulate that
changes in practice patterns ob
served either in Ontario or Quebec
also apply to other provinces, al
though some differences may be
present.
Over the past 10 years the num
ber of general surgeons in Quebec
decreased by 7.8%, from 579 in
1978 to 538 in 1988. During the
same period, manpower increased in
all other surgical specialties. Fur
thermore, there has been an 8.5%
decrease in the rate of surgical
procedures done by general sur
218
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geons, while most other surgical
specialties have experienced an in
crease. It is interesting to note that
T.A. MacKenzie, in a document
prepared on behalf of the CAGS
many years ago,1 reported a 7.4%
decrease in the rate of surgical
procedures in Canada from 1969 to
1977. The 8.5% decrease observed
in Quebec during the last 10 years
indicates a continuing decline in the
activities of general surgeons.
There has been a 20% to 30%
decrease in surgery of the appendix,
gallbladder, esophagus, spleen,
stomach, duodenum and thyroid.
However, there has been an 89.5%
increase in colorectal surgery, prob
ably due to the aging of the popula
tion and a higher incidence of can
cer in the older age group. The rate
of surgical procedures has also in
creased, but more moderately, in
surgery of the breast, pancreas,
diaphragm and parathyroid. It is
interesting that there has been an
increase of 25.5% and 57.4% re
spectively in operations done for
intestinal obstruction and resection
of the liver.
A study comparing the activities
of general surgeons with those of
other surgical specialists was made
to ascertain whether the decrease in
general surgery had been accompa

nied by a corresponding increase in
the activities of the surgical subspe
cialties. Three sectors were chosen,
vascular, thoracic, and head and
neck surgery. The following data
were obtained.
In vascular surgery, a detailed
survey was done of the following
procedures: aortofemoral and femoropopliteal bypasses; procedures for
aneurysm of the aorta; and carotid
or vertebral surgical procedures. It
showed clearly that general sur
geons have performed most of these
vascular procedures, although car
diovascular and thoracic surgeons
have maintained a comparable level
of activity in carotid or vertebral
surgery and in surgery for aneu
rysms of the aorta. Of interest is
that the total number of vascular
procedures performed has de
creased in Quebec in the past 2
years. The data concerning aor
tofemoral bypass illustrate these
two points (Fig. 1).
The same comments can be made
for thoracic surgery. The statistics
show that there has been a gradual
increase in the number of proce
dures done by general surgeons in
comparison with those performed
by cardiovascular and thoracic sur
geons (Fig. 2). During a 5-year
period, the number of pneumonec-

FIG. 1. Number of aortofemoral bypass procedures performed in Quebec by general
and cardiovascular and thoracic (C.V.T.) surgeons from 1979 to 1988.

REDEFINITION OF GENERAL SURGERY

tomies done by general surgeons
has increased significantly.
However, the results of the study
were markedly different for head
and neck surgery. The number of
procedures performed by ear, nose
and throat surgeons has increased
over the past 10 years, especially
conservative neck surgery, radical
neck and commando procedures,
and parotid surgery (Fig. 3). Otola
ryngologists are doing an increas
ingly large portion of head and
neck surgery. However, general
surgeons still perform most of the
thyroid surgery (Fig. 4), thus con
firming its special status as part of
the endocrine system.

Activities Relating to Teaching
and Training

FIG. 3. Number of procedures on parotid gland performed in Quebec by general
surgeons, ear, nose and throat (E.N.T.) surgeons and plastic surgeons from 1979
to 1988.

1979198019811982198319841985198619871988
FIG. 4. Number of thyroid surgical procedures performed in Quebec by general
surgeons, E.N.T. surgeons and plastic surgeons from 1979 to 1988.

A questionnaire was sent to the
departments of surgery of the 16
Canadian medical schools, with a
100% response. Since many ques
tions were very subjective, most
chairmen consulted their colleagues
in the various disciplines and added
some valuable personal comments.
Consequently, the information re
sulting from the questionnaire,
while interesting and meaningful,
should be interpreted in the light of
this.
With respect to the first question,
“ How do you evaluate in percent
age the contribution of general sur
geons to the teaching of surgery in
general (basic surgery) at the under
graduate and postgraduate level?” ,
most respondents were of the opin
ion that general surgeons contrib
ute more than 50% to the teaching
of surgery in general. This was
corroborated by the answer to a
second question: “ Of all the teach
ing activities taking place in your
department, what in your view is
the participation in percentage of
the surgical disciplines that are part
of your department?” The reCJS, VOL. 34, NO. 3, JUNE 1991
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sponses were similar; in most de
partments, teaching is done largely
by general surgeons. However, to a
similar question relating to research
activities, most respondents
thought that general and orthope
dic surgeons are responsible for
about 50% of the research, followed
closely by cardiovascular surgeons.
I also wanted to know the
amount of time general surgeons
devote to teaching. The following
question was asked, “How many
hours of teaching activities are pro
grammed every week in a general
surgical clinical teaching unit? How
many general surgeons contribute
to these activities?” There were
many differences in the opinions
expressed, depending on the size of
the department and the number of
trainees. On average, eight sur
geons in a clinical teaching unit
devote 7 hours a week to wellstructured clinical activities, semi
nars, lectures or formal rounds.
This means that general surgeons,
whether they are full-or part-time
teachers, spend at least 1 full day in
programmed activities and probably
1 additional day teaching in the
wards, outpatient departments and
the operating room.
Finally, the most interesting an
swers were those to the last ques
tion, “ How do you evaluate the
training given to general surgery
residents in the following sectors?”
This question concerned the prima
ry components of general surgery
which are part of the definition of
the specialty. In the majority of the
departments, the training in endos
copy, trauma, colorectal surgery,
critical care management and vascu
lar surgery was considered to be
either very good or excellent. How
ever, it was deemed only satisfacto
ry in oncology and surgical infec
tion. The evaluation of training in
head and neck surgery was particu
larly meaningful; it was judged to
be mediocre by 10 chairmen and
220
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satisfactory by 2. In only two de
partments of surgery was the train
ing in head and neck surgery
thought to be excellent.

Discussion
This study clearly shows that
general surgery continues to be a
strong basic specialty and, to quote
James B. Snow, “remains the unify
ing force in surgical practice, edu
cation and research upon which all
of the specialties of surgery de
pend.”2 All Canadian departments
of surgery have recognized the
leadership role of general surgery in
teaching, both at the undergraduate
and the postgraduate levels.
The study has also demonstrated
that, although general surgery is
proud of its role in education, re
search and clinical surgery, it pays
a high price for the assumption of
this role. General surgeons spend
more than 1 day a week in pro
grammed activities for the benefit of
residents in all surgical disciplines.
In addition, general surgeons spend
more time in other professional ac
tivities than any other specialty.
This observation has also been
made by the Council on LongRange Planning and Development
of the American Medical Associa
tion.3 In 1987 general surgeons in
the United States spent an average
of approximately 60 hours in pro
fessional activities, which is more
than all other physicians in the
medical and surgical specialties. Of
interest is the fact that this study
gives a global view of the activities
of all general surgeons in academic
centres and community hospitals.
My study has established that, at
least in the province of Quebec,
general surgeons have maintained
or increased their activity in most of
the areas identified as primary com
ponents of general surgery (e.g.,
abdomen and alimentary tract,

breast, vascular and thoracic).
Training in these areas was also
perceived as satisfactory to excel
lent by the chairmen of our 16
departments of surgery.
The situation is quite different in
head and neck surgery. It is clear
that the workload of general sur
geons has decreased over the last
10 years and that training given in
our departments of surgery is con
sidered to be mediocre by a majority
of chairmen. Therefore, the necessi
ty of keeping head and neck as a
primary component of general sur
gery should be questioned. The re
sults of this study do not seem to
justify the place of head and neck
surgery on the same level as, for
instance, vascular and thoracic sur
gery.

Conclusions
Evidence suggests that, over the
past 10 years, there has been a
further narrowing of the scope of
general surgery, but no correspond
ing changes in the range of train
ing, which has remained broad.
Given the decrease in their num
ber and the demands on their time
for teaching activities, general sur
geons should question their com
mitment, beyond a core program in
basic surgery, to the training of
surgeons going into some surgical
subspecialties.
The role of general surgeons in
head and neck surgery should be
redefined. Consideration should be
given to making head and neck
surgery only a secondary compo
nent of general surgery, thus limit
ing the scope of training.
Because advances in medical
technology will likely lead to fur
ther subspecialization and narrow
even more the practice of general
surgery, general surgeons should
promote the advances in the nonsurgical treatment of diseases that

REDEFINITION OF GENERAL
SURGERY

are part of their specialty, become
leaders in the development, by re
search, of new medical techniques
for the treatment of general surgi
cal conditions and include these
concepts in their educational pro
grams.
It is my belief that general sur
gery should be redefined. Our spe
cialty is in transition, but its defini
tion has not kept up with the
changes. For instance, we should
consider the inclusion of oncology
and critical care, two sectors where
general surgeons have been very
active during the last decade. In
addition, our definition should in
clude primary and secondary com
ponents of the specialty in order to
allow some flexibility in its content,
as the need arises. With this ap
proach, our definition could be eval
uated on an ongoing basis and
reviewed periodically.
I thank Drs. Fernand Hould and Robert
Cote, of the Regie de l’assurance-maladie du Quebec and Dr. Camille Gosselin
for their help in providing the statistical
data.
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Collagen Absorbable
Hemostat
DESCRIPTION:
INSTAT* Collagen Absorbable Hemostat is a
purified and lyophilized bovine dermal collagen.
The material, prepared as a sponge-like pad, is
lightly cross-linked, sterile, nonpyrogenic, and
absorbable. Hemostatic activity, which is an
inherent property of collagen, is largely dependent
on the basic helical structure of this protein. The
helical structure of native collagen is preserved
during the manufacture of INSTAT Absorbable
Hemostat. When collagen comes into contact with
blood, platelets aggregate on the collagen and
release coagulation factors which, together with
plasma factors, result in the formation of fibrin, and
finally in the formation of a clot.

INDICATIONS:
INSTAT Absorbable Hemostat is indicated in
surgical procedures (other than in neurosurgical,
urological and ophthalmological surgery) for use as
an adjunct to hemostasis when control of bleeding
by ligature or other conventional methods is
ineffective or impractical.

CONTRAINDICATIONS:
INSTAT Absorbable Hemostat should not be used in
the closure of skin incisions as it may interfere with
the healing of skin edges. This interference is due
to simple mechanical interposition of dry collagen
and not due to any intrinsic interference with wound
healing. It has been reported with another
absorbable collagen hemostat that, in filling
porosities of cancellous bone, collagen may reduce
the bonding strength of methylmethacrylate.
Therefore, INSTAT Absorbable Hemostat should not
be applied on bone surfaces to which prosthetic
materials are to be attached with
methylmethacrylate adhesives.

WARNINGS:
INSTAT Absorbable Hemostat is inactivated by
autoclaving. It should not be resterilized. As with
any foreign substance, use in contaminated wounds
may enhance infection.
INSTAT Absorbable Hemostat should not be used in
instances of pumping arterial hemorrhage.
INSTAT Absorbable Hemostat should not be used
where blood or other fluids have pooled or in cases
where the point of hemorrhage is submerged.
INSTAT Absorbable Hemostat will not act as a
tampon or plug in a bleeding site, nor will it close off
an area of blood collecting behind a tampon.
Only the amount of INSTAT Absorbable Hemostat
necessary to provide hemostasis should be used.
The long-term effects of leaving INSTAT Absorbable
Hemostat in situate unknown. Opened, unused
INSTAT Absorbable Hemostat should be discarded
because it cannot be resterilized.
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As with other hemostatic agents, it is not
recommended that INSTAT Absorbable Hemostat
be left in an infected or contaminated space, nor is it
recommended for use in persons known to be
sensitive to materials of bovine origin. When placed
into cavities or closed spaces, care should be
exercised to avoid overpacking INSTAT Absorbable
Hemostat as it may absorb fluid and expand and
press against neighbouring structures.

ADVERSE REACTIONS:
INSTAT Absorbable Hemostat is a collagen product.
Although several types of postoperative
complications were observed in INSTAT Absorbable
Hemostat-treated patients, none were attributed to
INSTAT Absorbable Hemostat except one case of
fibrotic reaction where INSTAT Absorbable
Hemostat involvement could not be ruled out.
Adverse reactions reported for other collagen
hemostats include hematoma, potentiation of
infection, wound dehiscence, inflammation and
edema. Other reported adverse reactions that may
be related to the use of collagen hemostats include
adhesion formation, allergic reaction, foreign body
reaction and subgaleal seroma (in a single case).
The use of microfibrillar collagen in dental extraction
sockets has been reported to increase the incidence
of alveolalgia. The possibility that all of the above
reactions may occur with INSTAT Absorbable
Hemostat cannot be excluded,

ADMINISTRATION:
INSTAT Absorbable Hemostat is applied directly to
the bleeding surface with pressure. INSTAT
Absorbable Hemostat can be cut to size. The
amount needed and the period of time necessary to
apply pressure will vary with the type and amount of
bleeding to be controlled. Hemostasis time depends
upon the type of surgery and degree of pretreatment
bleeding. It usually occurs between 2 to 5 minutes
with INSTAT Absorbable Hemostat.
INSTAT Absorbable Hemostat maintains its integrity
in the presence of blood and is not dispersed when
wet. It is easily removed from the site following
hemostasis. It is most effective when used dry.
INSTAT Absorbable Hemostat may be left in situ
whenever necessary. However, the surgeon, at his
discretion, should remove any excess of INSTAT
Absorbable Hemostat prior to wound closure.
Animal implant studies have demonstrated that
absorption and tissue reaction to INSTAT
Absorbable Hemostat are similar to those observed
with another absorbable collagen hemostatic agent.
In these studies, on visual examination, most of
INSTAT Absorbable Hemostat was found to be
absorbed within 8 to 10 weeks after implantation.

CLINICAL STUDIES:
The safety, effectiveness and handling
characteristics of INSTAT Absorbable Hemostat
were evaluated in a variety of surgical procedures.
The median time to hemostasis for INSTAT
Absorbable Hemostat was 3 minutes. Passive
Hemagglutination Assay (PHA) and Enzyme-Linked
Immunoabsorbent Assay (ELISA) methods have
been used to evaluate the immunologic potential for
INSTAT Absorbable Hemostat to produce
antibodies in patients. These assays revealed mild
elevation of antibody titers in both INSTAT
Absorbable Hemostat-treated patients and patients
treated with a collagen control hemostat, confirming
that INSTAT Absorbable Hemostat, like other
collagen hemostats, is a weak antigen.

HOW SUPPLIED:
INSTAT Absorbable Hemostat is supplied in a
sponge-like form in peelable plastic envelopes in the
following sizes:
2.5 cm x 5.0 cm (1 in. x 2 in.)
7.5 cm x 10.0 cm (3 in. x 4 in.)
The sterility of the product is guaranteed unless the
individual envelope is damaged or opened.

Safety of this product has not been established in
children and pregnant women. Therefore, INSTAT
Absorbable Hemostat should only be used when
benefit to risk clearly warrants its use.
INSTAT Absorbable Hemostat is not intended to be
used to treat systemic coagulation disorders.
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Sandostatin in the Management
of Nonendocrine Gastrointestinal and
Pancreatic Disorders: a Preliminary Study
L. Rosenberg, MD, PhD, FRCSC; R.A. Brown, MD, FRCSC, FACS
Between October 1987 and July 1990 a prospective, nonrandomized, preliminary
study was carried out to assess the efficacy of Sandostatin in treating complex
pancreatic and gastrointestinal disorders.
The study group consisted of 18 women and 12 men, ranging in age from 23 to
80 years (mean 50 years), in whom conventional medical or surgical therapy, or
both, had failed. Nineteen patients had pancreatic disease (5 had chronic
pancreatitis, 8 acute necrotizing pancreatitis and 6 pancreatic fistula). Thirteen
patients had disorders of the small intestine (7 had enterocutaneous fistula and 6
diarrhea-associated short-gut syndrome).
Sandostatin was found to be effective in the closure of pancreatic (five of six
cases) and enterocutaneous fistulas (five of seven cases), of benefit in controlling the
pain associated with chronic pancreatitis (three of five cases) and of some use in
achieving short-term control of intractable diarrhea in patients with short-gut
syndrome (five of six cases). It was of particular benefit in the management of acute
necrotizing pancreatitis.
The standard principles of surgical management must be adhered to when using
Sandostatin to treat patients with these disorders. Sandostatin can not correct
underlying problems such as pancreatic-duct obstruction, malignant disease or
unresolved sepsis.
These preliminary results justify more widespread use of Sandostatin as part of a
prospective randomized and controlled multicentre trial.
D’octobre 1987 a juillet 1990, une etude preliminaire prospective non randomisee a
ete menee afin d’evaluer l’efficacite du Sandostatin dans le traitement des affections
pancreatiques et gastro-intestinales complexes.
Le groupe a l’etude consistait de 18 femmes et 12 hommes dont Page variait de 23
a 80 ans (moyenne de 50 ans) chez qui les traitements medicaux ou chirurgicaux
conventionnels avaient echoue. Dix-neuf patients souffraient de pathologies du
pancreas (5 avaient une pancreatite chronique, 8 une pancreatite necrosante aigue et
6 une fistule pancreatique). Treize patients presentaient des affections de l’intestin
grele (7 avaient une fistule entero-cutanee et 6 une diarrhee due a une malabsorp
tion par resection intestinale etendue).
Le Sandostatin s’est revele efficace pour refermer les fistules pancreatiques (cinq
cas sur six) et entero-cutanees (cinq cas sur sept), utile pour ma triser la douleur
reliee a la pancreatite chronique (trois cas sur cinq) et d’une certaine valeur pour la
suppression de courte duree de la diarrhee rebelle chez les patients souffrant de
malabsorption par resection intestinale etendue (cinq cas sur six). II a ete
particulierement utile au traitement de la pancreatite necrosante aigu .
Les principes habituels du traitement chirurgical doivent etre respectes quand on
utilise le Sandostatin pour traiter les patients atteints de ces maladies. Le
Sandostatin ne peut corriger les problemes sous-jacents tels que l’obstruction d’un
canal pancreatique, une tumeur maligne ou une sepsie non jugulees.
Ces resultats preliminaires justifient l’emploi plus repandu du Sandostatin a
l’interieur d’une etude multicentre, prospective, randomisee et controlee.

he clinical importance of gas
trointestinal polypeptide hor
mones became apparent with the
description of the Zollinger-Ellison
syndrome, in which a gastrin-secret
ing tumour of the pancreas was
found to produce severe, intractable
peptic ulceration and diarrhea. With
the subsequent introduction of radi
oimmunoassay, measurement of the
serum levels of gastrin and other
peptides became possible. One such
hormone, somatostatin, is widely
distributed in the central nervous
system, gastrointestinal tract and
pancreas. It not only regulates neu
roendocrine physiology, but also
appears to have hormonal, para
crine and neurotransmitter activity .1
Most of the biologic actions of
somatostatin are inhibitory in na
ture.2 In the pancreas, somatostatin
inhibits basal and both secretin- and
cholecystokinin (CCK)-stimulated
pancreatic exocrine secretion. In
the intestine, motility and the secre-
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tion of water and electrolytes are
inhibited, but absorption of water
and electrolytes is increased. Soma
tostatin also causes a substantial
reduction in splanchnic blood flow.
These actions suggest that soma
tostatin might be of use in the
management of nonendocrine pan
creatic and gastrointestinal disor
ders, such as entero- and pancreaticocutaneous fistulas, diarrhea
states and pancreatitis. However,
the potential therapeutic benefits of
somatostatin are limited by its short
serum half-life (2 to 3 minutes).
Sandostatin (octreotide acetate;
Sandoz Canada Inc., Dorval, Que.)
is a synthetically produced octapeptide of somatostatin with a similar
spectrum of biologic activity and a
serum half-life of 2 to 3 hours. It
can be given subcutaneously and is
biologically active for up to 12
hours.3 Sandostatin has been used
successfully to control the hormon
al manifestations of neuroendocrine
tumours.45 In studies of long-term
use in the treatment of acromegaly,
it has been associated with only
minimal side effects.26 A minority of
patients have experienced abdomi
nal bloating, diarrhea and pain at
the injection site.
This study was designed to as
sess the benefit of Sandostatin to
patients with nonendocrine gas
trointestinal and pancreatic disor
ders.

Patients and Methods
Between October 1987 and July
1990, 30 consecutive patients (18
women, 12 men) were enrolled in a
prospective, nonrandomized, pre
liminary study of the efficacy of
Sandostatin. The sole criterion for
admission to the study was the
failure of conventional medical or
surgical therapy.
The patients ranged in age from
23 to 80 years (mean 50 years).
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There were 19 cases of pancreatic
disease (5 of chronic pancreatitis, 8
of acute necrotizing pancreatitis
and 6 of pancreatic fistula). There
were 13 patients with small intesti
nal disorders (7 with enterocutaneous fistula and 6 with diarrheaassociated short-gut syndrome).
Chronic Pancreatitis

The mean age of the five patients
with chronic pancreatitis was 35
years. The disease was idiopathic in
one patient, and it was due to
alcohol abuse in the four others.
Two patients were known still to be
imbibing alcohol. Two of the five
patients suffered from insulindependent diabetes and maldiges
tion. All had severe chronic pain
and all were taking narcotic medica
tion at the time of entry into the
study. The mean duration of symp
toms was 8 years. Four patients had
undergone previous pancreatic sur
gery (resection plus a drainage pro
cedure) for pain control, but the
results were short-lived in each
case. The indication for the use of
Sandostatin was persistent pain.

In two of the cases, already alluded
to, the fistula was the sequel to an
episode of acute necrotizing pan
creatitis. In the remaining four
cases, the fistula developed after an
elective pancreatobiliary surgical
procedure. All fistulas were well
established for at least 4 to 5 days
before Sandostatin was started, and
in all cases the fistula output was
more than 200 mL/d.
Enterocutaneous Fistula

Seven patients with enterocu
taneous fistulas had a mean age of
48 years. In one case each, fistulas
were associated with Crohn’s dis
ease and intraperitoneal trauma.
The remaining five cases occurred
after elective or semielective sur
gery. Among these five patients,
one had had previous radiotherapy
for bladder cancer and one was on
high-dose steroids for a vasculitis.
The remaining three patients were
found to have intra-abdominal ma
lignant tumours. The output of
these fistulas was greater than 200
m L/d. The patients were fully in
vestigated before the institution of
Sandostatin.

Acute Necrotizing Pancreatitis
Short-Gut Syndrome

The mean age of the eight pa
tients with acute necrotizing pan
creatitis was 59 years. The apparent
causes of the disease were: alcohol
(one), familial hyperlipidemia (one)
and gallstones (six). The mean Ranson score7 for these eight cases was
5.4 ± 0.8, and in five the disease
had progressed to pancreatic and
peripancreatic abscess formation.
Two patients subsequently had pancreaticocutaneous fistulas. The indi
cation for Sandostatin in these pa
tients was a persistent toxic state.
Pancreatic Fistula

The six patients with pancreatic
fistulas had a mean age of 59 years.

The six patients with short-gut
syndrome had a mean age of 55
years. Two patients had Crohn’s
disease and in the remaining four
patients an ischemic event precipi
tated the syndrome. Two of the six
patients had ileostomies. The indi
cation for the use of Sandostatin in
these patients was intractable diar
rhea.
All patients were admitted to the
Division of General Surgery at the
Montreal General Hospital and were
evaluated for entry into the study
by one surgeon. Informed consent
concerning the nature of the treat
ment, together with Health Protec
tion Branch approval, was obtained

SANDOSTATIN

from each patient. Routine blood
work, including complete blood
count, SMA-16 biochemical analysis
and serum amylase determinations
were done as necessary, but at least
twice weekly.
Treatment was begun with 50 ng
of Sandostatin subcutaneously
every 12 hours. In patients who did
not demonstrate an objective re
sponse to the drug, the dose was
raised incrementally up to 100 tig
three times a day.

Results
There were no serious complica
tions from Sandostatin administra
tion in this series. Several patients
complained of some discomfort at
the injection site, one patient com
plained of severe nausea after pro
longed use, and two patients with
short-gut syndrome reported ab
dominal cramping and bloating.
There were no significant
changes in blood count, liver func
tion test results, serum glucose,
blood urea nitrogen, creatinine, al
bumin and total protein levels in
these patients during treatment.

creatitis, was treated with Sando
statin for 2 years. During that time
she was completely free of pain but
had to progressively increase the
dosage to maintain the analgesic
effect. Eventually the side effect of
nausea became too uncomfortable,
the Sandostatin had to be discontin
ued and she reverted to her premorbid condition. A third patient, a
man with alcohol-related disease,
has been pain-free on Sandostatin
for 1 year and has not required an
increase in dosage.
The fourth patient, a woman with
alcohol-related disease, had some
relief from meal-stimulated pain and
began to gain weight. She has been
able to cease taking narcotic medi
cation.
The last patient, a man with
alcohol-related disease, underwent
pancreatic resection and drainage
but never achieved a pain-free state.
However, he had an excellent result
from Sandostatin within 48 hours
of administration. He was main
tained on the drug for 2 months.
He has since remained pain-free and
off all analgesic medications for 18
months.

After the initiation of Sandostatin
therapy, the mean output of the
pancreatic fistulas decreased by
58% ± 6% on the day 1 of treat
ment. The duration of treatment
ranged from 10 days to 2 months,
and the median time to closure was
6 days. Sandostatin was continued
for 3 days after fistula closure. In
one patient, administration of San
dostatin decreased fistula output by
90%, but closure and healing did
not occur for 3 months. A sinogram
in this patient showed a communi
cation between the pancreas and
the stomach.
Amylase remained present in sub
stantial concentrations in the fistula
drainage during Sandostatin admin
istration, but all fistulas closed
without requiring a surgical proce
dure, and there were no deaths.

Acute Necrotizing Pancreatitis

Enterocutaneous Fistula

All the patients in this group had
unresolved sepsis and hemodynamic
instability. Sandostatin was institut
ed only after at least one operative
procedure. It was then maintained
until the patients were taking food
by mouth. At the time Sandostatin
was instituted, all patients were
being cared for in an intensive care
unit. Within 24 hours of commenc
ing therapy, pulse rate and tempera
ture declined markedly in four of
the eight patients.
The mean number of surgical
procedures required was 2.7 and
sepsis resolved in all eight patients
under treatment. There were no
deaths, but four secondary compli
cations occurred in three patients.

The output of enterocutaneous
fistulas decreased 59% ± 7% within
48 hours of instituting Sandostatin
therapy. The duration of treatment
ranged from 7 days to 21 days with
a mean time to closure of 6 days.
In two cases, administration of
Sandostatin failed to achieve fistula
closure. In the first patient, the
fistula had developed as a result of
a leaking anastomosis following re
section to relieve a small-bowel ob
struction produced by advanced
ovarian cancer. Further investiga
tion after the fistula failed to close
indicated that the bowel was ob
structed distally, probably by a
metastatic implant. The patient died
shortly thereafter. The second pa-

There were two cases of pancreaticocutaneous fistula and two
pseudocysts; one pseudocyst re
solved spontaneously and the other
required urgent surgery because of
spontaneous rupture.
Pancreatic Fistula

Chronic Pancreatitis
The duration of treatment ranged
from 1 week to 2 years. Complete
control of pain was achieved in
three of the five patients, and they
were able to withdraw completely
from their narcotic medication. In
all but one instance, Sandostatin
was self-administered at home. In
this particular case, the patient,
who suffered from drug and alcohol
abuse, had good relief of pain with
in 36 hours of commencing Sando
statin, but complained of intense
intra-abdominal cramping shortly
after administration. The drug was
therefore discontinued.
The second case, a woman with
idiopathic chronic relapsing pan
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tient was on chronic steroid therapy
for a vasculitis at the time of an
emergency distal small-bowel and
cecal resection for a distal ileal
perforation associated with an in
flammatory mass. A primary anasto
mosis was performed and the anas
tomosis did not heal. The resulting
fistula required surgical interven
tion for closure. This patient subse
quently died of multiorgan system
failure.
Short-Gut Syndrome

After the initiation of Sandostatin
therapy, intractable diarrhea de
creased by 73% ± 7% in five of the
six patients. Sandostatin was not
well tolerated by two patients be
cause of abdominal cramping and
bloating. Although Sandostatin was
very effective in controlling the di
arrhea, these two patients refused
further treatment, and the drug was
discontinued. Two patients were
treated successfully as outpatients
for approximately 6 weeks, at
which time adaptation of the intes
tine permitted Sandostatin to be
stopped without the recurrence of
intractable diarrhea. One further pa
tient died as a result of rupture of
an unsuspected abdominal aortic
aneurysm while still in hospital.

Discussion
Over the past decade somato
statin has been advocated for the
treatment of a variety of complex
endocrine and nonendocrine disor
ders of the pancreas and gastroin
testinal tract. Several reports have
described the usefulness of somato
statin in controlling upper gastroin
testinal hemorrhage, in particular
that associated with portal hyper
tension. In addition, somatostatin
has been used to control secretory
diarrhea caused by several diseases,
especially that due to vasoactive
226
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intestinal polypeptide (VlP)-secreting tumours.8
The clinical usefulness of native
somatostatin is hindered by a very
short half-life; a continuous intrave
nous infusion is necessary for effec
tiveness. Sandostatin, however, is a
long-acting analogue of somato
statin and its biologic activity lasts
up to 12 hours after subcutaneous
administration.9 It has been used
effectively to control the hormonal
manifestations of neuroendocrine
tumours of the pancreas and gas
trointestinal tract.
Chronic Pancreatitis

A major component of the mor
bidity associated with chronic pan
creatitis is related to the debilitation
caused by severe pain. The cause of
the pain is probably multifactorial,
but may be related to an inflamma
tory neuritis, secretion against an
obstructed pancreatic duct or pan
creatic ischemia. We cannot predict
who will suffer from intractable
pain, but we do know that the
disease will burn itself out in 30%
to 40% of patients.
The available treatment modali
ties, which include pancreatic en
zyme replacement, narcotic analge
sia, celiac ganglion blockade, drain
age procedures and pancreatecto
my, produce results that are far
from satisfactory. None of these
treatments is uniformly effective,
and total pancreatectomy, in partic
ular, will create a brittle diabetic
state.
The effectiveness of Sandostatin
in pain management may relate to
three mechanisms of action: inhibi
tion of pancreatic function, which
would abrogate secretion in an ob
structed duct; enhancement of
blood flow — although Sandostatin
decreases mesenteric blood flow,
there is reason to believe it may
increase intrapancreatic blood flow;
and, finally, a central analgesic ef

fect of Sandostatin in the brain.
In this study we demonstrated a
beneficial effect of Sandostatin in
three of five patients with chronic
pancreatitis and pain. Those pa
tients who did not benefit continued
to imbibe alcohol. One may ques
tion whether abstinence from alco
hol was itself responsible for the
beneficial results observed in the
three cases; however, the patients
had not been drinking for some
time prior to entry into this study,
yet they still complained of severe
pain.
Patients who would derive some
benefit from the drug, did so as
early as 48 hours after instituting
therapy. It is also noteworthy, that
during long-term use in one patient,
tachyphylaxis developed, and the
dose of Sandostatin had to be in
creased progressively to achieve
pain relief. However, the develop
ment of dose-related side effects,
such as nausea and bloating, result
ed in withdrawal of the drug. These
findings, if borne out in a larger
study, could mean that Sandostatin
will not prove effective during long
term therapy for this, and perhaps
other, disease states.
Acute Necrotizing Pancreatitis

Acute necrotizing or hemorrhag
ic pancreatitis is a severe form of
acute pancreatitis. Several etiolo
gies have been identified, but the
exact pathophysiologic mechanisms
involved are poorly understood.
Ranson and Spencer7 have pro
posed a number of clinical parame
ters, which, when considered to
gether in relation to the time of
onset of an attack of acute pan
creatitis, form a useful prognostic
index of outcome. A Ranson score
of greater than 4 to 5 is associated
with severe disease and at least a
40% mortality. Amurawaiye and
Brown10 have reported recently that
the death rate from acute hemor-
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rhagic pancreatitis treated at the
Montreal General Hospital between
1956 and 1985 remained essentially
unchanged at 50%.
The patients in the current study
were cared for in the same institu
tion by the same senior surgical
staff. Although the number of pa
tients that we have treated to date
is small and it may be premature to
draw any definitive conclusions, it
appears that the death rate in this
very sick group of patients has been
reduced substantially (to 0%) with
the introduction of Sandostatin.
Of considerable interest was the
clinical observation that pulse rate
and temperature were both dimin
ished markedly in half the patients
within 24 hours of instituting San
dostatin therapy. It remains to be
determined whether this effect was
due to the direct inhibition of pan
creatic enzyme leakage, which in
itself may have contributed to the
continued toxic state of the pa
tients, or whether the improvement
was indirect by means of a cyto
kine-mediated mechanism.
Several small clinical trials have
been reported demonstrating the
effectiveness of somatostatin treat
ment for pancreatitis.1112 The re
sults of these studies are open to
question because the patients stud
ied had only mild edematous pan
creatitis, usually a self-limiting dis
ease. A multicentre double-blind
clinical trial, evaluating the effec
tiveness of a somatostatin analogue,
failed to demonstrate any definite
therapeutic benefit.13
Experimental studies to examine
the role of Sandostatin in the treat
ment and prophylaxis of pancreati
tis, using different models, seem
justified. In particular the timing of
when Sandostatin is introduced
needs to be addressed in view of the
report by Metrakos, Rosenberg and
Fried,14 which suggests that pre
treatment of rats with Sandostatin
produces a more severe form of

pancreatic injury in the ceruleininduced model of pancreatitis.
Pancreatic Cutaneous Fistula

Pancreatic cutaneous fistulas can
he a serious complication of intra
abdominal trauma, acute pancreati
tis and surgical procedures con
ducted on or in the vicinity of the
pancreas. Most of these will heal in
time with conservative medical man
agement, but many continue to
drain for weeks.
Numerous treatments have been
applied to decrease fistula output or
to hasten healing, including cholin
ergic agents, carbonic-anhydrase in
hibitors and glucagon, but each has
proven inadequate.
Hild and associates15 found that a
somatostatin infusion led to suc
cessful closure of three pancreatic
fistulas. Pederzoli and colleagues16
found that seven of eight pancreatic
fistulas closed within 12 days of
treatment with intravenous hypera
limentation and somatostatin infu
sion. This was much better than
with intravenous hyperalimentation
alone. Cavagni and colleagues17 re
ported similar good results in 24 of
28 patients, achieving closure with
1 week of somatostatin infusion
therapy. Rosenberg and associates18
reported the successful use of San
dostatin to achieve healing of a
pancreatic cutaneous fistula associ
ated with a pancreatic allograft.
The results from this study dem
onstrate, that in appropriately se
lected cases, Sandostatin can be a
very effective means of achieving
fistula closure. Sandostatin prompt
ly inhibited pancreatic fistula out
put, with a significant decrease ob
served for all cases within the first
24 hours. The median time to clo
sure was 6 days. This is similar to
the outcome achieved by Prinz,
Pickleman and Hoffman19 who re
ported a decrease in fistula output
in five of five patients with complete

healing in three. The benefit of
Sandostatin was perhaps greatest
for the two patients who were
placed on a normal diet and dis
charged early from hospital and
who then continued to self-administer Sandostatin at home.

Enterocutaneous Fistula

In this study we demonstrated
that Sandostatin inhibited enterocu
taneous output, reducing it subs
tantially within 48 hours. Five of
seven fistulas closed spontaneously
in an average of 6 days. In each of
the two remaining cases there were
reasons for persistence of the fistu
las. In one, the patient was on
long-term high-dose steroid medica
tion, and in the second case, paten
cy of the fistula was maintained by
a distal metastatic implant in the
bowel wall that produced a partial
obstruction. Both these patients
died.
The use of Sandostatin in the
treatment of small-bowel fistulas
has been reported previously.20 21 Di
Constanzo, Cano and Martin22 re
ported that somatostatin infusion
was successful in closing persistent
fistulas in five of six patients, all
within 24 hours of initiating thera
py. In a series of 27 patients with
postoperative small-bowel enterocu
taneous fistulas,21 21 patients (77%)
had spontaneous closure after a
mean of 5.8 days. A mean reduction
of 55% in fistula output was seen in
the first 24 hours of treatment.
Conservative treatment with intra
venous hyperalimentation usually
results in similar closure rates (60%
to 70%)2324 but requires prolonged
hospitalization for a month or lon
ger. In all instances in which treat
ment with Sandostatin was unsuc
cessful, some mechanical cause for
failure, such as distal obstruction or
anastomotic disruption, was found
on further investigation; all these
CJS, VOL. 34, NO. 3, JUNE 1991
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patients required further surgical
intervention for effective closure of
their fistulas.
Although Sandostatin is unlikely
to increase the proportion of fistu
las that close without surgical inter
vention, evidence suggests that it
greatly accelerates closure of fistu
las amenable to conservative thera
py and reduces fistula output in
most patients. Thus, Sandostatin
treatment should reduce the mor
bidity associated with high-output
fistulas and significantly reduce the
period of hospitalization.
Short-Gut Syndrome

We treated six patients with
short-gut syndrome. Four of these
had a gastrointestinal tract that was
in continuity, and two had ileosto
mies. This group of patients proved
the most difficult to treat. Although
intractable diarrhea was controlled
in five patients, the therapy was
poorly tolerated and Sandostatin
was discontinued by two patients
within 1 week of commencing treat
ment. Because of the nature of the
side effects (bloating and cramping)
one can speculate as to whether
Sandostatin caused bowel ischemia,
secondary to a decrease in mesen
teric blood flow to bowel that was
perhaps already somewhat compro
mised. Adequate dosage of Sando
statin also was difficult to achieve
compared with the other patient
groups treated in this study. No
patient in this group was main
tained for a long period on Sando
statin, so we could not assess its
long-term efficacy.
Cooper and colleagues25 have re
ported their experience with highoutput ileostomy diarrhea in which
somatostatin analogue proved of
benefit. Three patients had marked
decreases in output and prolonga
tion of small-bowel transit time dur
ing somatostatin treatment. Howev
er, long-term outpatient treatment
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of these patients proved less suc
cessful. Dharmsathaphorn and col
leagues26 reported a similar result,
but did not use Sandostatin.
General Comments

In summary, we found Sando
statin to be effective in the closure
of pancreatic and enterocutaneous
fistulas, of benefit in controlling the
pain associated with chronic pan
creatitis and of some use in achiev
ing short-term control of intractable
diarrhea in patients with short-gut
syndrome. Sandostatin was of par
ticular benefit in reducing the mor
tality associated with acute necro
tizing pancreatitis. It was of partic
ular benefit in the management of
acute necrotizing pancreatitis.
The standard principles of surgi
cal management must still be ad
hered to when using Sandostatin to
treat patients with these disorders.
Sandostatin can not correct under
lying problems such as pancreaticduct obstruction, malignant tu
mours or unresolved sepsis.
Our preliminary results justify
more widespread use of Sandostatin
as part of a prospective, randomized
and controlled multicentre trial.
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ment. The text is well referenced and is
enhanced by a figure depicting the
pathophysiology of the syndrome, a
flow chart on symptoms, diagnosis and
treatment and a concrete conclusion to
each chapter. Editorial commentary
provides a thoughtful overview and
highlights points of emphasis.
1 have a few criticisms. First, there is
some overlap in subject matter and a
differing philosophy between the au
thors. Thus, both subtotal para
thyroidectomy and total parathyroidec
tomy with autotransplantation are rec
ommended for familial hyperparathyroi
dism. There is no mention of medical
management for patients with the pseu
do Zollinger-Ellison syndrome. I cannot
endorse the recommendation of total
thyroidectomy for ophthalmopathy of
Graves’ disease. Surgery apparently
plays a much greater role in the control
of the hypermetabolic states in Sweden
than in the United States where radioac
tive iodine is the dominant mode of
therapy. The diagnostic approach out
lined for hyperparathyroidism seems
unnecessarily exhaustive. I rely heavily
on an inappropriate level of the intact
immunoparathyroid-hormone assay and
would restrict localization studies to
patients who undergo reoperation.
The binding and paper are of high
quality. By reducing the type size, the
authors have been able to double the
volume of information yet maintain ap
proximately the same number of pages
as the first edition.
This monograph clearly covers the
current state of the art in surgical
endocrinology. It should be regarded as

the consummate text for all those con
cerned with endocrinologic issues.

BOOK REVIEWS
continued from page 206

mours, stimulation and suppression
tests, localization of gastroenteropancreatic (GEP) tumours and general con
cepts of treatment and anesthetic con
siderations in endocrine surgery. The
last chapter is particularly appropriate
because of the associated metabolic
derangements.
The clinical syndromes are subdivid
ed according to their hormonal basis.
Part one, on amines, includes chapters
on the following: hypermetabolic syn
drome, hyperthyroidism; the panic syn
drome, pheochromocytoma; and the
carcinoid syndromes. Part 2 on poly
peptides covers endogenous hyperinsulinism, the diabetes-dermatitis syn
drome, somatostatinoma (the inhibitory
syndrome), the ulcerogenic (ZollingerEllison) syndrome, pseudo ZollingerEllison, Verner-Morrison or VIPoma
and hypercalcemic syndromes, multiple
endocrine adenopathy type 1 (MEA1),
medullary thyroid carcinoma and multi
ple endocrine neoplasia type 2 syn
dromes, and the ectopic hormone (paraendocrine) and pituitary syndromes.
Part 3 on steroids comprises chapters
on Cushing’s syndrome, Conn’s syn
drome and masculinizing and feminiz
ing syndromes.
The text is well balanced and indi
cates the rarity of some syndromes; for
instance 200 patients are reported with
VIPoma syndrome and 20 patients with
somatostatinoma. Each chapter con
tains a comprehensive, yet concise, de
scription of the clinical syndrome with
detailed information on its biologic ba
sis, diagnosis and perioperative, in
traoperative and postoperative manage

Colin G. Thomas Jr., MD
Department of Surgery
The University of North Carolina
Chapel Hill, NC
27599-7210

CANCER TREATMENT. 3rd ed. Edit
ed by Charles M. Haskell. 1098 pp.
Illust. W.B. Saunders Company/Harcourt Brace Jovanovich, Inc., Philadel
phia. 1990. Price not stated. ISBN 07216-2344-1
This is a useful textbook for providing
an overview of cancer therapy, particu
larly in medical oncology. It is well
written and easily understood. It begins
with a general section describing the
fundamentals of chemotherapy, immu
notherapy and radiotherapy.
The main body of the text focuses on
a complete overview of each tumour
type. The discussion of the surgical
problems associated with the disease is
necessarily limited, and other sources
would be necessary for the surgeon to
establish all the surgical principles
necessary to treat some of the tumours.
The text also deals with all the prob
lems associated with cancer, including
the handling of the patient with metastases from an unknown primary and an
appropriate section on supportive care

continued on page 250
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CANADIAN SOCIETY FOR VASCULAR SURGERY
SOCIETE CANADIENNE DE CHIRURGIE VASCULAIRE

Presidential Address, 1989. The Future
of Vascular Surgery in Canada
Peter D. Fry, MD, FRCSC, FRCS(I)
There has been an explosion of technology in the field of vascular surgery in the
latter half of the 1980s. Laser procedures, atherectomy catheterization, intra-arterial
stenting and balloon angioplasty have all been demonstrated, with varied degrees of
success, to play a role in the management of the patient with vascular disease.
Vascular surgeons must be wary of unproven devices that come complete with
extravagant claims of success. But, they should also show an interest in new
technology as it comes along and should be prepared to become involved in its
scientific evaluation. Some of these techniques, perhaps in a more refined state, will
play an important role in patient care in the future.
Vascular surgeons in Canada must also develop their interests and knowledge of
circulatory hemodynamics by committing themselves to using duplex scanning
equipment in their diagnostic vascular laboratories. Such laboratories must be
staffed by thoroughly trained directors and technologists, and to do this, we must
look to making vascular laboratory training part of the requirements for fellowship
in the Royal College of Physicians and Surgeons of Canada.

Au cours de la deuxieme moitie des annees 80, on a assiste a une explosion
technologique dans le domaine de la chirurgie vasculaire. Les interventions au laser,
l’atherectomie par catheterisme, la pose de manchons de soutien intra-arteriels et
l’angioplastie par ballonnet ont toutes demontre, avec des succes divers, qu’elles
pouvaient jouer un role dans le traitement des vasculopathies. Le chirurgien
vasculaire doit se montrer prudent devant des instruments auxquels on attache des
allegations extravagantes de succes. II doit neanmoins s’interesser aux nouvelles
technologies, au fur et a mesure qu’elles se presentent, et etre pret a participer a
leur evaluation scientifique. Certaines de ces techniques auront un role important a
jouer plus tard, possiblement apres raffinements, dans le traitement des malades.
Le chirurgien vasculaire canadien doit developper son interet et ses connaissances dans le domaine de l’hemodynamie circulatoire en s’impliquant dans 1’utilisation
d’equipement de scintigraphie bidimensionnelle. Les laboratoires de diagnostic
vasculaire doivent pouvoir compter sur des directeurs et des techniciens bien
entraines et, a cette fin, on doit voir a inclure une formation en laboratoire de
medecine vasculaire dans les exigences du «fellowship» du College royal des
medecins et chirurgiens du Canada.
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have chosen the topic “The fu
ture of vascular surgery in Cana
da” for my address, because over
the last 5 years I have been aware
of what appears, at least to me, to
be a significant change in our field.
I also chose this topic because a
presidential address is a unique op
portunity to make a statement,
right or wrong, without wondering
whether your p values will be statis
tically significant or if the editorial
board of some journal is going to
find your comments appropriate to
their individual style and format.
If what I say is not accepted, it
will soon be forgotten and Dr. Lye,
the Society’s next president, will
grapple with his own ideas for next
year. Most of all, I chose this topic
because 1 am deeply and genuinely
concerned that if our Society and
our members do not take a more
active role in developing and foster
ing new ideas and new techniques
in Canada we may be denying those
who follow us the opportunity of
being involved in the broad scope of
management and care of patients
with vascular disease.
This statement is not an endorse
ment of new technologic advances
or their success. I simply want to
see us as a Canadian society of
surgeons becoming more involved
in development and evaluation.
In the last 5 years there has been
an explosion of technology in the
field of vascular surgery, the like of
which we have never seen before
and may never see again. The new
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technology has come predominantly
from the United States, Japan and
Europe and has been fuelled by an
upbeat market and a prodigious
amount of venture capital. For ex
ample, companies marketing laser
devices germane to our field have
expanded from the 5 or 6 that
existed in 1987 to 45 or 50. There
are over a hundred different
atherectomy devices patented in the
United States. Many large medical
corporations are rapidly diversifying
into the field of prosthetic grafts,
lasers, atherectomy catheters and
balloons, or else are simply acquir
ing smaller companies whose pro
ducts they wish to add in order to
enhance their market share. Clear
ly, as happens in many other rapid
industrial overdevelopments, there
will be a market shakedown, and
ultimately only the best will survive.
This is why, if we vascular surgeons
decide to adopt any of these devel
opments, we must become efficient
consumers, because we are respon
sible to the public purse.
I believe that there will also be a
shakedown in medicine between the
various specialties that have shown
interest in treating patients who
suffer from peripheral arterial dis
ease. These include cardiologists,
interventional radiologists and vas
cular surgeons. When laser courses
started in the United States, the
majority of registrants were cardi
ologists; later radiologists and just
a few vascular surgeons became
interested. Fortunately, this ratio
has swung in our favour so that at
the Second Laser Congress in Ari
zona in 1989 and at many courses
the majority of registrants are now
vascular surgeons.
Should a busy vascular surgeon
be concerned or sensitive to the
issue of cardiologists or radiologists
conducting the majority of endovas
cular procedures? I believe that our
field is changing rapidly and will
continue to change over the next
232
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several years and that we must at
least be involved in endovascular
procedures. If these procedures are
lost to vascular surgeons, it is likely
that, as proven by history, they will
be lost forever. There are many
examples of this in the surgical
disciplines in Canada.
Have you ever picked up a jour
nal of 20 to 30 years ago and
recognized papers or editorials dis
cussing the possibilities of what
was then a new idea, a new tech
nique or a new treatment only to
realize that they were talking about
a procedure or treatment that in
your own practice has become al
most a standard and everyday pro
tocol? Imagine, then, whether a
surgeon in 30 years’ time will have
exactly the same perspective about
some of the following topics that
have been culled from vascular
meeting programs in the last 6
months; then ask yourself whether
we are really on track in Canada?

Current Topics at Vascular
Meetings
• Endoscopic intravascular sur
gery removes intraluminal flaps,
dissections and thrombus.
• Intraluminal sutureless graft
replacement of the descending and
thoracoabdominal aorta — a
12-year experience.
• A balloon expandable intravas
cular stent for obliterating experi
mental aortic dissection.
• Expanded indications for las
er-assisted balloon angioplasty in
peripheral arterial disease.
• Balloon angioplasty of iliac,
femoral and inguinal arteries, per
cutaneous and intraoperative strate
gies and techniques.
• Percutaneous balloon angio
plasty procedures — no longer a
spectator sport for the surgeon.
• New stenting repair for nut
cracker syndrome (mesoaortic com
pression of the left renal vein).

• Adjunctive use of balloon dila
tation catheter during vascular re
constructive procedures.
• Intraoperative colour flow im
aging of difficult arterial recons
tructions and intraoperative angioscopy in infrainguinal bypasses.
It is not by chance, of course,
that Edward Diethrich is the Ed
ward’s Lecturer this year. His inter
est, knowledge and development of
laser technology is recognized
world-wide. He afforded us, in his
lecture yesterday, an excellent in
sight into what we may be able to
offer patients in the future. We all
know that this whole area of sur
gery is extremely controversial.
Clearly, there are some glaring dif
ferences between what Dr. Die
thrich is achieving at the Arizona
Heart Institute and what we may or
may not be able to do in Canada.
First, I believe that it is unlikely
that anyone in Canada will ever
achieve the technologic supremacy
of the Arizona Heart Institute in
terms of utilizing the best imaging
systems with specially designed op
erating tables in a dedicated operat
ing suite, where the expense of
using several different endovascular
devices on the same patient is not a
serious financial burden to the hos
pital. Second, Dr. Diethrich’s suc
cess, at least in the relatively short
term, of treating superficial femoral
artery occlusion will not be repro
ducible in Canada because of our
technologic disadvantage, the inher
ent costs and our lack of experi
ence. This, in turn, will encourage
us to maintain our conservative
approach to the selection of pa
tients with occlusion of the superfi
cial femoral artery, few of whom
allegedly require surgery for claudi
cation.
At the University Hospital in Van
couver we have had some experi
ence with laser-assisted balloon an
gioplasties, but hardly enough for
discussion. Our results are certainly
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not comparable to those of the
Arizona Heart Institute, and I
would be misleading you if I
claimed that it was a routinely suc
cessful form of treatment. However,
anyone who has carried out a laser
procedure and has seen the patient
a year or so later with excellent
pulses after having undergone a
minimal procedure cannot help but
be excited by its potential. To the
detractors of these techniques who
claim that a bypass for occlusion of
the superficial femoral artery is
more durable, I say, without ques
tion, you are right! However, we
must bear in mind that the vasculopath with such an occlusion is
quite likely: (a) to continue to
smoke, thus affecting graft patency;
(b) to have angina, which may limit
activity and the ability to walk in
future years and (c) therefore, per
haps, not mind too much if the
endovascular procedure does fail
and the vessel occludes 2 to 3 years
later, so long as failure does not
exclude the possibility of a bypass.
The ability to resolve claudication
in a moderate-risk patient with a
minimal low-risk procedure is one
that perhaps should not be over
looked or downplayed. Remember,
too, that we are about 2 years into
clinical evaluation of this technolo
gy. I firmly believe that in 10 years
we will look back in awe at the
crude appliances we are using now
and that we can anticipate much
better results in the future with
more refined technology.
So, as someone who has experi
enced the concern of perforating an
artery with a laser probe, the frus
tration of seeing a successful laser
procedure fail 24 hours later but
the rewards of seeing some patients
ecstatic to be free of claudication 18
months after a laser procedure per
formed percutaneously or through
a small groin incision I believe we
must continue to develop and im
prove this technique. From a histor

ical perspective, and perhaps to
imply some analogy to this topic, it
is interesting to recall the com
ments made by Dr. Dwight Harkin'
in reference to the first and fre
quently disastrous attempts at mi
tral valvuloplasty. He asked himself,
“Now what does one have to have
to have a licence to do something
that has never been done before?”
and answered, “Well you must have
a definitive diagnosis and an incura
ble problem. Then, if you have any
rational concept of how to attack
this condition, you have a right to
try to do so.” Unfortunately, several
of his valvuloplasty patients died.
One day after a bad run, he with
drew to his bed for a few days. An
inquiring friend dropped by to see
how he was and asked if he was
feeling pretty bad. His wife replied,
“Yes he certainly is. He says he has
other ways of making a living and
supporting his family. He is going
to have nothing more to do with
heart surgery.”
He did, of course, go on to
develop a successful approach to
valvuloplasty. We can all relate to
his sentiments, but could there be
an analogy between the new en
dovascular technology and the val
vuloplasty that he was attempting
to achieve in those early years?
Before leaving this area, let us
take a quick look at the initial
levels of interest and the differences
between the United States and Can
ada with lasers and interventional
devices.
A recent questionnaire sent to 23
hospitals in the United States and
40 hospitals in Canada was directed
specifically to vascular surgeons.

The centres chosen were random
choices of university and communi
ty hospitals (Table I).
In Canada, 25% of hospitals
polled were either involved with
laser vascular procedures or actively
pursuing this area; 20% were com
munity and 80% university centres.
In the United States, the level of
interest was 47%. Of these 72%
were community hospitals, which
were much more involved than uni
versity hospitals at 28%. This prob
ably reflects the relative ease with
which community hospitals are able
to acquire new technology and
funding in a competitive arena and
privatized health care compared
with the university centres and
county hospitals. Similarly 43% of
Canadian hospital administrators
expressed active interest compared
with 70% of American hospital ad
ministrators in terms of developing
hospital-based endovascular pro
grams.
The question regarding interest
in a dedicated or a multi-user sys
tem revealed a preference for multi
user laser equipment in 92% of
Canadian hospitals compared with
55% in the United States. This
probably reflects two facts: first,
that funding is easier to achieve in
Canada if several divisions get to
gether to share capital and operat
ing costs; second, that the volume
of cases carried out in several US
centres can justify a dedicated sys
tem efficiently utilized by one divi
sion. The majority, 80% of sur
geons polled in both countries, be
lieved that the vascular surgical
specialist should be the primary
care physician responsible for as-

T able 1. Level o f In te re st in Laser V ascu la r Procedures
Institution
Canada active pu rsu it
C om m u nity
U niversity
U nited S tates active pu rsu it
C om m u nity
U niversity

N u m b e r/to tal questioned

%

1 0 /4 0
2
8
1 1 /2 3
8
3

25
20
80
47
72
28
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sessing the need for an endovascu
lar procedure, investigating the pa
tient and being actively involved in
the conduct of the procedure, and
handling any sequelae thereof.
As to where the endovascular
procedures should be carried out,
again the majority view was that
facilities be available both in radiol
ogy and the operating-room suite,
according to the specific needs of
the patient.
Of interest was the response to
the question, what percentage of
patients who would otherwise be
candidates for a femoropopliteal by
pass would polled surgeons consid
er for a laser or other endovascular
procedure. Surgeons in the United
States quoted an average of 25% of
such cases, Canadian surgeons
quoted less than 12%. In practice, I
believe the figure is approximately
4%.
Finally, 55% of polled surgeons
felt that endovascular procedures
should be carried out by a joint
team of vascular surgeon and inter
ventional radiologist whether per
formed percutaneously or as an
open procedure.

Investigation of Vascular
Disease
Let me move now to another area
of vascular surgery that I think is
changing in an important way —
the investigation of vascular dis
ease.
I am sure you would all agree
that the duplex scanner, conceived
and developed in large part by Dr.
Gene Strandness and his group, a
vascular surgeon well known to you
all, has changed the whole investi
gational process for the vascular
patient. Duplex scanning has given
us an objective ability to assess
plaques, valves and stenoses in a
highly accurate manner. Advancing
technology in this area has resulted
234
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in a real challenge to the heretofore
accepted gold standard of angiogra
phy and in a claim that duplex
scanning is, or will become, the new
gold standard. I believe that con
trast studies for investigating pa
tients with claudication and aneu
rysms will be phased out within the
next few years and will be replaced
with duplex scanning, magnetic res
onance imaging or computed to
mography (CT), or a combination
thereof.
At the University Hospital in Van
couver we have accepted the role of
duplex scanning by performing over
100 carotid thromboendarterectomies based on duplex scanning
alone in patients with focal signs,
focal symptoms and with a negative
CT scan of the brain. In only one
case did an operative finding not
correlate with that on duplex scan
ning and that was in a patient with
a high-grade stenosis whose vessel
had occluded between the time of
scanning and the time that surgery
was carried out. We have kept our
mortality to less than 0.5% and the
morbidity to 2% to 3%.
However, the question is: do we,
as vascular surgeons, feeling as we
do that we understand both the
physiology of flow and the patholo
gy of the disease, wish to be in
control of Doppler ultrasonography
and spectral analysis, which are the
keys to noninvasive assessment? Or
do we wish to relinquish the Bmode part of noninvasive investiga
tion, which is the imaging part, to
radiologists who lay claim to being
“the imagers”? Clearly, we have a
strong argument in terms of our
training, background, knowledge of
disease and use of Doppler ul
trasonography to claim expertise in
the spectral analysis mode, which in
my opinion is the most important
component, but perhaps less argu
ment when it comes to “images.”
However, which of us would rely on
a radiologist’s interpretation of an

angiographic image before operat
ing? Do we thus not have considera
ble experience already in the imag
ing field? So you see, adding the
image component to our existing
armamentarium is not a large move.
However, if we vascular surgeons in
Canada are going to be responsible
for the investigation of our patients,
it is time we took a look around and
developed our vascular laboratories
to an appropriate standard. This is
not going to be particularly easy. It
will involve turf battles, demands on
administration and our individual
involvement in fund raising at the
community level to acquire the
technology. The expertise I believe
we already possess! As we discussed
recently at our business meeting,
the Canadian Society for Vascular
Surgery is making significant ef
forts at provincial and federal levels
to establish accreditation standards
for laboratories, technologists and
indeed the directors. We will be
working with the Canadian and
American medical associations,
since an identical problem exists
south of the border. I think, if
anything, we are closer in Canada
to having these standards both ac
knowledged and accepted. So, there
will be considerable support, I be
lieve, for those of you who wish to
update or establish your diagnostic
vascular laboratories. A word of
warning though. If we pursue this
goal, we must incorporate the ap
propriate training of our fellows
into our programs in conjunction
with the Royal College of Physi
cians and Surgeons of Canada.

Vascular Laboratories in
Canada and the United States
First of all, what is a vascular
laboratory? My definition is that of
a dedicated investigational laborato
ry where the director may be a
vascular surgeon, technologists are
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highly trained and duplex scanning
assessments are routinely per
formed. Of 40 Canadian hospitals
polled, 53% of which were universi
ty based (Table II), dedicated vascu
lar laboratories existed in 26% of
community and 28% of university
hospitals. In 23 American hospitals
polled, there were dedicated labora
tories in 69% of community and
100% of university hospitals. The
ability to perform duplex scanning
examinations was present in 62% of
Canadian laboratories and 100% of
American vascular laboratories.
Training backgrounds for technolo
gists were similar in many ways. In
Canada, 81% of technologists had a
background in nursing, but in addi
tion were registered vascular tech
nologists (RVTs) or had a Bachelor
of Science degree. In the United
States, the number was 50%. How
ever, 40% of dedicated laboratories
in the United States also employed
ultrasonographers compared with
18% of Canadian laboratories. Fi
nally, vascular surgeons were direc
tors of Canadian vascular laborato
ries in 65% of cases as opposed to
17% directed by radiologists. In the
United States, 86% of dedicated
laboratories were directed by vascu
lar surgeons and the remaining 14%
by radiologists, cardiologists or in
ternists.
The concerns I have expressed
are not unique to Canada. The
presidents of the International Soci
ety of Cardiovascular Surgeons and
the Society for Vascular Surgery,

representing the largest vascular
society in the world, have voiced
their concern in a letter to our
society. In it Drs. Baird and Strandness stated, “As you know, we are
in the position of being told by
some of our colleagues (cardiolo
gists) that the field and its direction
(endovascular surgery) is now in its
hands. This came about with the
sudden entry into the field by cardi
ologists who have found the periph
eral arteries a useful site for laser
assisted angioplasty.” In addition,
Dr. DeMaria, the president of the
American College of Cardiology has
stated that it is time for their group
to become more active in this area.
Drs. Baird and Strandness conclud
ed, “We need to inform the profes
sion and the public about the field
and the expanding role that we as
vascular surgeons are playing in its
development.” Various solutions
are suggested to achieve this, but
as the outgoing president of the
Canadian Society for Vascular Sur
gery, I heartily endorse their con
cern and their opinion.
The future of vascular surgery in
Canada is, I believe, very bright. I
think our role as pure surgeons
may change and that we may be
come much more involved with the
nonsurgical aspects of the manage
ment of patients with vascular dis
orders. I strongly believe that in the
next few years we will see the
development and application of pho
todynamic therapy for the ablation
of atherosclerotic plaques. We have

T a b le II. E x is te n c e o f D e d ica te d V a s c u la r L a b o ra to rie s
Institutions
C anadian h o s p ita ls
C o m m u n ity h o s p ita ls
D edicated la b o ra to rie s
U n iv e rs ity h o s p ita ls
D edicated la b o ra to rie s
U n ite d S ta te s h o s p ita ls
C o m m u n ity h o s p ita ls
D edicated la b o ra to rie s
U n iv e rs ity H o s p ita l, V a n c o u v e r
D edicated la b o ra to rie s

N um ber

%

19
5
21
6

47
26
53
28

16
13
7
7

69
81
31
100

an opportunity to lead in this field
provided that we, as surgeons, can
apply endovascular techniques.
Furthermore, the federal and pro
vincial governments are at last mov
ing away from disease-orientated
application of health care dollars
into the field of preventive medi
cine. Tremendous effort is now
being put into the development of
hospital-based wellness programs,
which will have a significant impact
on our field. We should not, howev
er, fear these changes but rather
welcome them as part of the care of
patients referred to us — so that we
can be leading participants in this
area rather than camp followers. So
our ingenuity as interventionalists
must be equally matched by our
ability to focus also on prevention
and the assimilation of wellness
health care practices.
Let me close on what I hope is an
upbeat note. I like the words of
Mervin Smith, president of the
Royal Australasian College of Sur
geons: “Living on the other side of
the world has many disadvantages
but many compensations. One of
these is the capacity for sometimes
being able to break away from the
accepted conventions and doing
things in our own way.”2
We don’t live on the other side of
the world, but I do think we have to
break away a bit, at least maintain
co-ownership in this technology and
believe in our own ability to “pass
wires.”
Support for what I have said
today actually comes from many
quarters, not the least of which was
the presidential address by Charles
Drake, professor of neurosurgery,
University Hospital, London, Ont.,
to the American Surgical Associa
tion in 1987.3 His address, “The
craft of surgery, its changing face”
eloquently analysed many of the
changes that have affected surgery
during his professional career. In
reference to our field of vascular
CJS, VOL. 34, NO. 3, JUNE 1991
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surgery, the prominence of new
imaging techniques and endovascu
lar developments, he made two
most germane statements: “There
should be no thought that percuta
neous techniques are beneath the
dignity of a surgeon” and “Sur

geons might well regard this as the
age of imaging. I have recently
developed the conviction that before
it is too late, some young surgeons
should become involved with the
new imaging and the development
of endoscopic techniques, especially

M# ■

in vascular surgery.”
Finally, allow me to borrow one
further title from a paper that will
be presented to the Western Vascu
lar Society in January 1990 that
epitomizes to me the direction in
which we vascular surgeons must

VASCULAR SURGERY IN CANADA

move: “ Endovascular procedures
are no longer a spectator sport for
the surgeon.’’
Let us pursue our interest and
expertise in vascular surgery in
Canada by becoming more involved
in endovascular technology and no-

ninvasive investigation
the current decade.

during
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T w o Patients With Horseshoe Kidney
and Ruptured Abdominal Aortic Aneurysm
M. Yaman, MD, FRCSC; D. Wooster, MD, FRCSC; V. Bojanowski, MD, FRCSC;
R. Louch, MD, FRCSC
Renal anomalies present a challenge to surgeons who repair aortic aneurysms;
horseshoe kidneys occur in 1 out of 400 people in the general population. The
degree of fusion, accessory blood supply and ureteric anomalies all affect the
approach to aneurysm repair in the elective or emergency setting.
The authors report two patients with ruptured abdominal aortic aneurysms, who
were found at operation to have a horseshoe kidney. In both cases a thick renal
isthmus was found crossing the aorta between the inferior mesenteric artery and the
bifurcation. The kidney was preserved intact, accessory blood supply was controlled
from inside the aorta and the aneurysm was repaired with a Dacron graft. One
patient underwent ureterolysis; although renal failure subsequently developed, it
was likely related to prolonged preoperative hypotension. The other patient
recovered without complications.
Les anomalies renales sont un defi pour le chirurgien qui a a reparer un anevrisme
aortique; des reins en fer a cheval se retrouvent, dans la population, chez 1
personne sur 400. Le degre de fusion, les apports sanguins accessoires et les
anomalies des ureteres affectent tous l’abord a la reparation de l’anevrisme, que l’on
soit en situation elective ou en urgence.
Les auteurs decrivent les cas de deux patients souffrant d’une rupture d’anevrisme de l’aorte abdominale et chez qui on decouvrit, a l’operation, un rein en fer a
cheval. Dans les deux cas, un isthme renal epais a ete trouve croisant l’aorte entre
l’artere mesenterique inferieure et la bifurcation. Le rein fut conserve intact,
l’apport sanguin accessoire controle de l’interieur de l’aorte et les anevrismes
repares avec une toile Dacron. Un patient subit une ureterolyse; bien qu’une
insuffisance renale se developpa par la suite, elle etait possiblement reliee a une
hypotension preoperatoire prolongee. L’autre patient guerit, sans complication.

be found in the literature.13-7 Such
renal anomalies present a challenge
during repair of aortic aneurysm.
The challenge is even greater when
the aneurysm is ruptured. The de
gree of fusion, accessory blood sup
ply and ureteric anomalies all affect
the approach to aneurysm repair in
elective or emergency settings. Rec
ognition and minimal careful dissec
tion are essential when repairing
ruptured aneurysms in the presence
of a horseshoe kidney. We report
two cases of ruptured abdominal
aortic aneurysm with associated
horseshoe kidney and describe in
detail the operative approaches,
particularly as they apply to rup
tured aortic aneurysms.

Case Reports
Case 1

H

orseshoe kidney is a rare con
dition and is estimated to
occur in 1 out of 400 people in the
general population.12 It is generally
discovered in young people because
one-third of those having a horse
shoe kidney will have associated
anomalies.2 Abdominal aortic aneu-

rysm occurs in 2% of the elderly.3
The association of an abdominal
aortic aneurysm and horseshoe kid
ney is uncommon; autopsy series
report an incidence of 1 in 710.4
Fewer than 80 cases had been re
ported up to 1987, and only 8 cases
of rupture of the aneurysm are to
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A 77-year-old man who had faint
ed because of excruciating abdomi
nal and back pain was seen in the
emergency department of the St.
Joseph’s Health Centre. The pain
had been present for 1 week. He
had undergone right pneumonecto
my for tuberculosis 40 years before,
and had a history of hypertension,
myocardial infarction and serious
coronary artery disease. There was
no history of any anomalies or any
notable family history of disease.
The patient was alert but in pain.
His vital signs were as follows:
blood pressure 9 0 /7 0 mm Hg,
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pulse rate 95 beats/min, respirato
ry rate 16/min and body tempera
ture 36.8°C. His chest was clear,
and there was a right pneumonecto
my scar. Heart sounds were normal
with no gallop. Abdominal examina
tion revealed a tender, midline, midsupraumbilical, pulsating mass, 15
X 10 cm in size, extending into the
left lower quadrant. His femoral
pulses were equal but weak, and his
distal peripheral pulses were intact.
The rest of the physical examina
tion was unremarkable.
Initial biochemical investigations
gave the following results: hemo
globin 94 g /L , leukocyte count
14.5 X 109/L , platelet count 420
X 109/L . The blood urea nitrogen,
serum creatinine and electrolyte val
ues were within normal limits. The
chest x-ray film appeared normal
apart from the right pneumonecto
my.
Fluid resuscitation was instituted,
and the patient was taken immedi
ately to the operating room.
Through a standard midline trans
abdominal incision a large retroperi
toneal hematoma was found overly
ing the aneurysm and extending
into the left lower quadrant.
Proximal control was obtained
after the left renal vein was tied
flush with the inferior vena cava.
The left renal vein bifurcated
around the aorta. The posterior
branch was left intact. No renal
arteries were detected. The patient
was given 300 mL of 10% mannitol
before the aorta was cross-clamped.
A fleshy isthmus of the horseshoe
kidney was found overlying the
belly of the aneurysm, under the
inferior mesenteric artery. Both
renal pelves were seen, and the
right ureter was dilated and
stretched over the aneurysm. After
distal control was obtained at the
external iliac arteries, the aneurysm
was opened above the horseshoe
kidney. Multiple lumbar arteries,
the inferior mesenteric artery and

accessory branches of the renal ar
teries arose from the aneurysm.
Good back bleeding was noted from
these arteries. All were transfixed
with Prolene sutures.
Because the bifurcation was in
volved in the aneurysm, a bifurca
tion graft was passed under the
kidney and sewn to both common
arteries. The inside of the aneurysm
was inspected after revasculariza
tion and was dry. The dilated right
ureter was freed from the surround
ing adhesions.
The patient’s systolic blood pres
sure remained between 70 and 90
mm Hg throughout the procedure.
There was a minimal urine output
despite adequate fluid resuscitation.
The estimated blood loss of 3 L was
replaced with red packed cells and
fresh-frozen plasma.
The patient remained in the in
tensive care unit for 3 weeks postoperatively. He was extubated 1
week after his operation. His blood
urea nitrogen and serum creatinine
values are shown in Table I. Hemo
dialysis was instituted on day 5, and
the patient’s condition stabilized.
He had an uncomplicated cholecys
tectomy for acalculous cholecystitis
3 weeks after his surgery. He was
discharged on long-term hemodial
ysis.
Case 2
A 74-year-old man gave a 3-day
history of acute, central, abdominal
pain radiating to the back. He had
had significant coronary artery dis
ease, but otherwise had a negative
systems review. In the emergency

department his vital signs were as
follows: blood pressure 110/70
mm Hg, pulse rate 100 beats/m in,
respiratory rate 17/min. Abdominal
examination revealed a pulsating
aneurysm, 13 cm in diameter, with
normal peripheral pulses. The chest
x-ray film and electrocardiogram
were normal.
The patient was taken directly to
the operating room and explored
through a transabdominal midline
approach. There was a 10-cm intrarenal, leaking abdominal aortic
aneurysm. The left renal vein was
transected to obtain proximal con
trol of the aneurysm neck. Two
renal arteries were identified above
the clamp on the aorta.
There was a horsehoe kidney
with a thick isthmus overlying the
aneurysm and trapped below the
inferior mesenteric artery. The an
eurysm extended down to both
common iliac vessels. It was opened
above and below the isthmus of the
horseshoe kidney. Good back-bleed
ing was noted from the accessory
vessels. The accessory renal vessels,
lumbar vessels and inferior mesen
teric artery were controlled with
transfixing sutures. A no. 16 woven
Dacron graft was sutured to the
aorta and passed under the kidney
to both common femoral arteries.
The patient produced 1100 mL of
urine during the procedure and was
transfused with 1300 mL of blood.
His blood urea nitrogen and serum
creatinine levels pre- and postoperatively are shown in Table II. The
patient’s recovery was smooth and
he was discharged 2 weeks after his
admission.

Table I. Case 1. Renal Function Profile
Time postop, d

Parameter
Serum creatinine,
Mmol/L
Blood urea nitrogen,
m m ol/L urea
Potassium, mm ol/L

Preop

1

2

3

4

105

112

319

427

500

13.3
3.5

10.6
4.5

16.1
4.2

29.7
4.9

34.0
5.2
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Discussion
Horseshoe kidney was first rec
ognized at autopsy by DeCarpi in
1521.2 This anomaly is the most
common fusion defect of the kid
ney, occurring in 1 out of 400.
people. Horseshoe anomalies occur
with a male:female predominance of
3:2. The anomaly develops between
4 and 6 weeks of gestation. Fusion
of the two kidneys occurs before
the rotation and migration are com
plete, after the ureteral bud has
entered the nephroblastoma. Then
ascent is hindered by the retroperi
toneal structures, inferior mesenter
ic artery and base of the small-bow
el mesentery. This results in a
horseshoe-shaped kidney with the
lower poles joined in 95% of cases.
The isthmus usually overlies the
L3-4 vertebral body, anterior to the
aorta and inferior vena cava,
though occasionally behind or be
tween. The kidneys lie in a slightly
lower position than normal with a
vertical or obliquely lateral axis due
to the fusion. As a result of the
incomplete rotation, the collecting
system lies anterior to the kidney
and its vasculature. The ureter in
serts high on the renal pelvis and
lies laterally. The calyces point pos
teriorly and medially. In 1% of cases
there is ureteral duplication.6
The blood supply is variable;
three different patterns can be
found:389 a normal renal artery to
each side is found in 20% to 30% of
cases; minor renovascular abnor
malities are seen in 50% to 60% of
cases, the arteries arising inferior to
the aneurysm in 10%, the isthmic

artery arising from the aneurysm in
30% and one or more arteries aris
ing from the aneurysm in 20%;
major renovascular abnormalities
occur in 5% of cases, with multiple
arteries arising from the aneurysm.
The arterial supply to the isthmus
is variable in origin and number,
arising from the renal artery, aorta,
inferior mesenteric artery, common
or external iliac or sacral artery.
The venous anatomy is often abnor
mal with the venous drainage vary
ing in origin and number.
One-third of horseshoe kidneys
are asymptomatic. The diagnosis
can be missed even on both intrave
nous pyelography and arteriogra
phy. Arteriography and computed
tomography are recommended to
help delineate the vascular supply
in elective cases.6
The presence of an abdominal
aneurysm with a horseshoe kidney
can alter the surgical approach and
outcome in these patients; the tho
racoabdominal retroperitoneal ap
proach has been recommended by
some authors for technical rea
sons.10 This approach allows the
surgeon to avoid any dissection in
the area of the isthmus of the
horseshoe kidney and the associat
ed risks of arterial or ureteral trau
ma. Also, angiography was used as
a standard investigation in the pre
operative work-up of these patients
and as a road map for the opera
tion. The operative death rate for
abdominal aortic aneurysm is less
than 3%; when associated with a
horseshoe kidney the operative
death rate is 4.3%. In eight reported
cases of ruptured abdominal aortic

T able II. Case 2. Renal Function P rofile
Tim e postop, d
P a ra m ete r
Serum creatinine,
/u m o l/L
B lood urea
nitrog en ,
m m o l/L
P o ta ssiu m , m m o l/L
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Preop

1

2

3

4

Discharge

136

116

145

154

159

120

6 .6
4.1

5.4
3 .9

6.7
4 .0

6.3
4 .5

6.2
4.8

5.6
4.2
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aneurysm with associated horse
shoe kidney there were two
deaths.6711 Sidell, Pairolero and
Payne9 reviewed 53 cases of aortic
surgery with a transabdominal ap
proach and found that anomalous
arteries prevented aortic repair in 6
(11%) cases.
In ruptured abdominal aortic an
eurysm and associated horseshoe
kidney, the surgeon is faced with
many problems. There is no preop
erative work-up and evaluation of
any associated renal anomalies,
thus preventing planning of the
operation. Dissection is more diffi
cult, due to hematoma, and the
chance of injury of vital structures
is more common, especially as vas
cular and ureteral anomalies are
common. The patient’s condition is
unstable, so a fast and safe opera
tion is needed.
In both our cases, a generous
midline incision was used, extend
ing from the xiphoid to the pubic
symphysis. The left renal vein was
divided in both cases to obtain good
control of the neck of the aneu
rysm. Anomalies of the renal vein
suggest other associated vascular
or fusion anomalies. Partial ureteral
obstruction was noted in one case
and ureterolysis was done. In both
our cases the ureters were in an
abnormal position, and injury was
avoided by blunt dissection over the
anterior wall of the aneurysm. The
isthmus of the horseshoe kidney
was overlying the belly of the aneu
rysm in both cases and was difficult
to recognize because of the sur
rounding hematoma. Again, blunt
sweeping of tissues is a safe tech
nique to identify vital structures.
The graft was passed under the
isthmus in both cases without any
dissection or division of the struc
ture. Division of the isthmus has
been controversial. It is generally
considered that a thin fibrous isth
mus can be divided with impunity.
However, a thick isthmus may be
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very vascular, with several blood
supplies, and division may some
times be complicated by a urinary
fistula. This complication is rare,
and thus several studies state that
division can be done safely.1213 In
theory, there is an increased risk of
graft infection from urine colonized
with bacteria commonly present in
patients with horseshoe kidney.14
This risk of infection is increased
because the retroperitoneal hemato
ma of the ruptured aneurysm is a
good culture medium for these bac
teria.
Inspection of accessory renal ar
teries originating from the aneu
rysm is recommended. In both
cases, accessory arteries were not
ed, originating from the anterior
wall of the aneurysm, and were
transfixed. Reimplantation was not
considered because there was good
back-bleeding from these arteries.
Reinspection of the “bridge” of the
horseshoe kidney is vital to detect
any bleeding after revascularization
of the pelvis, since the incidence of
accessory renal arteries arising in
ferior to the aneurysm is 10%. Our
first patient had progressive nonoliguric renal failure. The major factor
contributing to this problem was
prolonged preoperative hypoten
sion. Other possible contributing
factors include warm ischemia to
the kidney from occlusion of the
accessory renal vessels and pre
existing renovascular disease. The
patient’s renal condition was suc
cessfully controlled by dialysis.

technique,” saving the isthmus of
the horseshoe kidney, is safe and
quick.

This list is an acknowledgement of
books received. It does not preclude
review at a later date.
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End -to-End Versus End-to-Side Proximal
Anastomosis in Aortobifemoral Bypass
Surgery: Does It Matter?
F. Michael Ameli, MB, ChB, FRCS(Edin), FRCS, FACS; Moni Stein, MD; Loris Aro, RN;
John L. Provan, MS, FRCS, FRCSC, FACS; Robin Gray, MD, FRCPC;
Harvey Grosman, MD, FRCPC
The proximal anastomosis is still a controversial issue in vascular surgery. To
compare end-to-end (EE) and end-to-side (ES) proximal anastomoses, the authors
undertook a prospective study with 3 years’ follow-up involving 120 patients, all of
whom had aortobifemoral bypass.
Fifty-one (42.5%) patients received the EE and 69 (57.5%) the ES anastomosis.
The indications for surgery were abdominal aortic aneurysm (EE 51%, ES 0%; p <
0.05), claudication (EE 33.3%, ES 53.6%; p < 0.05) and critical ischemia (EE 15.7%,
ES 46.4%; p < 0.05). Patients in the EE group were older (mean age; EE 66.1 ± 2.8
years, ES 60.9 ± 1.1 years; p < 0.05) and had more ischemic heart disease (EE
39.2%, ES 27.5%; p < 0.05). Postoperative mean increases in transcutaneous
oximetry (EE 15.5 ± 3.9 mm Hg, ES 12.6 ± 2.3 mm Hg) and the ankle-brachial
pressure index (EE 0.34 ± 0.05, ES 0.30 ± 0.03) were not significantly different in
the two groups. The operative death rate was higher for the EE group (EE 11.8%,
ES 1.4%; p < 0.05). Early thrombosis occurred in six patients, two in the EE group
and four in the ES group. Computed tomography, done 1 year postoperatively in 95
patients, revealed two small (less than 3 cm) distal anastomotic dilatations, one in
each group. At 3 years, cumulative survival and patency were similar in both
groups.
The authors conclude that the two anastomotic groups had very similar short- and
long-term results, except for the operative death rate which was higher in the EE
group. A selection bias likely predisposed the EE group to a higher operative risk.

L’anastomose proximale fait toujours l’objet d’une polemique en chirurgie vasculaire. Afin de comparer l’anastomose proximale bout a bout (BB) a celle qui est faite de
facon termino-laterale (TL), les auteurs ont entrepris une etude prospective avec
surveillance postoperatoire de 3 ans chez 120 patients qui ont tous subi un pontage
aorto-bifemoral.
Cinquante-et-un patients (42,5 %) ont eu une anastomose BB et 69 (57,5 %), une
anastomose TL. Les indications chirurgicales etaient l’anevrisme de l’aorte abdominale (BB 51 %, TL 0 %; p < 0,05), la claudication (BB 33,3 %, TL 53,6 %; p < 0,05)
et l’ischemie critique (BB 15,7 %, TL 46,4 %; p < 0,05). Les patient du groupe BB
etaient plus ages (age moyen : BB 66,1 ± 2,8 ans, TL 60,9 ± 1,1 ans; p < 0,05) et
souffraient davantage de coronaropathie (BB 39,2 %, TL 27,5 %; p < 0,05).
L’augmentation postoperatoire moyenne de l’oxymetrie transcutanee (BB 15,5 ± 3,9
mm Hg, TL 12,6 ± 2,3 mm Hg) et de l’indice tensionnel main cheville (BB 0,34 ±
0,05, TL 0,30 ± 0,03) n’etait pas significativement differente d’un groupe a l’autre.
La mortalite operatoire a ete plus elevee dans le groupe BB (BB 11,8 %, TL 1,4 %;
p < 0,05). Des thromboses precoces sont survenues chez six patients, deux dans le
groupe BB et quatre dans le groupe TL. Une tomographie pratiquee 1 an apres
l’operation chez 95 patients, a revele deux petites dilatations anastomotiques
distales (de moins de 3 cm), une dans chaque groupe. Apres 3 ans, le taux de survie
cumulatif et de permeabilite etait semblable dans les deux groupes.
Les auteurs concluent que les deux types d’anastomose ont donne des resultats
tres semblables a court et a long terme, sauf pour la mortalite operatoire qui a ete
plus elevee dans le groupe BB. Un biais dans le choix des malades a probablement
predispose le groupe BB a un risque operatoire plus eleve.

he proximal anastomosis in
aortofemoral bypass surgery is
still a controversial issue. The vas
cular surgeon has two options: to
perform the anastomosis end to end
(EE) or end to side (ES). This issue
has not been addressed extensively
in the vascular surgery literature,
and the studies that have dealt with
the subject were nonrandomized
and retrospective.1-8
In the late 1970s and early 1980s
it was generally believed1’35-6 that
EE proximal anastomosis produced
better results and was associated
with fewer complications. Recently,
however, studies that compared EE
to ES proximal anastomoses7-8 were
unable to demonstrate short- or
long-term differences between the
two.
In this paper we present a pro
spective study, with 3 years of
follow-up, of 120 patients who had
aortobifemoral bypass reconstruc
tion. The EE and ES proximal anas
tomoses were compared against the
following criteria: operative compli
cations, cumulative rates of surviv
al, graft patency and amputation,
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and improvement in postoperative
hemodynamic and peripheral oxy
gen delivery. Follow-up computed
tomography (CT) was done at 1
year in 95 patients to check for
long-term complications.

Patients and Methods
Patients
Over 3 years, 120 consecutive
symptomatic patients who under
went aortobifemoral bypass recon
structions were entered into the
study. They were divided into two
groups according to the type of
proximal anastomosis performed:
EE (51 patients) and ES (69 pa
tients) (Table I). The sex distribu
tion differed between the two
groups (males: EE 72.5%, ES
47.8%, p < 0.05 [Student’s f-test];
females: EE 27.5%, ES 52.2%, p <
0.05). Patients in the EE group
were older than those in the ES
group by a mean of 5.2 years (p <
0.05). The indications for surgery
were also significantly different in
the two groups. Only the EE anas
tomosis was performed in cases of
abdominal aortic aneurysm. Claudi
cation (EE 33.3%, ES 53.6%, p <
0.05) and critical ischemia (EE
15.7%, ES 46.4%, p < 0.05) were
commoner in the ES group. Critical
ischemia was defined as the pres
ence of one or more of the follow
ing: rest pain, night pain, ischemic
ulcers and gangrene. Coronary ar
tery disease was also more frequent
ly present in the EE group (EE
39.2%, ES 27.5%, p < 0.05).
Outcome Criteria
The following cumulative rates
were used in this study for compari
son: primary patency, amputation
and survival. The first postoperative
graft thrombosis, regardless of fu
ture interventions, was considered
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as graft failure. Operative complica
tions were considered as any mor
bidity and mortality occurring with
in 1 month of operation.
Two noninvasive techniques were
used for the vascular assessment:
transcutaneous oximetry (Ptc02)
and the ankle-brachial pressure
index (ABI). A Contron Ptc02 moni
tor (Contron Instruments, Everett,
Mass.) was used to measure trans
cutaneous oxygen tension on the
dorsum of the foot, with the patient
in the resting supine position. The
ABI was measured with the patient
in the same position by means of a
sphygmomanometer and a Doppler
ultrasound velocity detector. Post
operative increases in ABI and
Ptc02 were calculated and averaged
for each group.
Computed tomography (CT) was
done as part of the routine study
protocol 1 year postoperatively. The
proximal and distal anastomoses
were checked for aneurysmal dilata
tions.
Statistical Analysis
The data, collected prospectively
over 3 years, were entered into a
computerized data File. The SAS
statistical package9 was used for
data storage and analysis. Cumula
tive rates were computed by the

standard life-table method and com
pared by the log rank test. Means
were expressed with standard errors
and compared using the f-test.
Probability values less than 0.05
were accepted as statistically signifi
cant.

Results
The overall operative death rate
was 5.8% (EE 11.8%, ES 1.4%, p <
0.05) (Table II).
Analysis of the mean Ptc02 and
ABI scores pre- and postoperatively
showed that the ES group had
slightly lower Ptc02 scores than the
EE group (Table III). The postoper
ative mean Ptc02 increase was 15.5
mm Hg for the EE group compared
with 12.6 mm Hg for the ES group.
These differences were not statisti
cally significant. The ABI scores
showed similar trends. The postop
erative mean ABI increase was 0.34
for the EE group compared with
0.30 for the ES group.
Ninety-five patients (79%) under
went CT 1 year postoperatively.
There were no proximal aneurysmal
dilatations, graft infections, aortoduodenal or aortoureteric fistulas.
Two small (less than 3 cm) distal
anastomotic aneurysmal dilatations,
one in each group, were seen.

Table I. Characteristics and Risk Factors in 120 Patients Who Underwent Aortobifemoral Bypass
Reconstruction With Either an End-to-End (EE) or End-to-Side (ES) Proximal Anastomosis
Type of proximal anastomosis
Characteristic

EE (n = 51)

ES (n = 69)

p value

Mean age, yr
Sex, no. (%)
Male
Female
Indication for surgery
Aortic aneurysm
Claudication
Critical ischemia
Smoking history
Diabetes
Coronary artery disease
Previous vascular
surgery

66.1 ± 3.0

60.9 ± 1.1

< 0 .0 5

37 (72.5)
14(27.5)

33 (47.8)
36 (52.2)

< 0 .0 5
< 0 .0 5

26 (51.0)
17(33.3)
8(15.7)
50 (98.0)
6(11.8)
20 (39.2)

0
37 (53.6)
32 (46.4)
67 (97.1)
9(13.0)
19(27.5)

< 0.05
< 0 .0 5
< 0.05
NS
NS
< 0 .0 5

12(23.5)

18(26.1)

NS

NS = not significant.

ANASTOMOSES IN AORTOBIFEMORAL BYPASS

The overall early graft patency
was 95%, and both groups had
similar rates (EE 96.1%, ES 94.2%).
Patency rates at 3 years were simi
lar in the two groups (EE 93%, ES
94.2%, Table IV). The four graft
failures in the ES group all oc
curred in the early postoperative
period. Although the two groups
had significantly different early sur
vival rates, at 3 years the rates were
similar (EE 80%, ES 84.2%). There
were no early or late amputations.

tions can only be made through a
prospective, randomized study.
However, in some cases the choice
of proximal anastomosis is limited;
for example, the presence of an
abdominal aortic aneurysm ex
cludes the possibility of an ES anas
tomosis. A randomized study would
have to include patients who do not
have clear contraindications to a
certain type of anastomosis. Our
study was not randomized because
we included patients with absolute
anastomotic indications. However,
it was done prospectively according
to a comprehensive study protocol
that included CT at 1 year of fol
low-up.
The rationale for the routine use
of CT was to document objectively

Discussion
A satisfactory comparison of EE
and ES proximal anastomoses in
aortobifemoral bypass reconstruc

Table II. Operative Complications
Type of proximal anastomosis
Complication
Death
Graft thrombosis
Myocardial infarction
Stroke
Ischemic bowel
Wound infection

EE

ES

Number ("/»)

Number (%)

p value

6(11.8)
2 (3.9)
1 (2.0)
0
1 (2.0)
2 (3.9)

1 (1.4)
4(5.8)
0
1 (1.4)
0
1 (1.4)

< 0.05
NS
NS
NS
NS
NS

Table III. Mean Results of Noninvasive Tests
Type of proximal anastomosis
Test

EE

Transcutaneous oximetry,
mm Hg
Preop
Postop
Increase
Ankle-brachial index
Preop
Postop
Increase

ES

/rvalue

38.5 ± 3.9
54.0 ± 2.4
15.5 ± 3 .9

36.8 ± 2.3
49.4 ± 1.9
12.6 ± 2 .3

NS
NS
NS

0.40 ± 0.05
0.74 ± 0.04
0.34 ± 0.05

0.42 ± 0.02
0.72 ± 0.03
0.30 ± 0.03

NS
NS
NS

Table IV. Early and Late Cumulative Survival and Patency Rates (%)
Type of proximal anastomosis
Rate
Survival
1 mo
3 yr
Patency
1 mo
3 yr

EE

ES

p value

88.2
80.0

98.6
84.2

< 0 .0 5
NS

96.1
93.0

94.2
94.2

NS
NS

complications associated with the
aortobifemoral prosthesis. Comput
ed tomography is an excellent tech
nique for detecting early and late
complications of aortic prostheses.10-12 We paid particular at
tention to aneurysmal dilatations of
the proximal and distal anastomo
ses.
In a 30-year survey that included
1748 reconstructions for aortoiliac
occlusive disease, Szilagyi and col
leagues13 reported an incidence of
aneurysmal dilatations at the femo
ral anastomosis of 5.8%. Three of
1241 (0.24%) ES proximal anasto
moses were associated with aneu
rysmal dilatation, but of 197 EE
proximal anastomoses there was no
associated aneurysmal dilatation. In
our study there were no proximal
aneurysmal dilatations, but there
were two (one in each group) dilata
tions at the distal (femoral) anasto
mosis.
Patients in the EE group were
older than those in the ES group
and had a greater frequency of
ischemic heart disease. The two
groups also differed in the indica
tions for surgery and sex distribu
tion. This selection bias, with a
higher operative risk in the EE
group, may be the reason for the
higher operative death rate in the
EE group (Table II). In other stu
dies313-15 ischemic heart disease has
also been reported to be the most
important risk factor for early and
late death in patients who undergo
aortobifemoral bypass reconstruc
tion. Our indications for EE anasto
mosis were aneurysmal disease of
the aorta, occlusion of the aorta or
very extensive disease of the aor
toiliac region. An ES anastomosis
was preferred in patients with hypo
plastic aorta and those with primari
ly external iliac disease, in whom
preservation of flow into the inferi
or mesenteric and internal iliac ar
teries was important. In the absence
of any of these indications, our
CJS, VOL. 34. NO. 3. JUNE 1991
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preference was to do an ES anasto
mosis.
There are some important techni
cal considerations in performing an
ES anastomosis: proximal and distal
clamps should be applied, not a side
occluding clamp; the anastomosis
should be as proximal as possible
(i.e., near the renal vein); all debris
should be cleaned from the aorta;
the tube part of the graft should
not be too long; care should be
taken not to kink the limbs at their
take-off and to get them to lie
parallel at that point; there should
not be too much tension on the
graft; and, finally, care should be
taken to avoid contact between
prosthesis and bowel.
Aortoduodenal fistulas have been
reported to occur mostly in patients
with an ES anastomosis (up to
3%).34-8 In this study, there were no
aortoenteric or aortoureteric fistu
las in either group. We have not
encountered intraoperative emboli
zation, a complication that has been
associated with the ES anastomo
sis.3 One patient in the EE group
suffered bowel ischemia. The ES
anastomosis, with its preservation
of direct flow to the inferior mesen
teric, lumbar and internal iliac arter
ies, theoretically should protect the
patient from colonic or pelvic isch
emia.
Hemodynamic implications of the
type of proximal anastomosis were
assessed by Rutherford and associ
ates.7 The postoperative increases
in ABI did not differ significantly
between the two groups (EE 0.37,
ES 0.4). In our study, postoperative
ABI increases were measured, and
the results also showed no signifi
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cant difference between the two
groups (Table III). Both types of
proximal anastomosis offer similar
hemodynamic improvements. Fur
thermore, our results showed no
significant differences in Ptc02 in
creases in either group (Table III).
This means that peripheral oxygen
delivery improved similarly for both
groups.
Earlier studies12 reported higher
patency rates for the EE anastomo
sis. However, Dunn, Downs and
Lye,4 Rutherford and associates7
and Melliere and colleagues8 were
unable to demonstrate significant
differences in patency rates between
EE and ES anastomoses. Our study
followed this trend with similar
early and late patency rates for the
two groups (Table IV). The discrep
ancy between the early and more
recent reports is probably the result
of more careful selection of patients
for the two types of anastomosis
and of advances in operative tech
niques.
This prospective, nonrandomized
study, revealed no significant differ
ences between the EE and ES
groups in graft patency, late death
rate and improvements in hemody
namic status and peripheral oxygen
delivery. The operative death rate
was higher in the EE group most
likely because of a selection bias.
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A Prospective Evaluation of the Button
Gastrostomy in Children
Talal A1 Malki, MD;* Jacob C. Langer, MD, FRCSC;* Vivian Thompson, MBA;f Marion McQueen, RN;t
George Y. Lau, MD, FRCSC;* Robert M. Issenman, MD, FRCPC;$ Andrea L. Winthrop, MD, FRCSC;*
Gordon S. Cameron, MD, FRCSC*
The Button gastrostomy has become popular for patients requiring long-term
enteral feeding, because it is considered less irritating, more stable and more
asthetically acceptable than the traditional tube gastrostomy. By a standardized
questionnaire and personal interview, the authors evaluated prospectively the
efficacy and complication rate in 19 children who had a Button gastrostomy inserted
during a 6-month period. In 15 children the Button replaced a standard tube
gastrostomy, and in 4 the Button was inserted surgically initially. Thirteen children
had severe neurologic disabilities, and 6 required supplemental enteral feeding as
part of the nutritional management of another chronic disease.
In all 19 children, the Button was asthetically more acceptable and produced less
skin irritation than the standard tube gastrostomy. All but one caregiver thought
that the Button gastrostomy was preferable to a tube gastrostomy. This was
especially apparent in the six neurologically normal children who were able to be
more active and had an improved self-image. Cost analysis showed that, despite the
higher initial cost of the Button, elimination of the need for frequent tube changes
and hospital visits made it ultimately more cost effective than the standard tube
gastrostomy.
The authors conclude that the Button gastrostomy is a useful alternative to the
standard tube gastrostomy in selected patients. Close long-term follow-up is
extremely important to ensure a good result.

La gastrotomie Button est devenue populaire pour les patients qui necessitent une
alimentation enterale de longue duree, car elle est jugee moins irritante, plus stable
et esthetiquement mieux acceptable que le tube de gastrotomie traditionnel. Les
auteurs ont evalue de fa$on prospective a l’aide d’un questionnaire normalise utilise
lors d’interviews personnelles, l’efficacite et le taux de complications chez 19
enfants a qui on avait pose une gastrotomie Button pendant une periode de 6 mois.
Chez 15 enfants, l’appareil Button remplafait un tube de gastrotomie standard et,
chez 4 d’entre-eux, il avait ete installe initialement par voie chirurgicale. Treize
enfants souffraient d’un deficit neurologique grave et 6 necessitaient une
alimentation enterale en complement d’un traitement nutritionnel pour une autre
maladie chronique.
Chez les 19 enfants, l’appareil Button etait plus esthetique et causait moins
d’irritation cutanee que le tube de gastrotomie standard. Tous les preposes aux
soins sauf un trouvaient que la gastrotomie Button etait preferable a un tube de
gastrotomie. Ceci etait particulierement evident chez les six enfants
neurologiquement normaux qui etaient capables d’une plus grande activite et qui
avaient une meilleure image d’eux-memes. L’analyse des couts a revele, qu’en depit
du cout initial plus eleve de l'appareil Button, l’elimination des frequents
changements de tubes et des visites a l’hopital rend le rapport cout/benefices plus
avantageux que celui du tube de gastrotomie standard.
Les auteurs concluent que, pour des cas choisis, la gastrotomie Button represente
une alternative attrayante au tube de gastrotomie standard. Une surveillance etroite
a long terme est importante si Ton veut assurer un bon resultat.

astrostomy tube feeding is fre
quently used in patients who
require long-term caloric supple
mentation. This technique is conve
nient for the caregiver because it
enables them to give bolus feeds
and is associated with a relatively
low complication rate. With the
advent of percutaneous tech
niques1-3 it has become possible to
insert a feeding gastrostomy in chil
dren with minimal morbidity.
There are a number of problems
associated with tube gastrostomies4
(Table I). Many patients experience
leakage around the tube, with re
sultant skin excoriation and devel
opment of granulation tissue. Acci
dental dislodgement of the tube is
relatively common, and migration of
the tube into the duodenum or
esophagus may also occur. Gastro
esophageal reflux may be caused or
exacerbated by a gastrostomy, par
ticularly in the neurologically im
paired patient.5 Finally, many neu
rologically normal patients experi
ence psychological problems be-
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cause of the cosmetic appearance of
the tube.
The gastrostomy feeding “but
ton” was developed by Gauderer,
Picha and Izant6 in an attempt to
circumvent some of these problems,
and is available commercially from
the Bard Corporation (Mississauga,
Ont.) as the Button gastrostomy. It
is made of silicone rubber and con
sists of a shaft containing a one
way valve and an inner portion that
flares out in a mushroom shape to
prevent dislodgement (Fig. 1). The
outer end is sealed with a cap when
the button is not in use. Connecting
tubes can be inserted either directly
or at a 90° angle to the button.
We report a prospective evalua
tion of the Button gastrostomy in
children. Our goal was to assess the
potential benefits and possible com
plications of this device and to
determine which population of chil
dren, if any, would benefit from its
use.

Button gastrostomy inserted were
followed up prospectively and were
re-evaluated in May 1989. Evalua
tion consisted of a standardized
questionnaire, an interview with the
caregiver and examination of the
child. All interviews were done by
the same physician (T.A.M.), and all
children returned for follow-up.
Costs associated with gastrosto
my insertion and care were assessed
in the 15 children who originally
had standard tube gastrostomies
and in all 19 who received the
Button gastrostomy (Table II).
Costs were broken down into tube
costs, supply costs (gauze, tape,
bags and connecting tubing), and
the cost of emergency and clinic
visits. The visit costs included phy
sician fees and a cost-per-visil fee,
calculated with a fully allocated
overhead model developed at our
institution.

mentation because of chronic illness
(chronic renal failure in three, type
IV glycogen storage disease in two
and Crohn’s disease in one). Five
children had an antireflux proce
dure either previous to (four pa
tients) or concomitantly with (one
patient) insertion of the Button gas
trostomy.
Skin Irritation

Skin problems were present to
some extent in all children who had
had a previous tube gastrostomy.
There was substantial improvement
in skin excoriation and the forma
tion of granulation tissue in every
patient.
Dislodgement

There were no incidents of acci
dental dislodgement of the Button
gastrostomy.

Results

Complications

Methods

Patient Characteristics

Between September 1988 and
February 1989 we offered a Button
gastrostomy to all children under
our care who had an indwelling
gastrostomy tube. Of 29 such chil
dren, 15 chose to have their Malecot, Depezzer or Foley catheters
replaced with a Button gastrosto
my. This was done in the clinic,
with or without mild sedation. In
addition, we offered the Button to
six new patients who required inser
tion of a feeding gastrostomy, and
four agreed.
All 19 children who had the

The 19 children (12 boys, 7 girls)
ranged in age from 1 to 15 years
(median 5 years). Thirteen children
had significant neurologic impair
ment, which caused dysphagia or
chronic pharyngeal dyscoordination, and 6 required caloric supple

The most common complication
was accidental dislodgement of the
connecting tube from the button
during feedings (Table I). This
problem was usually the result of a
discrepancy between the size of the
button and of the connecting tube,
and was alleviated by changing the
tubing to an appropriate size. In
several cases, the child was persis
tently active during feedings, caus
ing repeated dislodgement of the
connecting tube. Secure taping of
the tube under protective clothing
successfully minimized this prob
lem.
Five neurologically impaired chil
dren had problems with valve plug
ging or incompetence, resulting in
leakage of feeds and gastric con
tents. We were able to prevent this
complication in each case by in
structing the caregiver to flush the
button after every feed with 20 to
50 mL of water.

S A F E IY 1-----P L U G --------- •
R A D IO P A Q U E /r
D O M E ------

U
A N T I-R E F L U X
p — V A (.V E

.

Table 1 Complications in 19 Children Who
Received the Button Gastrostomy
Complication
Accidental dislodgem ent of
connecting tube
Valve dysfunction
Leakage around feeding
jejunostom y
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FIG. 1. Diagram of gastrostomy feed
ing button. One-way valve prevents
reflux of gastric contents between
feeds. (Reprinted with permission of
the Bard Corporation, Mississauga,
Ont.)

BUTTON GASTROSTOMY

Three children suffered from gas
troesophageal reflux after insertion
of the button. Because of serious
associated medical problems, none
were considered candidates for an
antireflux procedure. These patients
had a Silastic catheter passed
through the button into the jeju
num. In all three patients, the jeju
nal tube rendered the valve in
competent, causing leakage of
gastric contents with resultant skin
breakdown. Although we have tem
porized in these children by plug
ging the button with karaya paste
or silicone glue, this has remained a
difficult problem.

level of activity and improvement in
their self-image.
Cost Analysis

The Button gastrostomy is cur
rently not covered at our institution
by the Ontario Ministry of Health
Assistive Devices Program. In most
cases, therefore, patients are re
sponsible for recovering the total
cost of the device from third par
ties, or for covering the cost them
selves (Table II). Consequently, al
though the total cost to the health
care system of the Button gastros
tomy is less, the financial burden
for the patient may be greater.

Comparison With Tube
Gastrostomy

Discussion
Comparison of the Button and
tube gastrostomies was possible
only in the 15 children who had
had a previous tube gastrostomy.
All but one of the caregivers of
these children felt that the Button
gastrostomy was preferable. The
caregiver who preferred the stan
dard tube gastrostomy had a
4-year-old child with Tay-Sachs
disease, and she experienced persis
tent problems with dislodgement of
the connecting tube. All caregivers
found the Button gastrostomies to
be esthetically more acceptable.
Preference for the Button gastros
tomy was expressed particularly
strongly by the children who were
neurologically normal. These chil
dren reported an increase in their

The results of our study are
consistent with the findings of sev
eral other groups7-9 and suggest
that the Button gastrostomy offers
distinct advantages over standard
tube gastrostomies in many in
stances. The observed improvement
in skin irritation and the elimination
of accidental tube dislodgement
were particularly impressive in our
series. In addition, there was a
definite improvement in perceived
self-image in the group of neurolog
ically normal children.
We did encounter a number of
problems. There was a high inci
dence of connecting-tube dislodge
ment during feeds. We were able to
minimize this problem by ensuring

T a b le II. C o s t A n a ly s is fo r S ta n d a rd T u b e and B u tto n G a s tro s to m ie s *
T y p e of g a s tro s to m y
Costs

S ta n d a rd tube

Button

T u b e (s)
S u p p lie s
E m e rg e n cy v is its
C lin ic v is its

4 2 .6 3
1 7 1 .4 7
9 2 .4 5
1 1 5 .8 5

2 2 6 .0 0
2 6 .6 0
1 6 .0 8
3 5 .6 5

T o ta l c o s t
C o st b o rn e b y th e p a tie n t

4 2 2 .4 0
0 .0 0

3 0 4 .3 3
2 5 2 .6 0

'C o s ts are e xp re s s e d in C a n adian d o lla rs (1 9 8 8 e q u iv a le n t) p e r p a tie n t p e r 1 2 -m o n th p e rio d .

that the tube size was matched
appropriately with the button and
by teaching the caregivers to fix the
tube securely. The second problem
was valve incompetence, which was
preventable by adequate flushing of
the button after feeds. These prob
lems illustrate the importance of
adequate education for the caregiv
er before insertion of the Button
gastrostomy and the need for fre
quent follow-up of these patients.10
The increased incidence of gas
troesophageal reflux in neurologi
cally impaired children is well
known and is particularly marked
after gastrostomy insertion.1112
Three of our patients had clinically
significant reflux after placement of
the Button gastrostomy and re
quired a transgastric jejunal tube.
Valve dysfunction in these patients
has been a persistent problem,
which may be alleviated by the
development of a special tube spe
cifically for this purpose.
Despite its high initial cost, the
Button gastrostomy was significant
ly more cost-effective to the health
care system than the standard tube
gastrostomy. Because of the de
creased maintenance cost of the
Button gastrostomy, this benefit in
creases the longer the device is
used. Since our calculations were
based on only one year of use, we
have probably underestimated the
financial advantage to the system.
Unfortunately, the need for the pa
tient to bear the capital cost has
continued to deter the parents of
many of our patients from choosing
a Button gastrostomy.
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associated case summaries. In this re
spect, the text serves as an adequate
reference for diseases commonly identi
fied at laparoscopy.
In the initial chapter the author
describes his technique and instrument
preferences for basic laparoscopy. De
tails are clearly presented and illustra
tions are appropriate. The author’s
preference for local anesthesia is inter
esting but not currently applicable in
face of more frequent therapeutic lapa
roscopy.
The next three chapters deal consec
utively with abdominal pain, abdominal

The next chapter deals with thera
peutic laparoscopy. Included are brief
descriptions o f abscess drainage, cyst
drainage, appendectomy, lupus of adhe
sions, and dialysis catheter placement
and adjustment, and a longer descrip
tion o f laparoscopic cholecystectomy.
Variations in technique are common in
surgery, and this author’s descriptions
are no exception. The information pre

BOOK REVIEWS
continued from page 229

including management o f pain, paraneo
plastic syndromes and psychosocial
problems.
Overall, I would recommend this as a
good basic textbook for someone who
is managing cancer patients and wishes
to understand the spectrum o f manage
ment options available for each tumour
type.
W alley J. Temple, MD, FRCSC, FACS
Director
Department of Surgery
Tom Baker Cancer Centre
1331 - 29 St. NW
Calgary, AB
T2N 4N2

LAPAROSCOPY FOR SURGEONS.
Barry A. Salky. 157 pp. Illust. IgakuShoin Medical Publishers Inc., New
York. 1990. Price not stated. ISBN 8 9 6 4 0 -1 6 6 -9
This book is directed to the practising
general surgeon who is initiating his
experience in laparoscopy for diagnostic
and therapeutic purposes. It is simply
written in a case-summary format.
The author has included 228 figures,
the majority of which are in colour and
o f excellent quality. Three-quarters of
these photographs are laparoscopic
documents of abdominal pathologic
conditions or technique described in the
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masses and liver disease. Illustrations
present the pathologic features, tech
niques of manipulation and direct-vision
biopsies. These chapters deal entirely
with diagnostic laparoscopy but include
a broad spectrum o f pathologic states,
accounting for the variable clinical con
ditions concisely summarized by 32, 14
and 47 cases, respectively. No advanced
or new techniques are presented in
these chapters; however, the content is
valuable as basic reference material for
the initiate to laparoscopic surgery.
The fifth chapter addresses laparos
copy for ascites. It illustrates the lapa
roscopic appearance o f 5 benign and 18
malignant causes o f exudative ascites
diagnosed by laparoscopy and biopsy
following paracentesis. This material
could easily have been assimilated in
the preceding three chapters.

sented is inadequate to serve as techni
cal reference material, although the
illustrations are excellent.
The last chapter on emergency lapa
roscopy is contributed by Dr. George
Berci and is an abbreviated, nonillustrated set o f guidelines for consider
ation in cases o f abdominal trauma or
perforated viscus. The contributor’s ex
perience is included in each brief over
view.
This book should be considered for
reference to diagnostic laparoscopy be
cause o f the numerous high-quality
laparoscopic photographs. It cannot be
recommended as an aid to the general
surgeon requiring technical information
for therapeutic laparoscopy.

Roger G. Keith, MD, FRCSC
Professor and head
Department of Surgery
University Hospital
University of Saskatchewan
Saskatoon, SK
S7N 0X0
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Laparoscopic Appendectomy
Patrick J. O’Regan, MB, BCh, BAO, FRCSC
In October 1989 the author began a study of laparoscopic appendectomy. This paper
presents the preliminary results in 21 patients. Laparoscopy was carried out for
diagnosis and 12 patients underwent laparoscopic appendectomy. The morbidity,
length of hospital stay and time lost from work was reduced in all 12 patients. The
author describes the technique of laparoscopic appendectomy and recommends that
only experienced laparoscopists should carry out this procedure.

En octobre 1989, l’auteur commen?ait une etude sur l’appendicectomie par voie
laparoscopique. Cet article porte sur les resultats preliminaries chez 21 patients.
Apres une laparotomie de diagnostic, 12 patients ont subi une appendicectomie par
laparoscopie. La morbidity la duree du sejour hospitalier et la duree d’absence au
travail ont ete reduites dans tous les cas. L’auteur decrit la technique d’appendicectomie laparoscopique et recommande que seuls les laparoscopistes experiments
utilisent cette intervention.

by placing the Verries needle at the
umbilicus, and the peritoneal cavity
is distended with approximately 3 L
of carbon dioxide. The telescope is
then inserted through an appropri
ate-sized cannula at the umbilicus.
A second puncture is made with a
5-mm trochar and cannula in the
midline above the pubis, and the
appendix is exposed with the aid of
a probe.
If the diagnosis of acute appen
dicitis is correct and the appendix
can be mobilized, then a laparo
scopic appendectomy is performed.
A third puncture is made with a
5-mm trochar and cannula laterally
to the right of the umbilicus. The
appendix is then held with a grasp
ing forceps so that the mesoappendix can be clearly visualized. The
mesoappendix is grasped with a

1989 I initiated a
InstudyOctober
of laparoscopic appendec
tomy. Up to that time laparoscopy
was performed frequently but selec
tively for the diagnosis of acute
appendicitis, and laparoscopic ap
pendectomy was performed only in
selected cases. In this paper I de
scribe the technique of laparoscopic
appendectomy and report the pre
liminary results from this study.

Methods
Every patient with suspected
acute appendicitis is assessed by
diagnostic laparoscopy unless some
contraindication is present. The na
ture of the procedure is explained
and informed consent is obtained. A
pneumoperitoneum is established

From the Department o f Surgery, University Hospital-Shaughnessy Site, Vancouver, BC

bipolar coagulation forceps and the
vessels of the mesoappendix are
carefully sealed with this device.1
The mesoappendix is then divided
with the scissors along its margin
with the appendix. A prepared liga
ture (Roeder loop) is introduced
into the abdomen and is placed
around the appendix at its junction
with the cecum, and the appendix is
ligated securely. A Maxon (Davis &
Geek) ligature, which slides easily
and is absorbable, is used for liga
tion of the appendix and this loop is
fashioned in the operating room at
the time of surgery. The appendix
is then divided leaving a short
stump to prevent the tie from slip
ping off. The appendix is held se
curely by the cut end to prevent
leakage of its contents. A 10- or
15-mm trochar and cannula, de
pending on the size of the appen
dix, are then introduced through
the right-sided puncture, and the
appendix is delivered through the
cannula. A pursestring suture to
bury the stump is not necessary.
Peritoneal lavage and aspiration of
pus can be performed as desired. A
fascial suture is placed as indicated
at the puncture sites. A special knot
guide and a 15-mm trochar and
cannula (Figs. 1 and 2), both of
which were developed in conjunc
tion with the Laborie Surgical Com
pany of Montreal, are helpful with
the procedure.

The Study
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Between October 1989 and Sep
tember 1990, 24 patients presented

LAPAROSCOPIC APPENDECTOMY

with a tentative diagnosis o f acute
appendicitis (Table I). Laparoscopy
was contraindicated in three preg
nant women. Of 21 patients who

underwent diagnostic laparoscopy,
17 were found to have acute appen
dicitis and 11 of those were treated
by laparoscopic appendectomy. A

FIG. 1. Top and middle: trochar and cannula, 15 mm in diameter; bottom: knot
guide and cannula. Suture loop of Maxon can be seen on left.

laparoscopic
appendectomy
was
performed
in one
patient,
a
17-year-old girl, who had had multi
ple hospital admissions for acute
abdominal pain but did not have
acute appendicitis. Five patients un
derwent appendectomy through a
transverse laparotomy incision over
the appendix after they were found

FIG. 2. Detail of tip of knot guide and
suture loop.

T a b le I. Data on 2 4 Patients W ho Presented W ith a Tentative D iagnosis o f A pp en dicitis
Patient
no.

Age, yr

Sex

1

31

M

M edium

A pp en dicitis

2
3

37
30

M
M

M edium
M edium

A pp e n d icitis
A pp e n d icitis

4

17

M

Thin

A pp e n d icitis

5
6

82
20

M
F

Obese
Thin

A pp en dicitis
A pp en dicitis

7
8
9
10
11

40
37
24
17
50

M
M
F
F
F

Thin
Obese
18 w k pregnant
Thin
M edium

P erforated ulcer
A pp e n d icitis
G astroenteritis
A pp en dicitis
A pp e n d icitis

12

18

M

Thin

A pp en dicitis

13
14
15
16

24
17
31
51

F
F
F
M

26 w k pregnant
Obese
23 w k pregnant
M edium

To rsio n o f tip of o m e n tu m
Ruptured ovarian c ys t
A pp en dicitis
A pp en dicitis

17
18
19
20

75
57
38
17

M
M
F
F

M edium
M edium
Obese
Thin

A pp en dicitis
G astroenteritis
A pp en dicitis
R etrograde m e nstruation

21

37

F

Thin

A pp en dicitis

22

51

M

Obese

23

25

F

Thin

A pp e n d icitis, perforated
appendix
A pp en dicitis

24

41

F

Obese

A pp en dicitis

Build

Diagnosis

Treatm ent

Operating tim e , m in

La paroscopic
ap pe nde ctom y
La paroscopy, la p a ro to m y
La paroscopic
ap pe nde ctom y
La paroscopic
ap pe nde ctom y
La pa roscop y, la p a ro to m y
Lapa roscop ic
ap pe nde ctom y
La pa roscop y
La pa roscop y, la p a ro to m y
La p a ro to m y
Lapa roscop y, la p a ro to m y
La paroscopic
ap pe nde ctom y
La pa roscop ic
ap pe nde ctom y
La p a ro to m y
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45
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to have a fixed, inflamed appendix
during diagnostic laparoscopy. Part
or all of the appendix was visible in
all of the patients who underwent
laparoscopy, so that an accurate
diagnosis was possible in every
case. One patient was found to have
a perforated duodenal ulcer, which
had leaked and resealed, and this
could clearly be seen at laparos
copy. This patient was treated nonsurgically with nasogastric suction,
intravenous fluids and antibiotics
without complications.
Postoperatively the patients who
underwent laparoscopic appendec
tomy were all ready for discharge
on the second postoperative day.23
They were treated with met
ronidazole and gentamicin intrave
nously, and the metronidazole was
continued orally for a further 5
days after discharge. No significant
complications were encountered.
One patient was readmitted on post
operative day 3 complaining of a
migraine headache, vomiting and
abdominal pain. She recovered
without incident and was dis
charged home 2 days later. All
patients were completely recovered
and fit to return to previous em
ployment in 1 week after laparo
scopic appendectomy.
In half the cases it was possible
to deliver the appendix through a
10-mm cannula; a 15-mm cannula
was required to deliver the other
half. To determine the cannula size
required the diameter of the appen
dix is measured against the jaws of
the scissors as the appendix is
being divided. When the appendix is
bulky it is especially important to
divide the mesoappendix along its
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margin with the appendix to facili
tate its delivery.

Discussion
Laparoscopy has not been widely
used in general surgery because the
indications are limited. It is difficult,
therefore, for general surgeons to
become well acquainted with laparo
scopic surgical techniques. An in
creasing number of procedures are
now being performed with the lapa
roscope.4 In our department we per
formed approximately 100 laparo
scopies before embarking on laparo
scopic appendectomy as a routine
procedure. Sometimes even those
patients who present with “classic”
symptoms and signs of acute appen
dicitis will, on exploration, prove to
have a normal appendix. The diag
nosis can be especially difficult in
women of childbearing age when a
number of gynecologic conditions
can be present. In some series close
to half of the appendices removed in
this group are normal.5
The advantages of laparoscopy in
the management of appendicitis are
numerous. First, the diagnosis can
be clearly established. A patient
who does not have appendicitis can
usually be discharged within 24
hours. If some other condition re
quiring treatment is diagnosed such
as pelvic inflammatory disease ap
propriate treatment can be institut
ed and complications such as infer
tility may be prevented. When lapa
roscopic appendectomy is possible
the morbidity is markedly reduced.6
I recommend that only surgeons
well versed in the techniques of

diagnostic laparoscopy should at
tempt this procedure. Complica
tions should be minimal with good
visualization, and wound infection
should be eliminated because the
inflamed appendix does not touch
and contaminate the layers of the
abdominal wall. The results so far
indicate that diagnostic laparoscopy
is valuable in establishing the diag
nosis in patients suspected of hav
ing acute appendicitis, and unneces
sary laparotomy can be avoided, as
was the case in four patients in this
study. When acute appendicitis is
found it appears that a laparoscopic
appendectomy can be performed
safely and with decreased disruption
of the patient’s daily routine in
about two-thirds of the cases. Lapa
roscopic appendectomy is more
likely to be possible in younger
patients than in the elderly.
I thank Ms. Gail Scarrow, RTR, re
search assistant, for her technical assis
tance.
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Recurrent Massive Subperiosteal
Hemorrhage in a Patient
With Neurofibromatosis: a Case Report
0. Huk, MD, FRCSC;* N. Newman, MD, FRCSC;f J.V. Fowles, MB, BS(Lond), FRCSC$
The authors report a rare complication of neurofibromatosis, recurrent rapidly
expanding massive subperiosteal hematomas, in the thigh of a 22-year-old woman.
The diagnosis was confirmed by plain radiography, ultrasonography and computed
tomography. The first two hematomas were drained through a longitudinal lateral
incision, tightly closing the periosteum over drains and applying a compression
dressing postoperatively. The third hematoma was treated expectantly.
Recurrent subperiosteal hematomas may lead to the formation of huge bone cysts
and grotesque limb deformity, for which amputation may be the only solution.

Les auteurs ont observe chez une femme de 22 ans, une complication rare de la
neurofibromatose, soit des hematomes sous-periostes recidivants de la cuisse. Le
diagnostic fut confirme par film simple, echographie et tomographie axiale. Les
deux premiers hematomes furent draines par incision laterale longitudinale,
fermeture serree du perioste sur les drains et application postoperatoire d’un
bandage compressif. Le troisieme hematome fut traite de fa?on conservatrice.
Les hematomes sous-periostes recidivants peuvent entrainer la formation d’enormes kystes osseux et de difformites importantes des membres pour lesquelles
l’amputation peut representer la seule solution.

eurofibromatosis classically
presents as cutaneous hyper
pigmentation, known as “cafe-aulait” spots, and multiple neurofi
bromas. The musculoskeletal sys
tem is affected in 50% of patients
and common abnormalities include

N

short-segment angular scoliosis,
pseudarthrosis of the tibia and par
tial or total limb gigantism.1 A rarer
manifestation or, more specifically,
complication of neurofibromatosis
is massive subperiosteal hemorrh
age whose ultimate radiologic ap
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pearance is that of a subperiosteal
or cortical bone cyst. Such bone
cysts were described as early as
1924 by Brooks and Lehman.2
Since then, isolated reports have
appeared in the literature.3"7 Clini
cally, the subperiosteal hemorrhage
poses a diagnostic and management
dilemma. We report the case of a
patient with neurofibromatosis and
recurrent femoral subperiosteal he
matomas.

Case Report

In April 1988 this 22-year-old
woman, a psychology student who
had had neurofibromatosis and gi
gantism of the left thigh from child
hood, presented with a 4-day histo
ry of progressive enlargement and
increasing tension of her left thigh
after swimming.
When she was 10 years old she
had experienced rapid swelling of
her right leg which was treated as a
case of osteomyelitis with intrave
nous antibiotics. The swelling had
occurred after a trivial fall, and an
infecting organism had never been
identified. She was well after that
until 1986 when she had an acute
swelling of the left thigh. She was
again treated at a pediatric hospital
where a massive subperiosteal he
matoma of the left thigh was in
cised and drained. Histologic examiCJS, VOL. 34, NO. 3, JUNE 1991
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nation of the hematoma capsule
revealed neurofibromas and richly
cellular granulation tissue.
On examination cafe-au-lait spots
and subcutaneous nodules were
seen over her entire body. She had
a large hairy patch over the right
parasacral region and a lumbar scar
from a fusion and Harrington-rod
fixation, which she required for
scoliosis at the age of 16 years. She
had gigantism and a varus deformi
ty of her right leg and foot. There
was a huge fluctuant mass in the
left thigh whose diameter was 10
cm greater than the right thigh.
The left thigh was neither warm nor
erythematous and there was no vas
cular dilatation or bruit. There was
a wide scar over the lateral aspect
of the distal one-third of the left
thigh from the incision and drain
age 2 years previously. She had
pleats of hypertrophied skin and
subcutaneous tissue about her left
knee.
The results of laboratory investi
gation, including a complete blood
count, coagulography and measure
ment of the sedimentation rate,

serum electrolytes and vitamin C
levels, were normal. A plain radio
graph of the left thigh and knee
showed massive soft-tissue swell
ing, an irregular tortuous femoral
contour and distal cortical cyst for
mation secondary to the previous
subperiosteal hematoma. Ul
trasonography of the thigh con
firmed the presence of a fluid accu
mulation. A computed tomography
scan showed a massive homoge
neous collection surrounding the
entire length of the femur, lifting
the muscles off the cortex to give
an appearance of subperiosteal
stripping (Fig. 1). Because this was
a recurrence in the same thigh, a
vascular anomaly was suspected.
However, other than vascular dis
placement by the fluid mass, the
arteriogram was normal.
After admission for observation,
the thigh continued to increase in
size. The patient had daily tempera
ture spikes to 39°C for 4 days, and
her hemoglobin level dropped from
132 g /L to 100 g/L . Blood cul
tures were negative.
Because of the increasing size of

FIG. 1. Computed tomography scan of both thighs in April 1986 shows massive
soft-tissue swelling around left femoral shaft, displacing all muscle groups to
periphery.
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the hematoma, we decided to drain
it through a posterolateral incision.
The hematoma was indeed subperi
osteal and encircled the entire ante
rior and medial surface of the fe
mur. There was continued diffuse
oozing of blood following the re
moval of 1.5 L of clot. The perioste
al wall was closed tightly over suc
tion drains and a Jones compression
bandage was applied to the lower
limb.
On histologic examination of the
capsular wall the findings were
compatible with an organizing he
matoma with much active fibrosis.
Neurofibromatous tissue was appar-

FIG. 2. Anteroposterior radiograph of
femoral shaft taken in September
1988, 5 months after drainage of he
matoma, shows new calcification in
recent hematoma (double arrows). Cor
tical bone cyst of 2 years earlier is
clearly visible distally (single arrow).
Smaller cortical bone cysts are evident
elsewhere in distal shaft.

SUBPERIOSTEAL HEMORRHAGE IN NEUROFIBROMATOSIS

ent in the specimen. Postoperatively, the patient’s thigh gradually
decreased to its normal size. A
radiograph of the femur 5 months
later showed new subperiosteal cal
cification (Fig. 2). One year postoperatively the patient had a recur
rence in the same thigh. This was
treated expectantly, and the swell
ing gradually subsided over the en

suing weeks. The patient has had
no further recurrence (Fig. 3).

Discussion
This case demonstrates a rare
musculoskeletal abnormality of
neurofibromatosis: the triad of limb
hypertrophy, recurrent subperios

FIG. 3. Anteroposterior and lateral radiographs of proximal and distal femur 6
months after last hematoma show thickened, remodelled cortex and partial
obliteration of medullary canal. Cystic cortical cavities are evident in femur and
proximal tibia, and femoral and tibial epiphyses are somewhat deformed.

teal hemorrhage without trauma
and subsequent subperiosteal newbone formation. The differential di
agnosis of the thigh mass included
osteomyelitis, arteriovenous malfor
mation, bleeding neurofibroma, coa
gulopathy and malignant transfor
mation of a neurofibroma. Careful
investigation clarified the diagnosis.
In retrospect, the previous swollen
leg was probably her first subperi
osteal hemorrhage.
There are two explanations for
the radiologic appearance of the
so-called “cortical bone cyst” in
patients with neurofibromatosis.
One theory, based on histologic
specimens, states that a cyst is a
periosteal reaction to neurofibromas
within the periosteum.23 Locht,
Huebert and McFarland3 were able
to demonstrate histologically an in
creased vascularity and looseness of
the periosteum containing neurofi
bromas. The second theory is one
put forth by Pitt, Mosher and
Edeiken4 who postulated that neu
rofibromatosis is not only a dyspla
sia of neuroectodermal structures,
but of mesodermal structures also.
Although not based on histologic
evidence, these and other authors
believe that the mesodermal dyspla
sia manifests as a fragile, nonadher
ent periosteum with little tamponading capacity, thus explaining
the rapid and extended periosteal
elevation.4-7 Histologic evidence
from this patient’s most recent op
eration was nonspecific, demon
strating only fibrosis and organiz
ing hematoma. On the other hand,
the capsule wall examined at the
time of her first surgical drainage
did indeed demonstrate neurofibromatous tissue.
The treatment of this rare com
plication is not well established.
Locht, Huebert and McFarland3 ar
gued that early surgical drainage is
not necessary because there is a
high rate of recurrence of the he
matoma. Although early evacuation
CIS, VOL. 34, NO. 3, JUNE 1991
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of the hematoma does not prevent
subsequent subperiosteal hemorrh
age and hematoma formation, it
may help to avoid grotesque defor
mity and consequent corrective sur
gery. Repeated episodes of un
treated hematoma formation some
times produce so much deformity
and loss of function that amputa
tion may be necessary.4
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ACTION
In vitro studies demonstrate that the bactericidal
action of cefoxitin, a cephamycin derived from
cephamycin C, results from the inhibition of
bacterial cell wall synthesis. Evidence suggests
that the methoxy group in the 7o position is
responsible for the resistance of cefoxitin to
degradation by bacterial beta-lactamases.

INDICATIONS AND CLINICAL USES
TREATMENT

The treatment of the following infections when
due to susceptible organisms:
1 - Intra-abdominal infections such as peritonitis
and intra-abdominal abscess
2 - Gynecological infections such as endo
metritis and pelvic cellulitis
3 - Septicemia
4 - Urinary tract infections (including those
caused by Serratia marcescens and Serratia
spp.)
5 - Lower respiratory tract infections
6 - Bone and jo in t in fe ctio ns caused by
Staphylococcus aureus
7 - Soft tissue infections such as cellulitis,
abscesses and wound infections
Appropriate culture and susceptibility studies
should be performed to determine the susceptib ilit y of th e ca u s a tiv e o rg a n is m (s ) to
MEFOXIN®. Therapy may be started while
awaiting the results of these tests, however,
modification of the treatment may be required
once these results become available.
Organisms particularly appropriate for therapy
with MEFOXIN® are:
Gram positive

Staphylococci, penicillinase producing and
non-producing
Streptococci excluding enterococci
Gram negative (beta-lactamase producing and
non-producing strains)

Escherichia coli
Klebsiella species (including K. pneumoniae)
Proteus, indole positive and negative
Haemophilus influenzae
Providencia species
Anaerobes

Bacteroides fragilis
MEFOXIN® may also be appropriate for the
treatment of infections involving susceptible
strains of both aerobic and anaerobic bacteria.
MEFOXIN® is not active against Pseudomonas
spp., most strains of enterococci, many strains
of Enterobacter cloacae, and m ethicillinr e s is ta n t s ta p h y lo c o c c i and L is te r ia
monocytogenes.
Clinical experience has demonstrated that
MEFOXIN® can be administered to patients who
are also receiving carbenicillin, gentamicin,
tobramycin, or amikacin (see PRECAUTIONS
and ADMINISTRATION).
PROPHYLACTIC USE

MEFOXIN® may be administered perioperatively (preoperatively, intraoperatively and postoperatively) to patients undergoing vaginal or
abdominal hysterectomy and abdominal surgery
when there is a significant risk of postoperative
infection or where the occurrence of post
operative infection isconsidered to be especially
serious.
In patients undergoing cesarean section, intra
operative (after clamping the umbilical cord)
and postoperative use of MEFOXIN® may
reduce the incidence of surgery related post
operative infections.

®Trademark Merck &Co., Inc.
Merck Frosst Canada Inc., R.U.

Effective prophylactic use depends on the time
of administration. MEFOXIN® usually should be
given one-half to one hour before the operation.
Prophylactic administration should usually be
stopped within 12 hours. It has been generally
reported that continuing administration of any
antibiotic beyond 24 hours following surgery
increases the possibility of adverse reactions
but, in the majority of surgical procedures, does
not reduce the incidence of subsequent
infection.
If signs of postsurgical infection should appear,
specimens for culture should be obtained for
identification of the causative organism(s) so
that appropriate treatment may be instituted.

CONTRAINDICATIONS
MEFOXIN® is contraindicated in persons who
have shown hypersensitivity to cefoxitin or to
the cephalosporin group of antibiotics.

WARNINGS
Before therapy with MEFOXIN® is instituted,
careful inquiry should be made to determine
whether the patient has had previous hyper
sensitivity reactions to MEFOXIN®, cepha
losporins, penicillinsorotherdrugs. MEFOXIN®
should be given with caution to penicillinsensitive patients.
There is some clinical and laboratory evidence
of partial cross-allergenicity between cephamycins and the other beta-lactam antibiotics,
penicillins and cephalosporins. Severe reactions
(including anaphylaxis) have been reported
with most beta-lactam antibiotics.
Pseudomembranous colitis has been reported
w ith v ir tu a lly a ll a n tib io tic s in c lu d in g
MEFOXIN®. This colitis can range from mild to
life threatening in severity. Antibiotics should
therefore be prescribed with caution in indi
viduals with a historyof gastrointestinal disease,
particularly colitis. It is important to consider a
diagnosis of pseudomembranous colitis in
patients who develop diarrhea in association
with antibiotic use. While studies indicate that a
toxin produced by Clostridium difficile is one
primary cause of antibiotic-associated colitis,
other causes should also be considered.
Any patient who has demonstrated some form of
allergy, particularly to drugs, should receive
antibiotics including MEFOXIN® with caution.
If an allergic reaction to MEFOXIN® occurs,
adm inistration of the drug should be dis
continued. Serious hypersensitivity reactions
may require treatment with epinephrine and
other emergency measures.

PRECAUTIONS
The total daily dosage should be reduced when
MEFOXIN® is administered to patients with
transient or persistent reduction of urinary
output due to renal insufficiency (see DOSAGE
AND ADMINISTRATION) because high and
prolonged serum antibiotic concentrations can
occur from usual doses.
In patients treated with MEFOXIN® a false
positive reaction to glucose in the urine may
occur with Benedict's or Fehling’s solutions but
not with the use of specific glucose oxidase
methods.
Using the Jaffe Method, falsely high creatinine
values in serum may occur if serum concen
trations of cefoxitin exceed 100 pg/mL. Serum
samples from patients treated with MEFOXIN®
should not be analyzed for creatinine if with
drawn within two hours of drug administration.
High concentrations of cefoxitin in the urine
may interfere with measurement of urinary 17hydroxy-corticosteroids by the Porter-Silber
reaction, and produce false increases of modest
degree in the levels reported.
Increased nephrotoxicity has been reported
fo llo w in g co n co m ita n t a d m in istra tio n of
cephalosporins and aminoglycoside antibiotics.
Prolonged use of MEFOXIN® may result in the
overgrowth of non-susceptible organisms.
Repeated evaluation of the patient’s condition is
essential and if super-infection occurs during
therapy, appropriate measures should be taken.
Should an organism become resistant during
antibiotic therapy, another antibiotic should be
substituted.

Use in Pregnancy
The safety of MEFOXIN® in the treatment of
infections during pregnancy has not been
established. If the administration of MEFOXIN®
during pregnancy is considered necessary, its
use requires that the anticipated benefits be
weighed against possible hazards to the fetus.
Reproductive and teratogenic studies have been
performed in mice and rats and have revealed no
evidence of impaired fertility or harm to the fetus
due to MEFOXIN®.
There are no controlled studies in pregnant
women.
Nursing Mothers
Cefoxitin is excreted in human milk. Caution
should be exercised if use is indicated.
Children
In children 3 months of age or older, higher
doses of MEFOXIN® (100 m g/kg /d a y and
above) have been associated with an increased
incidence of eosinophilia and elevated SGOT.

ADVERSE REACTIONS
MEFOXIN® is generally well tolerated. Adverse
reactions rarely required cessation of treatment
and usually have been mild and transient.
Local Reactions
Throm bophlebitis has occurred with intra
venous administration. Some degree of pain and
tenderness is usually experienced after intra
muscular injections using water. Induration has
occasionally been reported.
Allergic
M a c u lo p a p u la r rash, u rtic a ria , p ru ritu s ,
eosinophilia, fever and other allergic reactions
including anaphylaxis have been noted.
Gastrointestinal
Symptoms of pseudomembranous colitis can
appear during or after antibiotic treatment.
Nausea and vomiting have been reported rarely.
Blood
Eosinophilia, leukopenia, neutropenia, hemo
lytic anemia, and thrombocytopenia and bone
marrow depression have been reported. Some
individuals, particularly those with azotemia,
may develop positive direct Coombs tests
during therapy with MEFOXIN®.
Liver Function
Transient elevations in SGOT, SGPT, serum
LDH, and serum alkaline phosphatase and
jaundice have been reported.
Cardiovascular Function
Flypotension.
Renal Function
Elevations in serum creatinine and/or blood
urea nitrogen levels have been observed. As
with the cephalosporins, acute renal failure has
been reported rarely. The role of MEFOXIN® in
changes in renal function tests is difficult to
assess, since factors predisposing to prerenal
azotemia or to impaired renal function have
often been present.

TREATMENT OF OVERDOSE
Other than general supportive treatment, no
specific antidote is known. MEFOXIN® can be
eliminated by dialysis in patients with renal
insufficiency.

DOSAGE AND ADMINISTRATION
MEFOXIN® may be administered intravenously
or intramuscularly as required. (See complete
m o n o g ra p h on A D M IN IS T R A T IO N and
RECONSTITUTION.)
Intravenous Administration
The intravenous route is preferable for patients
with bacteremia, bacterial septicemia, or other
severe or life-threatening infections, or for
patients who may be poor risks because of
lowered resistance resulting from such debili
ta ting conditions as m alnutrition, trauma,
surgery, diabetes, heart failure, or malignancy,
particularly if shock is present or impending.
TREATMENT DOSAGE
Adults
The usual a d u lt dosage is 1 g or 2 g of
MEFOXIN® every 6 to 8 hours. Dosage and
route of administration should be determined by

severity of infection, susce p tib ility of the
causative orgenisms, and condition of the
patient. The usual adult dosages are shown in
the Table below.
Usual Adult Dosage
Type of
infection

Dally
Dosage

Frequency
and Route

Uncomplicated
forms* of infections such as
pneumonia,
urinary tract
infection, soft
tissue infection

3-4 g

Moderately
severe or severe
infections

6-8 g

1 g every 4 h
or
2 g every 6-8 h I.V.

Infections
commonly
needing anti
biotics in higher
dosage (e g. gas
gangrene)

129

2 g every 4 h
or
3 g every 6 h I.V.

I.V. orl.M .

Therapy may be started while awaiting the
results of susceptibility testing.
Antibiotic therapy for group A beta-hemolytic
streptococcal infections should be maintained
for at least 10 days to guard against the risk of
rheum atic fever or g lom erulonephritis. In
staphylococcal and other infections involving a
collection of pus, surgical drainage should be
carried out where indicated.
Adults with Impaired Renal Function
MEFOXIN® may be used in patients with
reduced renal function but a reduced dosage
should be employed and it is advisable to
monitor serum levels in patients with severe
impairment.
In adults with renal insufficiency, an initial
loading dose of 1 g to 2 g should be given. After
a loading dose, the following recommendations
for maintenance dosage may be used as a guide:
MAINTENANCE DOSAGE OF
MEFOXIN® IN ADULTS
WITH REDUCED RENAL FUNCTION

2 g adm inistered in tra m u scu la rly o r in tra 
venously just prior to surgery (approximately
one-half to one hour before initial incision).
The second and third 2 g doses should be
administered at 2-6 hour intervals after the
initial dose.
Cesarean Section
The first dose of 2 g should be administered
intravenously as soon as the umbilical cord has
been clamped. The second and third 2 g doses
should be given intravenously or intram us
cularly four hours and eight hours after the first
dose.

AVAILABILITY
MEFOXIN® is supplied as sterile powder in
boxes of 10 vials:
3356 Ca - 1 g cefoxitin as sodium salt
3357 Ca - 2 g cefoxitin as sodium salt
3548 Ca - 1 g c e fo x itin as sodium salt in
ADD-Vantage® vial
3549 Ca - 2 g c e fo x itin as sodium salt in
ADD-Vantage® vial
For full details on preparation and adminis
tra tio n w ith ADD-Vantage® vials - please
consult Product monograph.
Storage
MEFOXIN® in the dry state should be stored
below 30°C. The d ry m aterial as w ell as
solutions tends to darken, depending on storage
conditions; product potency, however, is not
adversely affected.

PRODUCT MONOGRAPH AVAILABLE
ON REQUEST

CREATININE
CLEARANCE
m L/m in

DOSE

FREQUENCY

50-30

1-2 g

every 8-12 h

Mild
impairment
Moderate
impairment
Severe
impairment
Essentially
no function

A t p re se n t th e re is in s u ffic ie n t d a ta to
recommend a specific dosage for children with
impaired renal function. Flowever, if the adminis
tration of MEFOXIN® is deemed to be essential
the dosage should be modified consistent with
the recommendations for adults (see Table
above).
PROPHYLACTIC USE
For prophylactic use, a three-dose regimen of
MEFOXIN® is recommended as follows:
V aginal or a b d o m in a l h y s te re c to m y and
abdominal surgery

1 g every 6-8 h

'Including patients in whom bacteremia is absent or
unlikely

RENAL
FUNCTION

In severe infections, the total daily dosage in
infants and ch ildren may be increased to
200 mg/kg, but not to exceed 12 g per day.
MEFOXIN® is not recommended for the therapy
of meningitis. If meningitis is suspected, an
appropriate antibiotic should be used.

29-10

1-2 g

every 12-24 h

9-5

0.5-1 g

every 12-24 h

<5

0.5-1 g

every 24-48 h

(342-a, 11,90)
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In patients undergoing hem odialysis, the
loading dose of 1 - 2 g should be given after each
hemodialysis, and the maintenance dose should
be given as indicated in the Table above.
Neonates (Including Premature Infants), Infants
and Children (See WARNINGS for Neonates
under ADMINISTRATION in the com plete
monograph.)
Premature Infants
w ith Body Weights
Above 1500 g

20-40 mg/kg every 12 h I.V.

Neonates

01 week of age20-40 mg/kg every 12 h I.V.
1- 4 weeks of age
20-40 mg/kg every 8 h I.V.
Infants

1 month to 2 years
of age

20-40 mg/kg every 6 h or
every 8 h I.M. or I.V.

Children

20-40 mg/kg every 6 h or
every 8 h I.M. or I.V.
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Brachial-Plexus Injury After Clavicular
Fracture: Case Report and Literature
Review
K.M. Rumball, MD;* V.F. Da Silva, MD;t D.N. Preston, MD;J C.C. Carruthers, MD§
Brachial plexus injury is a rare complication of the fractured clavicle. The authors
describe the second reported case of brachial plexus injury due to secondary fracture
displacement. This case emphasizes the following points: the neurologic status of
the arm after a fracture of the clavicle must be documented; fractures of the middle
one-third of the clavicle are prone to displacement; patients should be advised to
report immediately any new symptoms in the arm; when fracture displacement is the
cause of brachial-plexus compression then a trial of conservative therapy is
indicated; the prognosis for neurologic recovery after this injury is good.

Une lesion du plexus brachial est une complication rare de la fracture de la clavicule.
Les auteurs decrivent le deuxieme cas de lesion du plexus brachial consecutive au
deplacement d’une fracture. Ce cas met en lumiere les points suivants: il est
necessaire de bien definir l’etat neurologique du bras apres une fracture de la
clavicule; les fractures du tiers moyen de la clavicule sont sujettes a deplacement; les
patients doivent etre avises de signaler immediatement tout nouveau symptome du
bras; quand le deplacement d’un os fracture cause une compression du plexus
brachial, un traitement peut etre tente; apres une telle blessure, le pronostic de
guerison neurologique est bon.

fractured clavicle is rarely com
plicated by a brachial-plexus
injury. When a primary injury of
the plexus is seen in association
with a fractured clavicle it is usually
the result of a supraclavicular trac
tion injury.1 Secondary injury to the

A

infraclavicular portion of the plexus
has a number of causes,2-8 but the
role of fracture displacement is sel
dom mentioned.6 In this report we
describe a case of early secondary
injury to the brachial plexus after
displacement of a midclavicular
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fracture. Realignment of the frac
ture resulted in gradual, uncompli
cated clinical improvement.

Case Report
A 57-year-old man sustained a
closed fracture of the right clavicle
in a fall. Results of the initial
neurovascular examination were
normal. The initial film (Fig. 1)
showed a comminuted undisplaced
fracture of the middle one-third of
the clavicle. The arm was placed in
a sling, which he wore for 2 days.
Twenty-four hours after the injury
he noted numbness of the right
index and middle fingers. This pro
gressed to include the hand, and
there was diffuse weakness of the
arm.
Six days after injury the patient
returned for further investigation.
Physical examination revealed a
large area of ecchymoses in the
right pectoral area. There was no
local bruit. The radial and ulnar
pulses were normal. Pinprick sensa
tion was diminished. Two-point dis
crimination was absent in the right
hand. Because of discomfort we
could not test the shoulder girdle
muscles. However, there was grade
4 / 5 power in the flexor and exten
sor muscles of the elbow and wrist,
grade 3 / 5 power in the extensor
muscles of the fingers and absent or

BRACHIAL-PLEXUS INJURY

only slight contractility of the fin
ger flexor and intrinsic muscles of
the right hand. The right biceps
and triceps reflexes were absent.
The cervical spine had a normal
range of motion, and there were no
areas of tenderness.
Repeat x-ray films of the clavicle
(Fig. 2) showed fracture displace
ment, which was not present on the

initial film. A figure-of-eight ban
dage was applied. This improved
the alignment of the clavicle (Fig.
3). The patient was admitted to
hospital for observation. Within 2
days, there was a trace of finger
flexion and two-point discrimination
in the first and second fingers. A
physiotherapy program was started.
At 1 month, the ulnar intrinsic

muscles of the innervated hand
were graded at 2 /5 and the remain
ing muscle groups at 4 /5 . The
sensory evoked potentials of the
right median and radial nerves were
about 50% of normal. Electromyog
raphy of the ulnar intrinsic muscles
of the innervated hand revealed in
complete denervation. By 4 months
there was grade 4 /5 power of both
the intrinsic and extrinsic muscles
of the right hand and satisfactory
union of the clavicular fracture with
minimal malalignment.

Discussion

FIG. 2. Film at 6 days shows displacement of fracture.

The brachial plexus and subclavi
an vessels lie directly beneath the
middle third of the clavicle, separat
ed only by the subclavian muscle
and the clavipectoral fascia.7 Re
gardless of this anatomical proximi
ty, a closed fracture of the clavicle
is rarely complicated by an infraclavicular brachial-plexus injury.
A primary injury of the brachial
plexus as the direct result of a
clavicular fracture is unusual.
Rowe7 reported transient paresthe
sia in only 2 of 690 patients. More
commonly, a traction injury causes
disruption of the brachial plexus,
and the clavicular fracture is inci
dental. This results in a supra
clavicular plexus injury, which has
a less favourable prognosis.1 It is
important to distinguish this type of
lesion from a treatable secondary
injury to the plexus. This requires
careful examination and documen
tation of the neurologic status of
the extremity during the initial eval
uation of a patient with an acute
clavicular fracture.
Secondary injuries to the brachial
plexus following a clavicular frac
ture are also uncommon. In Rowe’s
series7 only two occurred. They may
be associated with manipulation of
the fracture,8 a tightly fitting fig
ure-of-eight bandage,5 an expandCJS, VOL. 34, NO. 3, JUNE 1991
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ing false aneurysm of the subclavi
an artery,2 exuberant callus forma
tion257 or nonunion.24 Displace
ment of a comminuted fracture also
appears to be a cause of early
secondary injury. Fractures of the
middle portion of the clavicle are
prone to displacement. The distal
fragment is pulled downward by the
weight of the arm and inward by
the pectoralis major and latissimus
dorsi muscles. The proximal frag
ment is pulled upward by the sternomastoid. Reichenbacher and Siebler6 reported a patient with a com
minuted midclavicular fracture who
suffered complete paralysis of the
brachial plexus after application of
a figure-of-eight bandage. After
open reduction and internal fixation
of the fracture, there was neurolog
ic improvement. They concluded
that loosening of the bandage had
allowed the injury to occur.
In the case reported, symptoms

began after 1 day and progressed.
Serial radiographs demonstrated an
undisplaced fracture initially, fol
lowed by gross displacement and
overt signs of brachial-plexus inju
ry. Realignment of the fracture re
sulted in gradual resolution of the
neurologic problem. At no time was
there evidence of any other injury
to account for the neurologic pic
ture.
Secondary injuries to the brachial
plexus associated with displacement
of a clavicular fracture are extreme
ly rare. Patients should be advised
to report immediately any numb
ness in the extremity after such a
fracture. A careful initial neurologic
examination is important to distin
guish the type of injury. When
fracture displacement is involved in
compression of the brachial plexus,
then conservative management,
aimed at realignment of the frac
ture, is indicated. It is known that

infraclavicular brachial-plexus inju
ries due to a shoulder injury have a
relatively good prognosis for neuro
logic recovery.1'9 Functional recov
ery may be enhanced by therapy to
prevent joint stiffness and edema of
the hand. Timely operative interven
tion may be required if there is
evidence of vascular injury or if the
expected improvement in symptoms
is delayed.
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Massive Intrapelvic Synovial Cyst
as a Complication of Total Hip
Replacement Arthroplasty: a Case Report
Robert W. McGraw, MD, FRCSC; Kenneth S. Morton, MD, MSc, FACS, FRCSC;
Clive P. Duncan, MD, FRCSC
The authors report a case of massive intrapelvic synovial cyst complicating total hip
arthroplasty in a 35-year-old woman with rheumatoid arthritis. The clinical
presentation raised the possibility of a coincidental soft-tissue malignant tumour.
This was ruled out by ultrasonography, computed tomography, fine-needle
aspiration with examination of cells and culture and, ultimately, by image
intensification in the operating room during aspiration of the cyst and injection of
the adjacent hip joint with Hypaque. The authors conclude that perforation of the
acetabular floor at total hip arthroplasty was likely the precipitating event. After 1
year there was no indication for surgical excision of the cyst.

Les auteurs decrivent le cas d’une femme de 35 ans souffrant de polyarthrite
rhumatoide qui a presente un kyste synovial intrapelvien massif comme complica
tion d’une arthroplastie complete de la hanche. Le tableau clinique a fait craindre la
presence simultanee d’une tumeur maligne des tissus mous. Cette possibility put
etre exclue par echographie, tomographie axiale, ponction-biopsie et examen des
cellules et cultures cellulaires et, ultimement, intensification d’image durant
l’aspiration du kyste dans la salle d’operation et injection d’Hypaque dans
1’articulation de la hanche adjacente. Les auteurs concluent que la perforation du
plancher acetabulaire lors de l’operation d’arthroplastie a pu provoquer cette
complication. Un an plus tard, rien n’indiquait qu’il y ait lieu d’exciser le kyste.

rthopedic surgeons who per
form total hip replacement ar
throplasty are familiar with the fre
quently encountered and discussed
local complications o f infection,
loosening and fracture. We recently
encountered an interesting and
alarming local complication of this
operation, which may be more com
mon than previously realized; a si
milar case was reported recently
from the Netherlands.1 Six years
after bilateral hip joint replacement

O

for juvenile rheumatoid arthritis,
our patient presented with a large
swelling in the left groin, which
raised the possibility of coincidental
development of a soft-tissue malig
nant tumour.

Case R eport
A 34-year-old woman presented
with a soft-tissue swelling in the left
inguinal region. The swelling,
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which had gradually increased in
size over a 2-year period, was pain
less and gave rise to no disability.
In February 1982 she had under
gone bilateral total hip replacement
arthroplasties because o f juvenile
rheumatoid arthritis, which was di
agnosed when she was 3 years o f
age. It was noted at the time o f
operation that the left acetabulum
was “ significantly deepened,” and it
was enlarged to accept a cup 49
mm in diameter. Postoperatively, a
mild sciatic-nerve paresis was ap
parent, but it quickly disappeared.
The right hip was operated on 3
weeks later. Her early postoperative
course was smooth, and she contin
ued to have satisfactory hip func
tion at yearly follow-up examina
tions. She subsequently had two
successful pregnancies, each com 
pleted by cesarean section, the most
recent of which was in 1986. Pfannenstiel incisions were used for
these procedures and in the second
instance a “ minor” wound infection
was recorded. It was immediately
after this second cesarean section
that note was made o f a swelling in
the left iliac fossa and the decision
was made simply to observe it. It
may have accounted for some dis
comfort she experienced after pro
longed standing and seemed to vary
in size, but it did not give rise to
gastrointestinal or genitourinary
symptoms, and she had no neuro
logic complaints.
Examination on Mar. 7, 1988
revealed a moderate concentric reCJS, VOL. 34, NO. 3, J U N E 1991
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duction of hip movement but no
pain, satisfactory peripheral pulses,
no edema and intact peripheral
nerves. In the left inguinal region
there was a soft-tissue mass, which
bulged anteriorly and displaced the
femoral artery anteriorly and medi
ally. The mass measured 5 X 8 cm
and extended deeply into the pelvic
cavity. It was smooth in outline,
firm and not fluctuant, red, hot or
tender. It was not pulsatile, and
there was no bruit. Overlying it was
a single enlarged lymph node.
The results of laboratory investi
gations were as follows: leukocyte
count 4.1 X 109/L , hemoglobin
concentration 127 g /L and an
erythrocyte sedimentation rate of 1
m m /h. Serum chemistry and uri
nalysis results were normal.
Plain radiographs of the left hip
(Fig. 1) showed the left total hip
arthroplasty with fairly extensive
radiopaque cement. Preliminary ul
trasonography confirmed the pres
ence of an extensive cystic soft-tis
sue mass, better shown (in spite of
scatter from the metallic implant)

FIG. 1. Plain radiograph of left hip 6
years after hip replacement arthroplas
ty. Extensive extraosseous bone ce
ment is evident.
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by computed tomography (Fig. 2).
The mass, which had a diameter of
5.4 cm, was of fluid density and had
a thin, regular, dense rim. It lay in
contact with the deep aspect of the
left acetabulum and displaced the
external iliac and femoral arteries
and the iliopsoas muscle medially.
Under general anesthesia a needle
biopsy was done; 30 mL of thick,
viscid fluid was aspirated. This pal
pably reduced the size of the mass.
The findings were consistent with
the diagnosis of synovial cyst. Cul
ture of the fluid produced no
growth, and pathologic examination
identified abundant mucoid materi
al, only a few macrophages and no
tumour cells.
At the same procedure a needle
was inserted into the left hip joint,
liberating a few millilitres of clear
yellow fluid. Hypaque-M 60% (Winthrop Diagnostic Imaging, Aurora,
Ont.) was then injected into the
joint. A connection to the intrapelvic cyst was quickly demonstrated
(Fig. 3) because there was palpable
enlargement of the mass. The cyst
was aspirated once more to remove
the Hypaque.

The patient was discharged from
hospital without further treatment
and has continued to function satis
factorily without complications for
the past year.

Discussion
Formation of para-articular syno
vial cysts in association with rheu
matoid arthritis is well known,2 but
we are aware of no reports of
para-articular synovial cysts associ
ated with rheumatoid arthritis oc
curring at the hip. There have been,
however, occasional reports3 of syn
ovial cysts that presented as groin
masses and were shown to commu
nicate with osteoarthritic hips.
However, this patient had suffered
from rheumatoid arthritis for more
than 30 years, but the intrapelvic
cyst became apparent only after
operative treatment of the hip dis
ease 4 years earlier.
In 1984, Awbrey and associates4
reviewed the literature on late com
plications of total hip replacement
from bone cement within the pelvis
but did not list intrapelvic cyst as
one of these. On the other hand,

FIG. 2. Computed tomography scan of pelvis immediately proximal to acetabulum.
Thin-walled intrapelvic mass, 5.4 cm in diameter, can be seen in left inguinal
region.

INTRAPELVIC SYNOVIAL CYST IN HIP ARTHROPLASTY

the report in 1988 by Svensson and
colleagues5 of a fulminant periar
ticular soft-tissue pseudotumour
after uncemented hip arthroplasty
described a thick-walled cyst sug
gestive of a hypersensitivity reac

tion to the cobalt-chromium-molyb
denum hip prosthesis. The case
reported by Van Mourik, Josaputra
and Axler,1 published later in 1988,
is, however, very similar to our case
(but in an 80-year-old woman with

osteoarthritis); the mass presented
as an obstruction to the nearby
femoral and iliac veins.
We do not believe that bone
cement played a significant role in
production of the cyst in our pa
tient; we believe that the cyst was
caused by the hydraulic pressure of
weight-bearing after the acetabulum
was perforated during the total hip
arthroplasty. Our patient was more
vulnerable to this complication be
cause of her rheumatoid arthritis.
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FIG. 3. Intraoperative, image intensification radiograph. After injection of contrast
medium into hip joint, bilobed intrapelvic mass can be seen.
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Prescribing Information
ACTION
ERGAMISOL (levamisole hydrochloride) is capable of
restoring impaired immune responses preferentially of
the cell mediated type in compromised hosts. Therapeutic
doses of levamisole restore to normal the functions of
monocytes (phagocytes) and T lymphocytes but do not
directly influence B cells.
Levamisole Is rapidly absorbed from the gastrointestinal
tract follow ing a single oral ingestion of 150 mg. In
patients with neoplastic disease, a mean peak blood level
of 0.86 m cg/m L is attained within 2 hours of intake.
The half-life of elimination of levamisole alone is between
3-4 hours. The metabolites are eliminated more slowly
w ith a term inal half-life of approximately 16 hours.
Levamisole is extensively metabolized by the liver in man
and excreted mainly by the kidneys (70% over 3 days).
Approximately 5% is excreted in the feces. Less than 5%
of the unchanged dose is excreted in the urine and less
than 0.2% in the feces.
INDICATIONS
ERGAMISOL (levamisole hydrochloride) is indicated as
adjuvant therapy in poor prognosis malignant melanoma
following complete surgical excision and exclusion of
metastatic disease. In such patients, levamisole has been
shown to produce an improvement in relapse free survival
and overall survival when compared to observation alone,
particularly in patients aged 55 years or older.

PRECAUTIONS
Drug Interactions: The therapeutic effect of levamisole
may be antagonized by concomitant administration of cor
ticosteroids.
Additional caution is necessary when levamisole is used
in combination with other drugs potentially affecting
hemopoiesis.
Levamisole has been reported to produce “ANTABUSF*1” like side effects when given concomitantly with alcohol.
ADVERSE REACTIONS
Approximately half of all patients treated with ERGAMISOL
(levamisole hydrochloride) experience adverse effects of
the medication. Due to the intermittent nature of the
dosage schedule, drug discontinuation may not be nec
essary for successful resolution.
The adverse reactions observed when levamisole is used
in combination with 5-fluorouracil are consistent with
those anticipated if 5-fluorouracil is given alone in a com
parable dose and schedule.
The incidence of adverse reactions for levamisole alone
in malignant melanoma patients and fo r levamisole plus
5-fluorouracil in colonic cancer patients is presented in
Table I.
An encephalopathy-like syndrome has been reported.
TABLE I: INCIDENCE OF ADVERSE REACTIONS
IN PATIENTS TREATED WITH LEVAMISOLE FOR
MALIGNANT MELANOMA OR COLONIC CANCER.

ERGAMISOL is also indicated as adjuvant therapy, in com
bination with 5-fluorouracil, in patients with completely
resected Dukes’ stage C colon cancer. Evidence of
metastatic disease must be excluded before initiating
therapy. In patients with Dukes’ stage C carcinoma of the
colon, a regimen of levamisole plus 5-fluorouracil has
been shown to produce significant reductions in both
cancer recurrence and overall death rate.
CONTRAINDICATIONS
Levamisole is contraindicated in patients with a known
hypersensitivity to the drug.
WARNINGS
ERGAMISOL (levamisole hydrochloride) has been asso
ciated with reversible leukopenia and agranulocytosis,
therefore it is essential that appropriate hematological
m o n ito rin g be done ro u tin e ly during therapy w ith
ERGAMISOL.
Patients should be instructed to report immediately any
sudden change in their state of health which may be man
ifested by influenza-like symptoms (fever, lassitude, sore
throat, shivering or sweating) so that appropriate hema
tological testing can be done.
Leukopenia (total WBC below 3000/m nf) is not neces
sarily a sign of impending agranulocytosis; recovery is
possible w ithout withdrawal of the drug. However, with
a reduced neutrophil count (less than 20% of the total
white blood cell count) levamisole should be discontinued
permanently. (Agranulocytosis is attributed to antibody
form ation and absorption of immune complexes. This
process initiates complement activation and cell lysis; lev
amisole itself does not directly damage granulopoiesis.)
The HLA genotype B27 predisposes to the development
of agranulocytosis, particularly in females with concomi
tant rheumatoid arthritis. The onset is frequently sudden
and may be asymptomatic. Following discontinuation of
levamisole, neutrophil counts normalize within a week to
10 days. There is no evidence that steroids or WBC trans
fusions are of significant therapeutic value; prophylaxis
of infection during the acute phase of agranulocytosis
should be an important consideration.

INCIDENCE (%)
LEVAMISOLE LEVAMISOLE+5-FU
COLONIC
MELA INDUC MAINTE
NANCE
NOMA
TION

ADVERSE REACTIONS
GASTROINTESTINAL
24
nausea
vomiting
6
diarrhea
taste change
10
1
anorexia
MUCOCUTANEOUS
1
stomatitis
4
dermatitis
severe
alopecia
conjunctivitis
hyperpigmentation
HEMATOLOGICAL
leukopenia
10
2000 to 4000/mm3
less than 2000/mms
thrombocytopenia
50000 to 130000 /mm®
less than 50000 /mm’
1.4
agranulocytosis
MUSCULOSKELETAL
8
arthralgia/myalgia
NEUROLOGIC
visual change
smell change
headache
dizziness/vertigo
ataxia
anxiety/irritability
depression
insomnia
somnolence
impaired thinking
OTHER
fatigue/weakness
8
fever
impaired liver function

37
8
25
2

56
17
47
7

27
8
1
4
1

28
22
1
22
7
2

38
7

38
2

4
2

18
4

2

4

1

2
2
5
4
3
2
2
1
1
2

5

11

1

2

1
1
1
2
1

SYMPTOMS AND TREATMENT OF OVERDOSAGE
There is no experience of overdosage with ERGAMISOL
(levamisole hydrochloride). At high doses ERGAMISOL
exhibits positive inotropic and chronotropic properties on
heart muscle as well as convulsant properties. General
supportive measures are recommended.
DOSAGE AND ADMINISTRATION
In patients with malignant melanoma
ERGAMISOL (levamisole hydrochloride) should be admin
istered at a dose of 2.5 mg/kg given as a single daily dose,
preferably at night, on 2 consecutive days every week.
Higher doses are not recommended as they are associated
w ith increased toxicity and have not been shown to
provide any additional therapeutic benefit.
In patients with Dukes’ stage C carcinoma of the colon
Levamisole plus 5-fluorouracil should be administered
only by or under the supervision of qualified physicians,
experienced in cancer chemotherapy, and well versed in
the use of potent antimetabolites.
Therapy with ERGAMISOL may be initiated as soon after
resection as patients are able to tolerate oral medication,
but no sooner than one week and no later than five weeks
after surgery.
ERGAMISOL should be administered orally at a dose of
50 mg t.i.d., forthree consecutive days, every two weeks.
This therapy should be continued for at least one year.
Administration of 5-fluorouracil should be timed to begin
concomitantly with the second three day course of lev
amisole. The initial dosage of 5-fluorouracil should be 450
mg/mVday, given intravenously, for five consecutive days.
Four weeks following the initial five day course of 5-flu
orouracil, patients should begin maintenance therapy on
a once weekly basis with an intravenous injection of 5fluorouracil at a dose of 450 mg/nT. Treatment should
continue for as long as levamisole is administered.
If the patient experiences stomatitis, diarrhea or leukope
nia, the weekly 5-fluorouracil administrations should be
deferred until these side effects have subsided. If these
side effects are moderate to severe in intensity, 5-flu
orouracil should be resumed with a 20% reduction in
the dose.
Dosage Forms:
Availability: ERGAMISOL tablets 50 mg are available in
blister packages of 36 tablets.
Storage:
ERGAMISOL tablets 50 mg should be stored
at room temperature and protected from
moisture and light.
Product monograph available on request.
1. Moertel CG et al. Levamisole and fluorouracil for adju
vant therapy of resected colon carcinoma. New Engl
J Med. 1990;322:352-8.
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Surgical Treatment of Colonic
Ganglioneuromatosis in Neurofibromatosis
J.D. Urschel, MD, FRCS(Edin);* R.C. Berendt, MD, FRCPC;t J.E. Anselmo, MD, FRCSC*
Gastrointestinal involvement in neurofibromatosis occurs in three forms:
neurofibromatous tumours, visceral vasculopathy and ganglioneuromatosis. A case
of colonic ganglioneuromatosis is reported and six similar cases from the literature
are reviewed. The clinical and pathological features of this condition are
summarized and guidelines for surgical therapy formulated. Subtotal colectomy is
recommended for pseudo-obstructive symptoms refractory to medical management.
Les atteintes gastro-intestinales de la neurofibromatose surviennent de trois facons :
tumeurs neurofibromateuses, vasculopathies viscerales et ganglioneuromatose. Un
cas de ganglioneuromatose colique est decrit et six autres cas repertories dans la
presse medicate sont passes en revue. On resume les caracteristiques diniques et
pathologiques de cette affection et des directives operatoires sont proposees. Une
colectomie sous-totale est recommandee pour les symptomes pseudo-obstructifs qui
ne cedent pas a un traitement medical.

he incidence of neurofi
bromatosis, a neuroectodermal
dysplasia that has autosomal domi
nant inheritance, is 1:3000.' Spon
taneous mutations are responsible
for approximately half the cases.
The classic neurofibromatosis type-I
gene has been mapped to chromo
some 17.2 Although penetrance is
high, gene expression is variable.
Clinical features vary, but defining
features include multiple cafe-aulait spots, multiple neurofibromas
and Lisch nodules (pigmented iris
hamartomas).
Gastrointestinal involvement in
neurofibromatosis occurs in three
major forms: neurofibromatous tu
mours, ganglioneuromatosis, and
visceral vasculopathy.3 Although
gastrointestinal tumours occur in
12% of patients with neurofi

T

bromatosis, ganglioneuromatosis is
rare.4 The frequency of visceral vas
culopathy is largely unknown.
We report a case of neurofi
bromatosis of the ileum and colon
that displays all three forms of
gastrointestinal involvement. To the
best of our knowledge this repre
sents the seventh case reported in
the English literature of colonic
ganglioneurom atosis associated
with neurofibromatosis. From this
case and a review of the literature
we have attempted to summarize
the features of this uncommon con
dition and formulate guidelines for
surgical management.

Case R eport

A 42-year-old man with known
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neurofibromatosis presented with a
2-week history of abdominal pain
and distension. He had not vomited
but was unable to eat. Although
obstipation was not present, he suf
fered from constipation. In the pre
vious 18 months he had lost ap
proximately 15 kg. He had recently
been investigated for iron-deficiency
anemia at another centre, but a
cause was not found.
As a child, he was frequently
constipated, and a megacolon was
diagnosed radiologically. At the age
of 21 years he had a laparotomy for
a bowel obstruction. A mesenteric
neurofibroma was found to be ob
structing the sigmoid colon. The
diagnosis of neurofibromatosis was
made at that time. Neither his par
ents nor his siblings displayed fea
tures of neurofibromatosis. The pa
tient has since fathered a son with
neurofibromatosis.
On examination he was afebrile
and had a normal pulse and blood
pressure. Cafe-au-lait spots and cu
taneous neurofibromas were evi
dent. He was thin but not emaciat
ed. The abdomen was distended and
mildly tender, but peritoneal irrita
tion was not present.
The hemoglobin level was 124
g /L , with a mean corpuscular vol
ume of 73.1 fL and a mean corpus
cular hemoglobin of 23.5 pg. The
leukocyte count and serum electro
lyte, urea and creatinine levels were
normal. Plain films of the abdomen
demonstrated a markedly distended
right colon.
The differential diagnosis includ
ed cecal volvulus and colonic ob
struction secondary to a neurofiCJS, VOL. 34, NO. 3, JUNE 1991
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bromatous tumour. A laparotomy
was performed. The terminal ileum
was thick-walled and dilated to ap
proximately 10 cm in diameter. The
appendix was markedly distended; it
was approximately 13 cm long and
3 cm in diameter at its base. The.
right colon was similarly dilated and
thick-walled. Although mildly dilat
ed, the transverse and left colons
were otherwise normal in appear
ance. No point of true mechanical
obstruction could be identified. The
mesentery of the terminal ileum and
right colon contained neurofibromatous nodules, numerous large
lymph nodes, measuring approxi
mately 2.5 cm in diameter, and
enlarged thick-walled mesenteric
vessels (Fig. 1). Vessels within the
peritoneal reflection of the right
colon were also abnormally large.
The right colon and approximate
ly 35 cm of terminal ileum were
resected along with their lymphnode-bearing mesentery. An end
ileostomy and colonic mucous fistu
la were created.
The postoperative course was
smooth. Over the subsequent 3
months he gained weight and his
hemoglobin level rose to 164 g/L .
Sections of the gross specimen
showed that the bowel wall was up
to 1.2 cm thick. Multiple mucosal
nodules, some with a diameter as
large as 4 cm, were apparent. Some
of these nodules displayed surface
mucosal ulceration (Fig. 2). Micro
scopic examination demonstrated
plexiform neurofibromatosis within
the wall of the bowel and its mesen
tery, with the majority of the tu
mours being submucosal. Focally,
the full thickness of the bowel wall
was involved by plexiform neurofi
bromas. Ganglioneuromatosis, the
dysplastic proliferation of nerves
and ganglion cells of the myenteric
plexus, was seen in the muscularis
mucosae and submucosa through
out the entire specimen (Fig. 3).
Vascular abnormalities were evident
272
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in both the small arteries of the
bowel and the large arteries of the
mesentery. Small arteries displayed
intimal expansion, and some larger
arteries showed prominent full
thickness permeation of the media
by proliferation of dysplastic spindle

FIG. 1. Cross-section of mesentery.
Hypertrophied nerve trunks surround
thick-walled arteries.

cells (Fig. 4). Large mesenteric
lymph nodes displayed reactive his
tiocytosis. There was no evidence of
malignant disease in any part of the
specimen.
Approximately 3 months after
discharge, the patient was readmit-

FIG. 2. Mucosal neurofibromatous pol
yps.

FIG. 3. Ganglioneuromatosis: dysplastic proliferation of ganglion cells and nerves
within submucosa (hematoxylin and eosin, original magnification X 250).

COLONIC GANGLIONEUROMATOSIS

ted for a subtotal colectomy and
restoration of intestinal continuity.
A side-to-side ileosigmoid anasto
mosis was performed with a GIA
stapling device (Auto Suture Co.,
Norwalk, Conn.). On the fifth post
operative day, the patient became
septic and was taken back to the
operating room. An anastomotic de
hiscence was found. The bowel was
exteriorized and peritoneal toilet
was performed. His postoperative
course was complicated by recur
rent abdominal sepsis, gastric he
morrhage (related to stress ulcer)
and pulmonary embolism. The pa
tient was eventually discharged
home 67 days after operation with a
functioning end ileostomy. Restora
tion of intestinal continuity will be
attempted later.
On gross examination of the sub
total colectomy specimen, the bowel
wall was seen to be mildly thick
ened; the mesentery was unremark
able. The multiple discrete and
plexiform neurofibromas that char-

FIG. 4. Visceral vasculopathy: dysplastic proliferation of spindle cells
expands arterial media (hematoxylin
and eosin, original magnification X
25).

acterized the original specimen
were conspicuously absent. As in
the previously resected ileum and
right colon, submucosal ganglioneuromatous dysplasia was evi
dent throughout the resected colon.
Ganglioneuromatosis was most
prominent at the margins of the
previous proximal transverse colon
ic resection. Arterial vasculopathy
was once again present, but only
small arteries were involved.

Discussion
Gastrointestinal involvement in
neurofibromatosis occurs in three
majors forms: neurofibromatous tu
mours, visceral vasculopathy and
ganglioneurom atosis.3 N eurofi
bromatous tumours, occurring in
approximately 12% of cases, are the
most common form of gastrointesti
nal involvement.45 Eighty percent
of the tumours are benign neurofi
bromas and leiomyomas, the over
whelming majority being the for
mer. Neurofibromas may be discrete
or plexiform. Neurofibrosarcomas
and adenocarcinomas also occur.56
The most common sites of involve
ment are the jejunum and stomach,
followed by the ileum, duodenum
and colon. Although usually located
serosally, tumours may be found in
any layer of the gastrointestinal
tract. When they are symptomatic,
tumours present with bleeding, ob
struction, perforation or obstructive
jaundice.57"9
Arterial lesions in neurofi
bromatosis are characterized by a
dysplastic proliferation of spindle
cells, most prominent in the intima.10 The nature of the spindle
cells, whether of smooth-muscle or
Schwann-cell origin, is unknown.
Intimal proliferation is often associ
ated with degeneration of the media
and fragmentation of the internal
elastic membrane.11 Vessels may be
extrinsically compromised by close
ly associated neurofibromatous tis

sue. Visceral artery vasculopathy,
although often asymptomatic, may
be associated with chronic intestinal
ischemia.12
Ganglioneuromatosis is a diffuse
nontumorous dysplastic prolifera
tion of the gastrointestinal myenter
ic plexus.13 A well-known compo
nent of the multiple endocrine neo
plasia type 2b (MEN 2b) syndrome,
ganglioneuromatosis is rarely found
in neurofibromatosis.1314 An over
production of nerve growth factor
may play a role in the etiology of
this condition.15 In the setting of
neurofibromatosis,
ganglioneuromatosis usually in
volves the colon and presents clini
cally as chronic intestinal pseudo
obstruction, with a megacolon dem
onstrated radiologically.5’1416"21 The
pathophysiology of pseudo-obstruc
tion is not known, but presumably
disordered myenteric neural func
tion parallels the histologic abnor
malities.14 Other terms used to de
scribe the pathologic lesion report
ed here as ganglioneuromatosis in
clude diffuse plexiform neurofi
bromatosis1617 and neuronal intesti
nal dysplasia.21
There is undoubtedly a close rela
tionship between the MEN 2b syn
drome and neurofibromatosis, two
disorders of abnormal differentia
tion of the neural crest.192122 Gang
lioneuromatosis and pheochromocytomas, common features of the
MEN 2b syndrome, are also seen in
neurofibromatosis, although much
less frequently. Occasionally, a pa
tient may display features sugges
tive of both syndromes.19 The oc
currence of diarrhea in the MEN 2b
syndrome prevents the extrapola
tion of treatment strategies to cases
of neurofibromatosis.
On reviewing the English litera
ture, six cases of neurofibromatosis
with colonic ganglioneuromatosis
were found (Table I). Two of the
cases were reported twice.514'16-17
Three adults, two children and one
CJS, VOL. 34, NO. 3, JUNE 1991
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adolescent have been reported. No
sex predilection was apparent. Of
the four cases for whom hereditary
information was available, two had
a positive family history, and in the
other two neurofibromatosis pre
sumably arose by spontaneous mu
tation. All patients had a history of
chronic constipation, but this find
ing was most prominent in the two
children. One patient presented
with acute sigmoid volvulus. 20 Co
lonic dilatation was demonstrated
radiologically in all cases. It is of

interest that the two children dis
played narrowing of the sigmoid
colon suggestive of Hirschsprung’s
disease. One further case, a patient
with colonic plexiform neurofi
bromas, has been reported, but the
histologic features in this case were
not sufficiently suggestive of ganglioneuromatosis to include it in this
review. 23
Although some authors used dif
ferent terminology, histologic fea
tures of colonic ganglioneuromatosis were present in all cases . 1 6 1 7 -21

In one case in which an autopsy
was possible, the entire gastrointes
tinal tract was involved by ganglioneuromatosis. 19 Coexisting gas
trointestinal neurofibromas were
mentioned in two cases .5 1 4 -21 Vascu
lar abnormalities were reported in
one case, but insufficient histologic
detail was available to conclude that
visceral vasculopathy was present. 18
The patient described here exhib
ited gastrointestinal disease of
greater extent and variety than in
previously reported cases. In addi-
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leak)
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tion to colonic ganglioneuromatosis, the distal ileum was also promi
nently involved with ganglioneuromatosis. Two other cases of
neurofibromatosis with ileal ganglioneuromatosis, both children,
have been reported in the English
literature.1924
It is possible that colonic ganglioneuromatosis occurs with greater
frequency in patients with neurofi
bromatosis than is suggested by the
paucity of case reports. There ap
pears to be a spectrum of clinical
severity ranging from chronic con
stipation to a disabling condition
mimicking Hirschsprung’s disease.
Cases of lesser severity are probably
treated medically with some suc
cess. In one case from the literature
and in the patient reported herein,
surgical therapy was not required
until the patients were in their fifth
decade.21 In a study of 238 patients
with neurofibromatosis, 3.4% suf
fered from constipation that was
thought to be related to their neu
rofibromatosis.3 A large autopsy
study would be required to deter
mine the true incidence of ganglioneuromatosis in neurofibromato
sis.

Surgical Considerations
Surgical treatment was undertak
en in five of the six cases reported
in the literature (Table I). Three of
these patients required two opera
tions because the first procedure
did not relieve the pseudo-obstruc
tive symptoms.51416"18 In contrast
to the results of segmental colonic
resection, subtotal colectomy pro
duced good results in two cases,
one with primary anastomosis514
and one with a permanent ileosto
my.21
In the patient described in this
report, the initial right hemicolecto
my with ileostomy produced a good

clinical result. Because the distal
resection margin was involved with
ganglioneuromatosis and the re
maining colon was noted to be
dilated at the time of the original
resection, subtotal colectomy with
ileosigmoid anastomosis was con
sidered the procedure of choice to
restore intestinal continuity. Anas
tomotic healing may have been ad
versely affected by two features of
gastrointestinal neurofibromatosis:
visceral vasculopathy and neurofi
bromas. Occult anastomotic isch
emia secondary to visceral vas
culopathy may have occurred. We
now feel that the anastomotic meth
od employed, a side-to-side ileosig
moid anastomosis done with a GIA
stapler, was a poor choice. Al
though the anastomotic site was
grossly clear of neurofibromas, the
GIA technique made detailed exami
nation at the anastomosis difficult.
The scarcity of reports of colonic
ganglioneuromatosis in neurofi
bromatosis makes it difficult to for
mulate surgical guidelines for this
condition. It is reasonable to follow
the general treatment approach to
other colonic pseudo-obstructive
conditions and reserve surgical
therapy for intractable constipation
that is refractory to medical man
agement.25 Since the two children
reported in the literature had partic
ularly severe symptoms, early surgi
cal therapy is warranted in this age
group. Although the limits o f co
lonic resection may appear to be
best guided by the extent of gang
lioneuromatosis, the poor results of
segmental resection5-1416 and the fa
vourable outcome after subtotal co
lectomy51421 dictate caution in the
use of limited resection. Subtotal
colectomy is the most logical surgi
cal procedure for colonic gang
lioneuromatosis. Examination of
frozen sections of the resection
margins to ensure complete resec
tion of bowel involved with gang
lioneuromatosis is advisable.

Conclusions
Colonic ganglioneuromatosis oc
curs infrequently in patients with
neurofibromatosis. On the basis of
our experience with one case and
review of six cases from the litera
ture, the following recommenda
tions for surgical treatment of
ganglioneuromatosis in patients
with neurofibromatosis are made.
• As with other chronic pseudo
obstructive conditions, surgical
therapy is indicated for intractable
constipation that is refractory to
medical management.
• Early surgical therapy is war
ranted in children.
• Subtotal colectomy with ex
amination of frozen sections of the
resection margins is the procedure
of choice.
• A hand-sutured anastomotic
technique is favoured.
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( 1.6% ).

Gastrointestinal

8.0%

■l V

Nausea
Vomiting
Anorexia
Abdominal discomfort
Dry mouth

1.6%
0.9%
0.5%
0.3%
0.2%

Nervous System/Psychlatrtc

7.3%

Insomnia
Somnolence
Anxiety
Paresthesia
Depression
Libido decreased

0.6%
0.4%
0.3%
0.3%
0.2%
0.1%

Respiratory
Bronchospasm

4.4%
<0.1%

Body as a Whole

3.0%

Fatigue
Asthenia
Fever

0.6%
0.3%
0.2%

Musculoskeletal

1.7%

Musculoskeletal pain
Arthralgia

0.1%
0.1%

Drug Interactions
Studies with famotidine in man, in animal models,
and in vitro have shown no significant interference
with the disposition of compounds metabolized by
the hepatic microsomal enzymes, e g., cytochrome
P450 system. Compounds tested in man have
in c lu d e d w a rfa rin , th e o p h y llin e , p h e n yto in ,
diazepam, am inopyrine and antipyrine. Indo
cyanine green as an index of hepatic blood flow
and/or hepatic drug extraction has been tested and
no significant effects have been found.

Skin

1.7%

Pruritus
Rash
Alopecia
Flushing
Acne
Dry skin

0.4%
0.3%
0.2%
0.2%
0.1%
0.1%

Cardiovascular

1.0%

Palpitations

0.2%

Special Senses
Taste disorder
Tinnitus
Orbital Edema

0.9%

Since the safe use of PEPCID® in pregnant women
has not been established, the benefits of treatment
with PEPCID® should be weighed against potential
risks.

A

<1

Patients with Severe Renal Insufficiency
Dosing intervals may need to be prolonged in
p a tie n ts w ith advanced renal in s u ffic ie n c y
(creatinine clearance <10 mL/min.) to adjust for the
longer elimination half-life of fam otidine. (See
CLINICAL PHARMACOLOGY and DOSAGE AND
ADMINISTRATION.)

Use in Pregnancy
Reproductive studies have been performed in rats
and rabbits at oral doses of up to 2000 and
500 mg/kg/day, respectively (approximately 2500
and 625 times the maximum recommended human
dose, respectively), and have revealed no evidence
of impaired fertility or harm to the fetus due to
PEPCID®. There are, however, no adequate or wellcontrolled studies in pregnant women.

|

Other reactions have been reported in clinical trials
but occurred under circumstances where a causal
relationship could not be established. However, in
these rarely reported events, that possibility cannot
be excluded. Therefore, these observations are
listed to serve as alerting information to physicians.

PRECAUTIONS

Use In Gastric Ulcer
Gastric malignancy should be excluded prior to
initiation of therapy of gastric ulcer with PEPCID®.
Symptomatic response of gastric ulcer to PEPCID®
therapy does not preclude the presence of gastric
malignancy.

4

Urogenital

0.1%
0.1%
<0.1%
0.9%

The adverse reactions reported fo r PEPCID®
Tablets may also occur with PEPCID® I.V. In
addition, transient irritation at the injection site has
been observed with PEPCID® I.V.
Laboratory Abnormalities
Laboratory parameters may be affected during
treatment with PEPCID®, but the changes are
usu ally not considered serious. Am ong the
laboratory changes that were reported during
clinical trials were increases in AST, ALT, BUN, and
serum creatinine. These changes were rarely of
clinical significance.

*■
> r
4

J

Ai

A

1

A

-A

*1

Only three patients had to be discontinued from
therapy because of laboratory adverse experiences,
however laboratory abnormalities were present at
baseline.

RECO NSTITU TION

The oral LD^ of famotidine in male and female rats
and mice was >5000 mg/kg.

DOSAGE AND ADMINISTRATION
DUODENAL ULCER
Acute Therapy

The recommended adult oral dosage of PEPCID®
(famotidine) for acute duodenal ulcer is 40 mg once
a day at bedtime. Treatment should be given for
4-8 weeks, but the duration of treatment may be
shortened if healing can be documented. Healing
occurs within 4 weeks in most cases of duodenal
ulcer.
Maintenance Therapy

For the prevention of recurrence of duodenal ulcer,
it is recommended that therapy with PEPCID® be
continued with a dose of 20 mg once a day at
bedtime, for a duration of up to 6-12 months
depending on the severity of the condition.
BENIGN GASTRIC ULCER
Acute Therapy

The recommended adult oral dosage for acute
benign gastric ulcer is 40 mg once a day at bedtime.
Treatment should be given for 4 to 8 weeks, but the
duration of treatment may be shortened if healing
can be documented.
P A T H O L O G IC A L H Y P E R S E C R E T O R Y C O N 
D IT IO N S (S U C H AS Z O L L IN G E R -E L L IS O N
SYNDROME)

The dosage of PEPCID® in patients with
pathological hypersecretory conditions varies with
the individual patient. The recommended adult oral
starting dose for pathological hypersecretory
conditions is 20 mg q6h. In some patients, a higher
starting dose may be required.
Doses should be adjusted to individual patient
needs and should continue as long as clinically
indicated. Doses up to 160 mg q6h have been
administered to some patients with severe
Zollinger-Ellison syndrome.
Intravenous Administration

In some hospitalized patients with pathological
hypersecretory conditions or intractable ulcers, or
in patients who are unable to take oral medication,
PEPCID® I V. may be administered. The recom
mended dosage is 20 mg every 12 hours.
Intravenous injection therapy should be changed to
oral treatment as soon as the acute situation is
under control.
Concomitant Use with Antacids

Antacids may be given concomitantly if needed.
Dosage Adjustment for Patients with Severe Renal
Insufficiency

In patients with advanced renal insufficiency, i.e.,
with a creatinine clearance less than 10 mL/min.,
the elimination half-life of PEPCID® may exceed
12 hours reaching approximately 24 hours in anuric
patients.
To avoid excess accumulation of the drug, the
dosing interval of PEPCID® may be prolonged to
36-48 hours as indicated by the patient’s clinical
response.

PHARMACEUTICAL INFORMATION
COMPOSITION
Tablets

Each tablet for oral administration contains either
20 mg or 40 mg of famotidine.
Injection

Each mL of the solution for intravenous injection
contains 10 mg of famotidine and the following
inactive ingredients: L-aspartic acid 4 mg,
mannitol 20 mg, and Water for Injection, q.s., 1 mL.
The multidose injection also contains benzyl
alcohol 0.9% added as preservative.

Other effects

Dilution of PEPCID® I.V.
for Infusion

SYMPTOMS AND TREATMENT
OF OVERDOSAGE
There is no experience to date with deliberate
overdosage. Doses of up to 640 mg/day have been
employed in patients with pathological hyper
secretory conditions with no serious adverse
effects. In the event of overdosage, treatment
should be symptomatic and supportive. Un
absorbed material should be removed from the
gastrointestinal tract, the patient should be
monitored, and supportive therapy should be
employed.

emptying and exocrine pancreatic function are not
affected by PEPCID®.

Parenteral Products

P E P C ID * I.V .
S o lution

of
C o m pa tib le
I.V . S o lu tio n

Final
V o lu m e

Final
C o ncen tration

Rate of
In fu s io n

2 mL

3m L

5m L

4 mg/mL

Not less than
2 minutes

2mL

8 mL

10 mL

2 mg/mL

Not less than
2 minutes

2mL

100 mL

102 mL

0.196 mg/mL

15-30 minutes

PEPCID® I.V. Solutions are compatible with:
Water for Injection
0.9% Sodium Chloride Injection
5% Dextrose Injection
10% Dextrose Injection
Lactated Ringer’s Injection
Sodium Bicarbonate Injection 5%
STABILITY AND STORAGE
RECOMMENDATIONS
PEPCID® I.V. Solution

Store at 2 - 8°C. Protect from light. If solution
freezes, bring the solution to room temperature;
allow s u ffic ie n t tim e to solubilize all the
components.
Diluted PEPCID® I.V. Solutions should be used
within 24 hours due to the possibility of microbial
contamination during preparation.
NOTE: Parenteral drug products should be
inspected visually for particulate matter and
discolouration prior to administration
whenever solution and container permit.

DOSAGE FORMS AND AVAILABILITY
Tablets PEPCID® (fam otidine tablets) are
D-shaped, film-coated tablets supplied as follows:
No. Ca 8102 - 20 mg beige co lo u re d ,
coded 963. Available in bottles of 100 tablets.
No. Ca 8103 - 40 mg light brownish orange,
coded 964. Available in bottles of 100 tablets.
No. Ca3539 - PEPCID® I.V., 10 mg per 1 mL, is a
clear, colourless solution and is available as a nonpreserved unit dose containing 2 mL of injectable
solution. Available in 1 0 x2 mL vials.
No. Ca3541 - PEPCID® I.V., 10 mg per 1 mL, is a
clear, colourless solution and is available as a
preserved m ultiple dose containing 4 mL of
injectable solution. Available in 4 mL vip.ls.

HUMAN PHARMACOLOGY
In both normal volunteers and hypersecretors,
PEPCID® inhibited basal nocturnal and daytime
gastric secretion, as well as secretion stimulated by
a variety of stimuli, such as pentagastrin and food.
After oral administration, the onset of the antisecretory effect occurred within one hour; the
maximum effect was dose-dependent, occurring
within one to three hours. Duration of inhibition of
secretion was 10 to 12 hours. After intravenous
administration, the maximum effect was achieved
within 30 minutes. Single intravenous doses of 10
and 20 mg inhibited basal nocturnal secretion for a
period of 10-12 hours. The 20 mg dose was
associated with the longest duration of action in
most subjects. Single oral doses of 20 and 40 mg
inhibited basal nocturnal acid secretion in all
subjects; mean gastric acid secretion was inhibited
by 86% and 94%, respectively, fora period of at least
10 hours. Similar doses given in the morning
suppressed food-stimulated acid secretion in all
subjects, with mean suppression of 76% and 84%,
respectively, 3 to 5 hours after d rug, and of 25% and
30%, respectively, 8 to 10 hours after drug;
however, in some subjects who received the 20 mg
dose, the antisecretory effect was dissipated earlier,
within 6-8 hours. There was no cumulative effect
with repeated doses. The basal nocturnal intragastric pH was raised by evening doses of 20 and
40 mg of PEPCID® to mean values of 5.0 and 6.4,
respectively When PEPCID® was given in the
morning, the basal daytime interdigestive pH at 3
and 8 hours after 20 or 40 mg of PEPCID® was
raised to about 5.0.
Fasting and postprandial serum gastrin levels may
be slightly elevated during periods of drug
antisecretory effect, and with chronic therapy an
increase in gastric bacterial flora may occur. Gastric

Systemic pharmacologic effects of PEPCID® in the
CNS, cardiovascular, respiratory or endocrine
systems have not been found to date. Serum
prolactin levels do not rise after intravenous bolus
doses of 20 mg PEPCID® and no antiandrogenic
effects have been detected.
Pharmacokinetics

PEPCID® is incompletely absorbed. The bioavaila
bility of oral doses is 40-45%. Bioavailability may be
slightly increased by food, or slightly decreased by
acntacids; however, these effects are of no clinical
consequence. PEPCID® undergoes minimal firstpass metabolism. After oral doses, peak plasma
levels occur in 1-3 hours. Plasma levels after
multiple doses are similar to those after single
doses. Fifteen to 20% of PEPCID® in plasma is
protein bound. PEPCID® has an elimination half-life
of 2.5-3 5 hours. PEPCID® is eliminated by renal
(65-70%) and metabolic (30-35%) routes. Renal
clearance is 250-450 mL/min., indicating some
tubular excretion.
Twenty-five to 30% of an oral dose and 65-70% of an
intravenous dose are recovered in the urine as
unchanged compound. The only m etabolite
identified in man is the S-oxide. There is a close
relationship between creatinine clearance values
and the elimination half-life of PEPCID®. In patients
with severe renal insufficiency, i.e., creatinine
clearance less than 10 mL/min., PEPCID® elimi
nation h a lf-life may exceed 20 hours and
adjustment of dosing intervals may be necessary
(see PRECAUTIONS, DOSAGE AND ADMINIS
TRATION). In elderly patients, there are no
clinically significant age-related changes in the
pharmacokinetics of PEPCID®.
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ORIGINAL ARTICLES

Prospective Evaluation of a Totally
Implantable Drug Delivery System.
Improved Results at 4-Year Follow-up
Carlos Del Campo, MD, FRCSC;* Vincent W.K. Ing, MD, FRCPC;t Oliver H. Millard, MD, FRCSC;$
Jean MacDonald, RN
Totally implantable drug delivery systems have facilitated chemotherapy in cancer
patients. The incidence of complications has been acceptable but not optimal. A
series of 140 consecutive implants over a 4-year period is presented. The total
follow-up was 41 185 days. Reversible obstruction was present in 12.8% of portals.
The infection-erosion rate was 4.2%; only 6.3% of patients required removal of the
system because of failure. In the last 111 patients only one device failed (0.9%). The
reasons for these improved results are analysed, and recommendations are made to
improve the current management of these devices.

Des systemes de livraison des medicaments totalement implantables ont facilite la
chimiotherapie chez le patient cancereux. La frequence des complications est
demeuree acceptable, sans toutefois etre optimale. On decrit une serie de 140
implants consecutifs poses sur une periode de 4 ans. La surveillance des suites
therapeutiques porte sur un total de 41 185 jours. Une obstruction reversible s’est
presentee dans 12.8% des voies d’entree. Le taux d’infections-erosions a ete de
4.2%; seulement 6.3% ont vu leur appareil retire pour cause d’echec. Sur les 111
derniers patients, un seul instrument n’a pas fonctionne (0.9%). Les raisons de
1’amelioration des resultats sont analysees, et on propose des recommandations pour
ameliorer l’emploi de ces instruments.

ver the past two decades nota
ble advances have been made
in the treatment of malignant dis
ease with chemotherapeutic agents.
Prolonged remissions and survival
are now common. Diseases like
childhood leukemia, lymphoma and
testicular tumours can often be
cured. Most chem otherapeutic
agents have to be administered in
travenously. Multiple injections or
continuous infusions at 3- or
4-week intervals are usually re
quired and, since most of these

O

agents severely irritate the vein
walls, thrombophlebitis and sclero
sis are common. Venous access be
comes increasingly difficult and ex
travasation of these agents from
damaged small veins may lead to
ulceration. Pain, anguish and de
creased patient compliance often re
sult in the treatment being post
poned or abandoned.
Physicians become frustrated by
patient suffering and by the amount
of time spent in vein cannulation.
The recent introduction of totally

implantable systems for venous ac
cess has minimized some of these
problems.
The type and number of compli
cations related to the implantation
and use of these systems vary from
institution to institution. In spite of
their increasing acceptance compli
cations have been reported as high
as 67%' and as low as 2.3%.2 To
justify the use of these systems the
incidence of complications must be
minimal. Since most series have
dealt with specific groups we ques
tioned whether patients who have a
specific malignant tumour would be
more susceptible to complications
than others: for example, those
with solid tumours as opposed to
those with hematologic malignant
disease.
A prospective study was designed
to evaluate whether complications
could be uniformly minimized by
following a meticulous protocol.
The study included a heterogeneous
group of adult patients in our insti
tution who were undergoing che
motherapy for all types of malig
nant disease. We report our experi
ence with the first 135 patients
receiving the implantable drug de
livery system.

Patients
From the *Department o f Surgery, fDepartment o f Medicine and fDepartm ent o f Urology, Camp
H ill Medical Centre and Dalhousie University, Halifax, NS
Accepted fo r publication June 27, 1990
Reprint requests to: Dr. C. Del Campo, Rm. 412, 5303 Morris St., Halifax, NS B3J 1B6
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All patients were studied prospec
tively. All the devices were implant
ed by one of us (C.D.C.). The
patients were placed in a registry
when they agreed to have the de-

TOTALLY IMPLANTABLE DRUG DELIVERY SYSTEM

vice implanted. All cases were con
secutive and no patient was exclud
ed. In patients with sepsis implanta
tion was postponed until the sepsis
was eradicated. All data relating to
the use of the device and complica
tions associated with it were collect
ed and entered by an observer
(J.MacD) not involved at any time
with the implantation or manage
ment teams. In five patients who
required a second device, each im
plantation was recorded separately.
All complications of catheter use
were evaluated by the treating in
vestigator and the implanting sur
geon at the time the complication
occurred.

Materials
A single-lumen Port-a-Cath
(Pharmacia [Canada] Inc., Dorval,
Que.) was implanted on 138 occa
sions. Two patients received dual
chamber Port-a-Caths. The devices
consist of a conical titanium cham
ber with a self-sealing silicone rub
ber septum. The port is implanted
subcutaneously in the anterior
chest wall. It is connected to a
catheter (two catheters if a dual
chamber port is used) that is intro
duced to the junction of superior
vena cava and right atrium through
a subclavian vein. A Huber-point
needle, size 19 or 21, was used for
all injections to minimize damage to
the septum.

Operative and Flushing
Techniques
The system was implanted under
local anesthesia in 133 operations;
in 7 others general anesthesia was
used to comply with the patients’
demands. Our technique has been
reported previously.34 Operative
times were recorded by the operat
ing-room charge nurse, as for any

other operation and according to
institution policy. The wound was
irrigated with bacitracin solution
before closure. Systemic antibiotics
were not given. Our first 30 pa
tients had their Port-a-Cath flushed
with heparin at the time of implan
tation and then daily for 3 days, as
recommended by the manufacturer.
All subsequent implants were
flushed once, in the operating
room, with 2000 units of heparin
and were not flushed again until
after the first dose of chemothera
py, 3 weeks later.
Ward nurses and rotating
housestaff were instructed in the
sterile procedure for dressing
changes and puncture. All punc
tures were done by attending physi
cians and housestaff while the pa
tients were in hospital or as outpa
tients. The Port-a-Cath was not
used for the first 3 weeks in an
attempt to minimize infection, ex
cept when there was no other meth
od of obtaining venous access (Ta
ble I).
Failure of the Device
The inability to infuse intrave
nous solutions with a gravity drip
was considered an occlusion, but
the inability to withdraw blood from
a port was not, as long as the
catheter could be used to infuse
fluids freely without increased re
sistance. Obstructed catheters were
originally managed by injection of
streptokinase into the port. Over
the past year 0.1 N hydrochloric
acid was added when the occlusion
appeared to be caused by precipita

tion.5 Systems that failed to recanal
ize with this technique were consid
ered failures and were removed.
Infected or eroding portals were
removed, and no attempt was made
at prolonged antibiotic therapy be
cause of the high-risk population
involved.
For the purpose of statistical
analysis, removal of the Port-a-Cath
upon completion of therapy or in
the case of a patient’s death was
considered as “withdrawn while pa
tent.” Complication rates were cal
culated and evaluated statistically
by Student’s f-test.

Results
One hundred and thirty-five pa
tients received 140 Port-a-Caths.
The proportion of men to women
was 1.0:1.07. The mean age (±
standard deviation) was 55 ± 17.8
years. Most patients had received
several cycles of chemotherapy be
fore insertion of the Port-a-Cath
(Table II). The main indication for
insertion of the Port-a-Cath in all
but two cases was the need for
venous access for chemotherapy
(Table III). Over 60% of patients
had hematologic disease. The two
patients with no malignant condi
tion had Christmas disease and
aplastic anemia respectively.
Local anesthesia was used in 133
implantations. In one patient the
subclavian vein could not be canT a b le II. Data on 135 Patients Who Had

140 Port-a-Cath Systems Implanted

3
2
1
< 1

122
7
9
2

Mean age, yr
55.04 ± 17.8
Sex, M/F
70/65
Previous chemotherapy, no.
91 (± 5 *)
No previous chemotherapy,
no.
44
Local anesthesia, no.
implants
133
General anesthesia, no.
implants
7
Operative time, min.
38.5 ± 14.5

Total

140

’ Second implants in single patients.

Table 1. Interval Between Implantation and

First Use of 140 Port-a-Caths in 135
Patients
Tim e, wk

N um ber of im plants
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nulated percutaneously, so the ce
phalic vein was cannulated by cutdown. Intraoperatively two patients
had a 10% pneumothorax, but it
resolved spontaneously. The mean
duration of operation was 38.5 ±
14.5 minutes.
One patient refused further treat
ment after the first cycle of chemo
therapy for personal reasons. One
patient moved to another province
where chemotherapy was continued
for eight more cycles; the Port-aCath continued to function well to
the conclusion of treatment.
Thirty-nine patients who died of
their underlying disease had a func
tional Port-a-Cath at the time of
T a b le III. Diagnosis in Patients Who

death. The total follow-up in accu
mulated time was 41 185 days with
an average of 294 days per device.
Four patients were followed up for
over 1100 days each, with the lon
gest follow-up being 1317 days to
the conclusion of therapy. After
Port-a-Cath removal the follow-up
was discontinued for the purposes
of this study.
Reversible obstruction occurred
in 12.8% of the implants. The inci
dence of infection or erosion was
4.3% (Table IV). Irreversible ob
struction occurred in only one pa
tient (0.7%). The overall failure rate
was 6.4% (Table V). Statistical eval
uation of patients by disease did not
demonstrate any significant differ
ence.

Underwent Port-a-Cath Insertion
Number

Diagnosis

48
24
16
12
11
6
3
2
2
11

Lymphoma
Leukemia
Multiple myeloma
Ovarian cancer
Bladder cancer
Testicular cancer
Cancer of fallopian tube
Sarcoma
Metastatic bowel cancer
Miscellaneous

135

Total

Discussion
Totally implantable systems for
venous access are becoming in
creasingly popular among physi
cians and patients. They provide
easy accessibility and have several
advantages over external indwelling
catheters. They require minimal
maintenance, they do not alter body

Table IV. Major Complications Leading to Port-a-Cath Removal
Num ber

%

Infection or erosion
Occlusion
Stenosis of subclavian vein

6
1

2

4.3
0.7
1.4

Total

9

6.4

C om plication

image6 and patients have no impedi
ment to normal activities.7 Their
lower incidence of infection com
pared with external catheters has
been demonstrated in prospective89
and randomized2 trials.
Previous reports vary considera
bly in the type and incidence of
complications. Gyves and col
leagues7 and Cruz and associates10
noted a small number of cases of
venous thrombosis, but Lokich and
colleagues6 reported an incidence of
16%. The incidence of infection and
sepsis also varies from centre to
centre. Becton and colleagues1 re
ported bacteremia in 67% of their
pediatric patients, although bacteri
al cultures were not always positive.
Fourteen of their portals had to be
removed. Pegelow and associates11
had a similar 13% failure rate in
children.
Carde and colleagues,2 in their
randomized trial, reported 42 pa
tients with totally implantable sys
tems followed up for a minimum of
6 months. Their rates of infection
(2.3%) and thrombosis (2.3%) were
excellent, but because their popula
tion was limited to patients with
solid tumours who underwent only
intermittent nonaplastic chemother
apy, their results cannot be extrapo
lated to all patients. These results
are superior to a previously report
ed 9.3% infection and 26.7% inci
dence of complications also in pa
tients with solid tumours.12 Our
series represents a heterogeneous

Table V. Data on Patients Whose Port-a-Cath Was Removed Because of Failure
Patient
num ber

Sex

Age, yr

2
3
20
25

M
M
F
F

30
63
77
58

32
39

F
F

50
60

F
F

64
68

53
59

Diagnosis

Testicular cancer
Leukemia
Hodgkin's disease
Fallopian tube
cancer
Lymphoma
Bowel cancer
(second implant)
Ovarian cancer
Leukemia

'D ifficult insertion.
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Previous
chem otherapy

Flushed on
first 3 days

Days of
function

Y
Y
Y

r
Y
Y

224
8
32

Y
N
N
N
Y
Y

Y
N
N
N
N
N

57
165
30
10
50
273

Tim e to
first use, wk

5

N um ber of
cycles used

Reason lor
removal

2

Infection
Infection
Sepsis

—

—

—

—

4
4

1
3

—

—

—

—

4
8

1
4

Stenosis
Stenosis
Infection*
Infection
Erosion
Occlusion

TOTALLY IMPLANTABLE DRUG DELIVERY SYSTEM

adult population, including patients
with solid and nonsolid tumours.
Hematologic malignant disease was
present in 65% of our patients. The
overall incidence of infection or ero
sion in our series was only 4.2%
over a follow-up period of 41 185
days. Patients on aplastic chemo
therapy had the same incidence of
infection as patients with nonaplastic chemotherapy (p = 0.98). Thus,
it is our impression that technique
and management may be more im
portant than the underlying disease.
The fact that 75% of complications
requiring catheter removal occurred
in the first 40 patients and no such
complications have occurred in our
last 68 patients confirms this im
pression.
Early in our series, lack of famil
iarity with the system, mainly with
the thickness of the portal septum,
led to multiple punctures in two
patients. Timing for implantation
and use may have been another
important factor in our low inci
dence of infection. Portals were
implanted at a time when the level
of chemotherapeutic activity in
these patients was minimal; that is,
2 or 3 days before one of their
chemotherapeutic cycles. This as
sures optimal fibroblastic activity
for wound healing and minimal im
munosuppression. We could not
prove this in our series since a
control group was not designed for
this purpose. We believe that the
risk of an elective operation in a
severely immunosuppressed patient
should not be taken.
Manufacturers do not object to
use of the system as soon as it is
implanted, and this has been done
in most series. Wounds are more
susceptible to infection in their
early stages because of fibrin depo
sition, skin and fat violation. We
believe that early cannulation may
introduce bacteria in the area sur
rounding the portal because it does
not become encapsulated for several

days. In our series three infections
occurred among the first 30 im
plants (10%). At that point we
changed the protocol in an attempt
to prevent violation of a fresh
wound. Because a 3-day flush (rec
ommended by the manufacturer)
may not have an advantage over a
single flush we eliminated the daily
heparin flush for the first three
days. The infection rate was re
duced to 2.7% (p < 0.001), and
there was no significant difference
in the occlusion rate. Minimum re
quirements for heparin flush con
centration, volume and frequency
have not been established.13 The
portal was not used for chemothera
py until 3 weeks after implantation.
Preoperative antibiotics were not
used in this series. Avoidance of
general anesthesia and short opera
tive time minimize insult to the
immune system and decrease costs.
The efficacy of specialized person
nel for cannulation and care of
these devices decreased the infec
tion rate from 33% to 1.3% in
Nehme’s series14 and may also have
accounted for our low infection
rate.
We conclude that meticulous pa
tient selection, operative technique
and follow-up will reduce complica
tions, discomfort and costs in all
patients receiving chemotherapy
through the Port-a-Cath system.
Our recommendations are as fol
lows:
• Earlier implantation — 3 to 4
weeks before the expected date for
use.
• Implantation at the time of
low chemotherapeutic activity (just
before a chemotherapeutic cycle).
• Postponement of the implan
tation if the patient has evidence of
sepsis.
• Use the nondominant chest
and arm for portal location (mini
mizes trauma).
• Only one flush, in the operat
ing room, with 1 to 2 mL of

heparin (1000 units/mL) and every
3 to 4 weeks thereafter.
• Portal puncture done by
trained personnel familiar with the
device.
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NARCOTIC EFFICACY W ITHOUT NARCOTIC DRAWBACKS
TORADOL (ketorolac tromethamine) 10 mg tablets
TORADOLIM (ketorolac tromethamine) 15 mg/mL and 30 mg/mL intramuscular Injections
THERAPEUTIC CLASSIFICATION
Analgesic Agent
ACTION
Toradol (ketorolac tromethamine) is a non-steroidal anti-inflammatory drug that exhibits analgesic activity. Its mode of
action is to inhibit the cyclo-oxygenase enzyme system, thereby inhibiting the synthesis of prostaglandins, and is consid
ered to be a peripherally acting analgesic. At analgesic doses it has minimal anti-inflammatory and antipyretic activity.
Ketorolac tromethamine is rapidly and completely absorbed when administered by both the oral and intramuscular routes,
and pharmacokinetics are linear following single and multiple dosing.
Steady state plasma levels are attained after one day of Q.I.D. dosing. Based oniy on pharmacokinetic principles, a faster
attainment of the steady state plasma level might be achieved with a loading dose of about twice the m aintenance
dose. This occurs when the dosing interval is approximately equal to the drug's half-life.
Following oral administration, peak plasma concentrations of 0,52 to 1.31 mcg/ml occurred 35 minutes after a single 10 mg
dose. The terminal plasma elimination half-life ranged between 4.1 and 6.1 hours in healthy adults, while in elderly sub
jects (mean age: 72 years) it ranged between 3.0 and 6.1 hours. A high fat diet decreased the rate but not the extent
of absorption o f oral ketorolac tromethamine, while antacid had no effect.
Following intramuscular administration, peak plasma concentrations of 2,2 to 3.0 m cg/m l occurred an average of 50
minutes after a single 30 mg dose. The terminal plasma half-life ranged between 3.8 and 6.3 hours in young adults and
between 4,4 and 8.6 hours in elderly subjects (mean age: 72).
The primary route of excretion of ketorolac tromethamine and its metabolites (conjugates and the p-hydroxy m etabo
lite) is in the urine (91.4%) and the remainder is excreted in the feces.
More than 99% o f the ketorolac in plasma Is protein bound over a wide concentration range.
INDICATIONS
Orally administered Toradol (ketorolac tromethamine) is indicated for the short-term management of mild to moderately
severe pain, including post-surgical pain (such as general, orthopedic and dental surgery), acute musculoskeletal
trauma pain and post-partum uterine cramping pain.
Intramuscular injection of Toradol is indicated for the short-term management of m oderate to severe pain, including pain
following major abdominal, orthopedic and gynecological operative procedures.
CONTRAINDICATIONS
Toradol (ketorolac tromethamine) should not be used where there is a known or suspected hypersensitivity to the drug.
Because of the possibility of cross-sensitivity, ketorolac tromethamine should not be used in patients in whom acetylsalicylic acid (ASA) or other non-steroidal anti-inflammatory agents induce acute asthmatic attacks, urticaria, rhinitis or other
allergic manifestations. Fatal anaphylactoid reactions may occur in such individuals,
Toradol (ketorolac tromethamine) also should not be used in patients with peptic ulcer or active inflammatory disease
of the gastrointestinal system.
WARNINGS
Long-term administration of ketorolac tromethamine oral formulation has shown that this drug shares the risks th a t other
non-steroidal anti-inflammatory drugs pose to patients when taken chronically. Peptic ulceration, perforation and gas
trointestinal bleeding, sometimes severe and occasionally fatal have been reported during therapy with non-steroidal
anti-inflammatory drugs and may occur with ketorolac tromethamine, both in the presence or absence of previous symp
toms. Elderly and debilitated individuals are most susceptible to these complications, the incidence of which increases
with dose and duration of treatment. Close medical supervision is recommended in patients prone to gastrointestinal
tract irritation, particularly those with a history of peptic ulcer, diverficulosts a other inflammatory disease of the gastrointestinal
tract. In these cases the physician must weigh the benefits of treatment against the possible hazards.
Patients taking any non-steroidal anti-inflammatory drug including ketorolac tromethamine should be instructed to con
tact a physician immediately if they experience symptoms or signs suggestive of peptic ulceration or gastrointestinal bleeding.
These reactions can occur at any time during the treatment. If peptic ulceration is suspected or confirmed, or if gastrointestinal
bleeding occurs, ketorolac tromethamine should be discontinued and appropriate treatment instituted and the patient
closely monitored.
Ketorolac tromethamine is not recom mended for routine use with other non-steroidal anti-inflammatory drugs because
of the potential for additive side effects.
Use in pregnancy, lactation and labour: The administration of ketorolac tromethamine is not recommended during preg
nancy or lactation.
Ketorolac tromethamine is not recom mended for use as an obstetrical preoperative medication or for obstetrical anal
gesia because o f the known effects of non-steroidal anti-inflammatory drugs on uterine contraction and fetal circulation.
Use in children: Safety and efficdcy in children have not been established. Therefore, Torado! is not recom mended for
use in children under age 16.
Use in the elderly: Because ketorolac is cleared somewhat more slowly by the elderly (See PHARMACOKINETICS) who
are also more sensitive to the renal effects of non-steroidal anti-inflammatory drugs, extra caution and the lowest effec
tive dose should be used.
PRECAUTIONS
Renal effects: As with other drugs that inhibit prostaglandin biosynthesis, elevations of blood urea nitrogen (BUN) and cre
atinine have been reported in clinical trials with ketorolac tromethamine, Since ketorolac tromethamine and its metabolites
are excreted primarily by the kidney, patients with significant impairment of renal function (serum creatinine values greater
than 5 mg/dL) should not receive ketorolac tromethamine unless the expected benefits outweigh the risks. In patients
with moderately impaired renal function serum creatinine values ranging from 1.9 to 5,0 mg/dL, the rate of ketorolac
clearance was reduced to approximately half of normal. The total daily dose of ketorolac tromethamine should be reduced
by half in such patients. The disposition of ketorolac in dialysis patients has not been studied.
Patients who are volume depleted because of blood loss or severe dehydration may be dependent on renal prostaglandin
production to maintain renal perfusion and therefore glomerular filtration rate. In such situations the use of drugs which
inhibit prostaglandin synthesis might be expected to further decrease renal blood (low. Caution is advised if ketorolac
tromethamine is used in such circumstances. Close monitoring of urine output, serum urea and serum creatinine is rec
ommended until the patient is normovolemic.
Hepatic effects: Meaningful elevations (greater than 3 times normal) of serum transaminases (glutamate pyruvate (SGPT
or ALT) and glutam ic oxalacetic (SGOT or AST)) occurred in controlled clinical trials In less than 1% of patients. If clinical
signs and symptoms consistent with liver disease develop, or if systemic manifestations occur (e.g.,eosinophilia, rash, etc.),
ketorolac tromethamine should be discontinued. Patients with impaired hepatic function from cirrhosis do not have any
clinically im portant changes in ketorolac tromethamine clearance. Studies in patients with active hepatitis or cholesta
sis have not been performed.
Fluid and electrolyte balance: Fluid retention and edem a have been observed in patients treated with Toradol. Therefore,
as with many other non-steroidal anti-inflammatory drugs, the possibility of precipitating congestive heart failure in
elderly patients or those with compromised cardiac function should be borne in mind. Toradol should be used with cau
tion in patients w ith cardiac decompensation, hypertension or other conditions predisposing to fluid retention.
Hematologic effects: Ketorolac tromethamine inhibits platelet function and may prolong bleeding time. It does not affect
platelet count, prothrombin time (PT) or partial thromboplastin time (PIT). Patients who have coagulation disorders or
are receiving drug therapy that interferes with hemostasis should be carefully observed when ketorolac tromethamine
is administered. Unlike the prolonged effects from aspirin, the inhibition of platelet function by ketorolac tromethamine
is normalized within 24 to 48 hours after the drug is discontinued.
Blood dyscrasias associated with the use of non-steroidal anti-inflammatory drugs are rare, but could occu r with
severe consequences.
Infection: in com m on with other anti-inflammatory drugs, ketorolac tromethamine may mask the usual signs of infection.

Drug Interactions: Toradol (ketorolac tromethamine) is highly bound to human plasma protein (mean 99.2%) and bind
ing is independent of concentration.
Prothrombin time should be carefully monitored in ail patients receiving oral anticoagulant therapy concomitantly with
ketorolac tromethamine.
Ketorolac tromethamine does not alter digoxin protein binding.
In vitro studies indicated that at therapeutic concentrations of salicylates (300 mcg/mL), the binding of ketorolac
tromethamine was reduced from approximately 99.2% to 97.5%. Therapeutic concentrations of digoxin, warfarin,
acetaminophen, phenytoin, tolbutamide and piroxicam did not alter ketorolac tromethamine protein binding. Since ketoro
lac tromethamine is a highly potent drug and present in low concentrations in plasma, it would not be expected to displace
other protein-bound drugs significantly.
There is no evidence in animal or human studies that ketorolac tromethamine induces or inhibits the hepatic enzymes
capable of metabolizing itself or other drugs. Hence, it would not be expected to alter the pharmacokinetics of other
drugs due to enzyme induction or inhibition mechanisms.
Ketorolac tromethamine mildly reduces the diuretic response to furosemide in normovolemic subjects. Inhibition of renal lithium
clearance leading to an increase in plasma lithium concentration and potential lithium toxicity has been reported with some
non-steroidal anfl-inflammatory drugs. The effect of ketorolac tromethamine on lithium plasma levels has not been studied.
Concomitant administration of methotrexate and some non-steroidal anti-inflammatory drugs have been reported to
reduce the clearance of methotrexate, enhancing the toxicity of methotrexate. The effect of ketorolac tromethamine
on methotrexate clearance has not been studied.
There is limited experience on concurrent administration with morphine. Available information shows no evidence of adverse
interactions. The extent o f a possible narcotic-sparing effect of ketorolac tromethamine is currently under investigation.
ADVERSE EFFECTS
Toradol tablets: The incidence of adverse reactions in approximately 600 patients and subjects receiving short-term ora!
therapy (less than 2 weeks) with Torado! (ketorolac tromethamine) are listed below. The most common adverse effects
include: Gastrointestinal: dyspepsia (2%), gastrointestinal pain (2%), nausea (2%), Centra! nervous system: headache (2%),
dizziness (2%).
The following adverse events are rare but have been reported (less than 1%): Gastrointestinal: flatulence, gastritis.
Respiratory: dyspnea. Dermatologic: urticaria, rash, pruritus. Metabolism/nutritional: edema. Body as a whole: asthenia.
Hemic and lymphatic: purpura. Musculoskeletal: myalgia.
Toradol IM: The adverse reactions listed below were reported to be probably related to Toradol IM in clinical trials in which
patients received up to 20 doses of 30 mg of intramuscularly administered Toradol over a period of up to five days.
Incidence between 3 and 9%: Gastrointestinal: nausea, dyspepsia, gastrointestinal pain. Central nervous system: drowsiness.
Incidence between 1 and 3%: Gastrointestinal: diarrhea. Central nervous system: dizziness, headache, sweating. Body as
a whole: edema. Injection site pain was reported by 2% of patients in multi-dose studies (vs. 5% for morphine control group).
Incidence 1% or less: Gastrointestinal: constipation, flatulence, gastrointestinal fullness, liver function abnormalities,
melena, peptic ulcer, rectal bleeding, stomatitis, vomiting. Body as a whole: asthenia, myalgia. Cardiovascular: vasodi
latation, pallor. Hemic and lymphatic: purpura. Nervous system: dry mouth, nervousness, paresthesia, abnormal thinking,
depression, euphoria, excessive thirst, inability to concentrate, insomnia, stimulation, vertigo. Respiratory: dyspnea,
asthma. Urogenital: increased urinary frequency, oliguria. Dermatologic: pruritus, urticaria. Special senses: abnormal taste,
abnormal vision.
OVERDOSAGE
The absence of experience with acute overdosage precludes characterization of sequelae and assessment of antido
tal efficacy at this time. In a gastroscopic study of healthy subjects, daily doses of 360 mg given over an 8-hour interval
for each of five consecutive days (3 times the highest recom mended dose) caused abdominal pain and peptic ulcers
which recovered after discontinuation of dosing.
DOSAGE AND ADMINISTRATION
Adults: Dosage should be adjusted according to the severity of the pain and the response of the patient.
Oral: The usual ora! dose of Toradol (ketorolac tromethamine) is 10 mg every 4 to 6 hours for pain as required. Doses exceeding 40 mg per day are not recommended.
Toradol is recommended for short-term use only i.e. for a maximum of a few weeks.
Parenteral: The recommended usual initial dose is 30 mg. Subsequent dosing may be 10 mg to 30 mg every 4-6 hours as
needed to control pain. A lower initial dose may be suitable for patients under 50 kg in body weight, over age 65 years
and/or with less severe pain at baseline. In the initial post-operative period, mote frequent dosing (e.g„ every 2 hours)
may be employed, but the total daily dose should not exceed 120 mg. Dose above 120 mg could cause drug toxicity
(see Warnings & Precautions). If supplemental analgesia is required, a concomitant low dose of opiate can be used.
The administration of continuous multiple daily doses of Toradol IM should not exceed 5 days for Injection dosing. There
has been limited experience with dosing for more than 5 days since the vast majority of patients have transferred to oral
medication or no longer required analgesic therapy after this time.
Directionsfor use: Insertthe plunger intothe syringe barrel and thread it onto the screw. WITHOUT REMOVING THENEEDLEGUARD,
apply quick, firm pressure to the plunger to break the inner seal (you will feel it let go). Pull back on the plunger slightly to relieve
pressure. Remove the needle guard by twisting as you pull. Use the unit as you would a normal syringe. Dispose of property.
CONVERSION FROM PARENTERAL TO ORAL THERAPY
Toradol tablets may be used either as monotherapy or as follow-on therapy to parenteral ketorolac. In the latter case,
the total combined daily dose of ketorolac should not exceed 120 mg on the day the change of formulation is made,
this includes a maximum of 4 of the 10 mg tablets.
Toradol (ketorolac tromethamine) is a Schedule F drug,
COMPOSITION
Toradol Tablets: Each Toradol tablet contains ketorolac tromethamine, the active ingredient, with microcrystalline cel
lulose, lactose and magnesium stearate. The coating suspension contains hydroxy-propyi-methyicellulose, titanium
dioxide and polyethylene glycol.
Toradol IM: Toradol IM is available for Intramuscular administration as: 15 mg in 1 mL (1.5%), or 30 mg in 1 mL (3%) of ketoro
lac tromethamine in sterile solution. The 15 mg/mL solution contains 10% (w/v) alcohol, USP. and 6.68 mg sodium chloride
in sterile water. The 30 mg/mL solution contains 10% (w/v) alcohol, USP and 4,35 mg sodium chloride in sterile water. The
pH is adjusted with sodium hydroxide or hydrochloric acid. The sterile solutions are dear and slightly yellow in colour,
STABILITY AND STORAGE RECOMMENDATIONS
Toradol Tablets: Store a t room temperature. The blister package tablets should be protected from light.
Toradol IM: Store a t room temperature with protection from light.
AVAILABILITY OF DOSAGE FORMS
Toradol (ketorolac tromethamine) is available as 10 mg white round film coated tablets with one side printed in red with
TORADOL inside a bold T and the other side with Syntex. Toradol (ketorolac tromethamine) 10 mg tablets are available
in bottles of 100 tablets.
Toradol IM is available in 1 mL syringes containing 15 or 30 mg/mL of ketorolac tromethamine.
Product Monograph available on request.
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Mechanism of Injury Influences the
Pattern of Injuries Sustained by Patients
Involved in Vehicular Trauma
Cynthia D. Rogers, BSc, RN; Giuseppe Pagliarello, MD; Barry A. McLellan, MD;
William R. Nelson, PhD
The authors examined the patterns of injury and death rates of patients involved in
vehicle-related accidents who were admitted to the Regional Trauma Unit of
Sunnybrook Health Science Centre in Toronto. Information was collected
prospectively over a 36-month period. The subjects were placed in one o f three
mechanism-of-injury categories: four-wheel passenger vehicles, motorcycles and
pedestrians. The patterns of injury were classified as primarily to the craniofacial
and neck area, the torso, the extremities or to multiple regions. There were 815
patients who were involved in vehicle-related crashes and who suffered moderate to
severe injuries (at least one region scoring more than 3 on the abbreviated injury
scale). The death rate was 13% overall but was 21% in the group receiving multiple
injuries. By mechanism of injury the death rates were: pedestrian group 20%,
motorcycle group 18% and passenger-vehicle group 11% (p < 0.01, x 2 analysis).
There was no difference in the mean injury severity score among the mechanism of
injury groups. A higher proportion of the passenger-vehicle group sustained
isolated craniofacial and torso injuries, and the pedestrian and motorcycle groups
sustained more extremity injuries (p < 0.001, x 2 analysis). The results reveal a clear
association between mechanism of injury and the patterns of injury observed.

Les auteurs ont passe en revue les caracteristiques des blessures subies et les taux
de mortalite des victimes d’accidents de la route, qui ont ete revues a l’Unite
regionale de soins aux traumatises du Sunnybrook Health Science Centre au
Toronto. L’information a ete recueillie de fafon prospective au cours d’une periode
de 36 mois. Les sujets ont ete places dans l’une ou l’autre des trois categories
suivantes: les passagers de vehicules a quatre roues, ceux de motocyclettes et les
pietons. Les caracteristiques des blessures ont ete classifies selon qu’elles
touchaient surtout la region craniofaciale et le cou, le tronc, les membres ou des
regions multiples. Au cours de cette periode, 815 patients ont ete impliques dans
des collisions leur causant des blessures allant de moderees a graves (avec au moins
une region presentant une gravite de cote 3 sur l’echelle abregee devaluation des
blessures). La mortalite globale fut de 13 % mais la mortalite chez les polytraumatises fut de 21 %. Les taux de mortalite selon le mecanisme implique furent: 20 % chez
les pietons, 18 % chez les motocyclistes et 11 % chez les passagers de vehicules
automobiles (p < 0.01, analyse de x2)- On n’a observe aucune difference dans la cote
moyenne de gravite des blessures entre les trois mecanismes. Un plus fort
pourcentage de passagers de vehicules automobiles ont subi des blessures limitees a
la region craniofaciale et au tronc alors que les pietons et les motocylistes
subissaient plus de blessures des membres (p < 0.001, analyse de x 2)- Cette etude
met en relief une nette association entre les mecanismes impliques et les
caracteristiques des blessures observees.

njury patterns associated with
accidents involving motorcycles,
four-wheel passenger vehicles or pe
destrians struck by vehicles have
been studied in isolation .1-3 Knowl
edge about expected patterns o f
injury dictates the focus o f therapy
to some extent. The extent to
which the mechanism o f injury de
termines which body regions are
most likely to sustain significant
injuries has been reported infre
quently.4'5 We undertook a prospec
tive analysis o f the trauma patient
population entering the Sunny
brook Health Science Centre Re
gional Trauma Unit to establish the
dominant injury patterns that may
result from these types o f crashes.
The effects o f these patterns upon
the use o f hospital resources are
also discussed.
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Methods
The Regional Trauma Unit cur
rently treats more than 450 polytraumatized individuals annually.
Patients admitted to the unit typi
cally have an injury severity score
(ISS)6-7 greater than 20. Seventy
percent of the trauma patients are
referred from rural institutions sur
rounding Metropolitan Toronto.
Ninety-five percent of the cases are
the result of blunt injury. Motorvehicle accidents are involved in
almost 70% of the cases.89 Clinical
and resource utilization data were
collected prospectively and comput
erized for all trauma patients treat
ed at our unit. Detailed injury data
on all patients resuscitated between
January 1986 and December 1988
were reviewed. Patients were in
cluded only if they were injured
while in a car or truck (MVA) or on
a motorcycle (MOT) or were pedes
trians (PED). Those whose hospital
stay was greater than two standard
deviations above the mean were
eliminated from the study.
Differences in rates and propor
tions among the mechanisms of
injury were analysed by x 2 analysis.
Differences in means among the
groups were analysed by analysis of
variance.
All injury descriptions for each
patient were coded according to the
conventions of both the abbreviated
injury scale (AIS)-8510 and the In
ternational Classification of Diseas
es, 9th revision, clinical modifica
tion (ICD9-CM).11 A computerized
table was constructed linking all
AIS codes to the compatible ICD
code. The AIS code was then as
signed to each description. The ISS
was calculated through the execu
tion of a program run on an IBMcompatible desktop computer. This
system produced a standardized
coding, eliminating all mathematical
errors in computation of the ISS
and deriving a true ISS for each
284
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the mechanism of injury was MVA
for 587 (72%), MOT for 94 (12%)
and PED for 134 (16%) (Table I).
Overall the differences were signifi
cant (p < 0.001 by x2 analysis),
indicating that the distribution of
injuries by region was unique for
each mechanism of injury. The
MVA group had a higher incidence
of isolated craniofacial and neck
injuries (22%) and torso injuries
(24%) than the PED and MOT
groups. The latter two mechanisms
caused isolated limb injuries more
frequently, at rates of 17% for MOT
and 19% for PED, compared with
the MVA group rate of 8%. The
differences for each of the regions
of injury were found to be statisti
cally significant (Table I).
Approximately half the patients
in each mechanism-of-injury group
had moderate to severe injuries
(AIS 3 or more) in more than one
body region and were assigned to
the MULT category. Again the dif
ferences between MVA (46%), MOT
(59%) and PED (59%) were signifi
cant (p < 0.01).
The mean age for patients in the
MVA group was 35 years, for those
in the MOT group 26 years and for
those in the PED group 43 years.
These differences were found to be
statistically significant (p < 0.001).
The mean ISS for the 815 pa
tients was 27.75 (Table II). No
significant difference was found in
the ISS between the mechanism-ofinjury groups. The overall ratio of
men to women was 2:1. The MOT

patient.
Six body regions were defined
and used to calculate the ISS.
When combining regions (excluding
external and integumentary), 31
unique combinations were possible.
For the purpose of this study, the
injuries to body regions were re
grouped as follows: craniofacial and
neck area (CF), torso (T), extremi
ties (E) and multiple regions
(MULT). All spinal, abdominal and
thoracic injuries, except those to
the cervical spine, were considered
T injuries, as were bony pelvic
injuries. A region was acknowl
edged only if it contained at least
one significant injury with an AIS
value of 3 or more. The injuries
were placed in the MULT category
when two or more regions sus
tained injuries with an AIS of 3 or
greater. Since a patient was as
signed to only one of the pattern-ofinjury groups, the regions were
mutually exclusive.

Results
Of the 1314 cases reviewed over
the 36-month period, 873 were
cases of motor-vehicle-related trau
ma. Eliminated from the total were
33 patients who were not admitted
to hospital, 24 whose hospital stay
was excessive (more than two stan
dard deviations above the mean)
and one patient who sustained sig
nificant external injuries (burns).
There was no predominant mecha
nism of injury in the cases eliminat
ed. Of the remaining 815 patients,

Table I. Cases by Region and Mechanism of Injury
Mechanism of injury*
MVA
(n = 587)

MOT

PED

(n = 94)

(n = 134)

Region of injury

Number

°/o

Number

%

Number

%

p value

Craniofacial and
neck
Torso
Extremities
Multiple

129
141
48
269

22
24
8
46

11
12
16
55

12
13
17
59

14
15
26
79

10
11
19
59

<0.01
< 0.001
< 0.001
<0.01

*MVA = four-wheel motor vehicle, MOT = motorcycle, PED = pedestrian.

INJURY MECHANISMS IN VEHICULAR TRAUMA

group was almost exclusively men
(94%), and the MVA and PED
groups were 66% and 67% men
respectively (Table II).
The overall death rate was 13%.
Most deaths (21.1%) occurred in the
MULT group (Table III). The death
rates for the groups with isolated
injuries were as follows: CF, 11.7%;
T, 0.6%; and E, 2.2%. In the mechanism-of-injury groups, the death
rate was highest for PED, at 20%,
Table II.

compared with 18% for MOT and
11% for MVA (p< 0.01).
On average, pedestrians were
hospitalized 7 days longer than car
or truck occupants and 9 days
longer than motorcyclists, which
was statistically significant (p <
0.01) (Table IV). The PED and
MOT groups were significantly (p <
0.001) more likely to require blood
products and to undergo operation
than the MVA group. The highest

requirement for blood products was
in the MOT group, which received a
mean of almost 10 units of packed
cells per patient.
The frequency of alcohol use was
known in 665 cases (82%). Of
these, 53% of patients in the MOT
group were reported as positive for
alcohol use. In the MVA and PED
groups alcohol use was found in
35% (p < 0.02) (Table V).

Discussion

In ju ry S e v e rity S c o re (IS S ), A ge and S e x

Mechanism of Injury
Data

MVA

MOT

PED

Overall

M ean ISS

2 7 .7 8

2 7 .7 8

2 7 .5 7

2 7 .7 5

NS

M ean age, y r

3 4 .9 2

2 5 .7 7

4 2 .6 6

3 5 .1 4

< 0.0 0 1

/rvalue

S ex, %
F em ale

34

6

33

31

M ale

66

94

67

69

Table III.

D e a th s b y R eg ion a n d M e c h a n is m o f In ju ry

Mechanism of injury
Region of Injury

MVA

MOT

PED

Total

14

0

4

18

T o rs o

1

0

0

1

0 .6

E x tre m itie s

0

0

2

2

2 .2

M u ltip le

47

17

21

85

21.1

T o ta l n u m b e r

62

17

27

106

D eath rate, %

1 0 .6

18.1

20.1

C ra n io fa cia l and n e ck

Table IV.

1 1 .7

A d d itio n a l D a ta *

Mechanism of injury
Data

MVA

H o sp ita l sta y, d

MOT

2 5 .6

N u m b e r o f o p e ra tio n s

PED

24.1

1 .3 8

/rvalue

3 3 .2

1 .9 4

< 0 .0 1

1 .9 6

< 0 .0 0 1

N u m b e r o f o p e ra tin g ro o m
p ro ce d u re s
Packed c e lls tra n s fu s e d , u n its

3 .2 6

4 .7 8

4 .2 6

< 0 .0 0 1

5 .5 2

9 .9 3

7.21

< 0 .0 0 1

'V a lu e s are m e a n s.

Table V.

A lc o h o l U s e a n d M e c h a n is m o f In ju ry

Mechanism of injury
MVA
Alcohol use
U nknow n

(n = 587)

MOT
94)

(n —

PED
(0 = 134)

Total

101

18

31

P o sitive

1 72

40

36

248

N egative

314

36

67

417

486

76

103

35

53

35

150 (1 8 % )

Known

T o ta l k n o w n
P e rce n t p o s itiv e

665 (8 2 % )
37

In this study the MVA group
demonstrated a higher incidence of
CF and T involvement than the
other two groups. Civil4 also found
a higher incidence of head and
neck, facial and chest injuries in
this group than in motorcyclists
and pedestrians.
The MOT and PED groups dem
onstrated more involvement of iso
lated extremities than did the MVA
group. These results are consistent
with data presented by Mackay,3
which indicated that in the 78 mo
torcycle accidents reviewed, for in
juries with AIS values 3 or greater,
limb involvement occurred eight
times more frequently than injuries
to any other body region.
The PED patients also had great
er limb involvement than the MVA
patients and were more likely to
have injuries to multiple regions
(59%) and to die (20%) than the
MVA patients. Fatal results were
consistent with those presented by
Atkins and associates1 and Derlet,
Silva and Holcroft.2
The differences in death rate be
tween the three mechanisms cannot
be attributed to variations in the
ISS between groups, since they
were nonsignificant. However, a
significant (p < 0.001) difference in
the mean age of the mechanism-ofinjury groups was found. Chan,
Kraus and Riggins12 reported that
the elderly are more likely to be
CJS, VOL. 34, NO. 3, JUNE 1991
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injured in pedestrian accidents.
Baker and colleagues6 suggested
that advanced age could contribute
to an increased death rate in the
PED group. Patients in that group
also required more operations and
transfusions than did those in the
MVA group, factors that may in
crease the likelihood of complica
tions and therefore deaths.13
The MOT group demonstrated
the highest incidence of operative
procedures and blood transfusions
but the shortest mean hospital stay
(24.1 days). This shorter stay, on
first examination, appears to be a
function more of age than of mech
anism. However, when 74 PED pa
tients younger than the mean age
of 42.7 years (range from 13 to 41
years, mean 25.6 years; mean ISS
27.11) were isolated they continued
to experience a longer length of
stay (mean 34.5 days). This indi
cates that the differences in age
between the mechanisms did not
account for the variations in length
of hospital stay. These results sug
gest that, in this study, the mecha
nism of injury may be at least a
partial predictor of resource con
sumption.
Alcohol use was not discussed or
was poorly reported in the literature
we reviewed. In the study of Atkins
and associates,1 59% had used alco
hol; of these, 16% were pedestrians.
This rate is less than half of that
reported in the present study.
Although injury trends for each
mechanism of injury were estab
lished, a large percentage of the
patients in each of the three groups
were assigned to the MULT group.
From our experience it should be
noted that patients in this category
had a death rate (21.1%) almost
double that of any of the three
isolated regions.
In summary, this study demon
strates that the mechanism of in
jury can be a predictor of injury
patterns and death rates. One
286
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should expect that in those sustain
ing severe injuries (AIS value 3 or
more) to two or more of the defined
regions (extremities, craniofacial
and torso) the death rate would
approach 21%. Also, the mecha
nism of injury should direct the
trauma team to observe for the
specific subset of injuries noted (the
MVA group having a higher inci
dence of craniofacial and torso inju
ries than the PED and MOT groups,
and the latter populations experi
encing a higher incidence of ex
tremity injuries).
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NOTICES
AVIS
Obesity Surgery — A New Journal
For those surgeons interested in the
research and treatment of massive obe
sity, the new international journal Obe
sity Surgery is now available. Original
research, review articles, modern tech
nical innovations, scholarly presenta
tions, invited commentaries and ab
stracts from international meetings are
included. For those wishing to submit
manuscripts, the Editorial Office is: Dr.
M. Deitel, Editor, Obesity Surgery, Ste.
201, 2238 Dundas St. W, Toronto, ON
M6R 3A9, Canada. The annual sub
scription rate is $110 US, available
from Rapid Communications of Oxford
Ltd., The Old Malthouse, Paradise St.,
Oxford OX1 1LD, UK (members of the
American Society for Bariatric Surgery
receive the subscription as part of their
annual membership).

Symposium on Small-Bowel
Transplantation
An international symposium on smallbowel transplantation, sponsored by the
Transplantation Society, will be held
Oct. 3 -5 , 1991, at the University Hos
pital, London, Ont. Attendance will be
limited to 250, and priority will be given
to members of the Transplantation So
ciety. Topics will include experimental
models, clinical experience, graft physi
ology, pathology, intestinal preserva
tion, immunology, immunosuppression
and multivisceral grafting. For further
information please contact: Dr. David R.
Grant, c / o Continuing Medical Educa
tion, Faculty of Medicine, The Universi
ty of Western Ontario, London, ON
N 6A 5C 1; tel: (5 1 9 )6 6 1 -2 0 7 4 ; fax:
(519) 6 6 1 -3 7 9 7 .

ORIGINAL ARTICLES

Productivity of Needle Localization
to Facilitate Excision of Nonpalpable,
Mammographically Suspicious Lesions
Gayle Higgins, MD, FRCSC; A. Abdulkareen, MD, FRCSC; Antoine Loutfi, MD, FACS, FRCSC;
Jean H. Gagnon, MD, FRCPC; Henry R. Shibata, MD, FACS, FRCSC
The use of needle localization to aid excisional biopsy of nonpalpable breast lesions
is now common, and the literature suggests that 13% to 33% of such lesions are
malignant. During the 4 years from 1984 to 1988, all women who underwent
fine-needle localization in preparation for biopsy were studied to identify factors that
might facilitate the selection of those more likely to harbour a cancer, thus sparing
patients with benign disease operative intervention.
In all, 124 biopsies were performed on nonpalpable lesions that were suspicious
on mammography; 51 lesions were malignant and 73 benign. The average age of the
patients was 56 years (55 years for those with benign lesions and 61 for those with
malignant lesions). The family history, history of breast disease, symptoms and
calcification seen on mammography were not significantly different between the two
groups.
Only 25% of the malignant lesions were noninvasive. In 10% of the patients who
had invasive lesions there was lymph-node involvement.
The rate of malignancy in this patient population (41%) was slightly better than
that reported in the literature, and a larger proportion of patients had noninvasive
disease.
The authors conclude that none of the above-mentioned risk factors could be used
in the preoperative selection of patients for open biopsy.

he use of needle localization to
facilitate the surgical removal
of suspicious masses or calcifica
tions detected only by mammogra
phy has become an acceptable pro
cedure for nonpalpable breast le
sions. A review of the literature
revealed that only 13% to 33% of
these lesions were malignant at the
time of biopsy.'-6
The purpose of this review was to
assess our results with needle local
ization over time, to evaluate the
productivity of this technique in our
clinical setting and to identify fac
tors that may aid in the selection of
patients more likely to harbour a
cancer.

T

Methods
L’emploi de la localisation a l’aiguille pour faciliter l’excision-biopsie des lesions
mammaires non palpables est maintenant frequent et la litterature indique que 13 %
a 33 % de ces lesions sont malignes. Sur une periode de 4 ans, de 1984 a 1988,
toutes les femmes qui ont eu une localisation a l’aiguille en preparation pour une
biopsie ont fait l’objet d’une etude visant a identifier les facteurs qui pourraient
faciliter le choix de celles qui sont le plus susceptibles d’etre porteuses d’un cancer,
evitant ainsi a celles qui ont une tumeur benigne d’etre soumises a une intervention
chirurgicale.
Au total, 124 biopsies ont ete pratiquees sur des lesions non palpables, suspectes
a la mammographie; 51 lesions etaient malignes et 73 benignes. L’age moyen des
patientes etait de 56 ans (55 pour celles qui etaient porteuses de tumeurs benignes
et 61 pour les porteuses de tumeurs malignes). Les antecedents familiaux, l’histoire
de la maladie mammaire, les symptomes et la calcification observee a la mammogra
phie ne montraient pas de differences significatives entre les deux groupes.
Seulement 25 % des lesions malignes n’etaient pas invasives. Chez 10 %des
patientes qui avaient des tumeurs invasives, il y avait atteinte ganglionnaire.
Le taux de tumeurs malignes dans cette population (41 %) est legerement meilleur
que ce qui est rapporte dans la litterature et un plus grand nombre de patientes
avaient des tumeurs non invasives.
Les auteurs conduent qu’aucun des facteurs de risque mentionnes precedemment
ne peuvent etre utilises pour choisir les patientes devant etre soumises a une
excision biopsie.

A retrospective review was done
of all patients seen between 1984
and 1988 at the Royal Victoria
Hospital in Montreal who under
went excisional biopsies o f ques
tionable nonpalpable breast lesions.
The lesions were localized by fineneedle placement, and the screen
film mammographie technique was
used.
Most biopsy specimens, especially
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The average age of the patients
with benign disease was 55 years,
and of those harbouring malignant
disease 61 years.
No factor or group of known risk
factors (Table II) was of use as a
predictive tool, although a history
of breast cancer was present in 6 of
the 51 patients with biopsy proven
malignant disease. Overall, positive
family history, personal history of
benign or malignant breast disease,
symptomatology or mammographic
calcifications could not be used to
aid in the selection of patients for
biopsy of suspicious lesions.
Because the number of patients
in our study is small, no statistical
analysis was done. However, 47% of
the benign lesions contained mi
crocalcifications compared with
57% of the malignant lesions. This
is not statistically significant.
In our study group 75% of the
malignant lesions had an invasive
component (Table III); 10% of these
were stage II cancers (positive
nodes). The remaining 25% of the
malignant lesions were noninvasive.

those with fine calcifications, were
x-rayed by the pathologist and com
pared with the preoperative mam
mogram to confirm that the area in
question was actually removed.
The patients were divided into
those who had malignant disease
and those who had benign lesions
in order to determine the percent
age of malignant biopsy specimens
detected by this technique. The risk
factors were assessed from the his
tory taken before needle localiza
tion. Size of the lesion was not a
factor, because all of these lesions
were nonpalpable.
The malignant lesions that were
removed were identified as invasive
or noninvasive to determine the
nature of the disease. Furthermore,
the patients with invasive lesions
were divided into node-negative and
node-positive groups, on the basis
of histology reports after formal
mastectomy (modified or partial)
and lymph-node dissection.

Results
During the study period 124 bi
opsies were performed (Table I);
there were 51 malignant tumours
and 73 benign tumours. The overall
rate of malignancy was 41%.

Discussion
Mammographic techniques have

Table 1. Breast Biopsies Performed With the Aid of Fine-Needle Localization in 124 Women

Between 1984 and 1988
Tumour
Year

Benign, no.

Malignant, no. (% )

1984
1985
1986
1987
1988

6
20
8
15
24

5(45)
13(39)
10(56)
9(38)
14(41)

Total

73

51(41)

improved markedly in recent years;
technologic advances have pro
duced better-quality images and
markedly reduced exposure of
breast tissue to radiation.7-8. In June
1971 xeromammography was intro
duced; there was initial interest in
this new technique, but the screenfilm technique, which results in a
lower dose of radiation,9 is still used
most often.
Preoperative needle localization
for nonpalpable, mammographically
suspicious lesions was introduced
to aid the surgeon in determining
when to perform the biopsy and to
minimize the removal of uninvolved
breast tissue, and therefore reduce
breast distortion. This was first re
ported by Dodd, Fry and Delany10
and was refined by Feig.11
Although the total number was
small, our biopsied specimens
showed an overall malignancy rate
of 41%. This rate is much better
than those reported by others1*6-12
and may indicate a better selection
of such patients. Taken by year, the
rate of malignancy showed a slight
fluctuation, but was in the range of
37% to 55%, indicating a fairly
consistent pattern.
The risk factors that were as
sessed are only a small part of the
many factors associated with breast
cancer. Those that were analysed
could not be used as tools to predict
malignant lesions. Tumour size,
which is an important prognostic
sign, could not be utilized with
these minimal lesions. The presence
of previous biopsy proven cancer
was also not useful for determining
malignancy in this study group.
The malignant lesions detected

Table II. Risk Factors for Malignancy Related to Biopsy Findings
Tumour
Factor

Malignant, no.

Total

9
2
14
6
34

5
6
6
5
29

14
8
20
11
63

Positive family history
History of breast cancer
History of biopsy
Symptoms
Microcalcifications
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Table III. Malignant Lesions and Invasion

Benign, no.
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Type of lesion

Invasive
Noninvasive

Number

%

39
12

75*
25

*0 f patients with invasive lesions 10% had
stage II disease (positive nodes).

NEEDLE LOCALIZATION IN BREAST LESIONS

by this technique proved to be
noninvasive in only 25% of the
cases, indicating that the majority
were already invasive. It was also
interesting to note that once a
formal surgical procedure was per
formed, only 10% were noted to be
node-positive (stage II disease). The
follow-up of these patients would
prove interesting to see if they have
a better or worse prognosis than
the stage II patients who had larg
er, palpable tumours.
The ideal situation would involve
biopsies only on patients with a true
cancer. Detection by mammogra
phy, needle localization and open
biopsy under local or general anes
thesia is time consuming and trau
matic to the patient with these
minimal cancers.
For patients with palpable le
sions, fine-needle aspiration cytolo
gy (FNAC) is now becoming an
accepted method of tissue diagno
sis, and basing treatment decisions
on the cytologic finding is becom
ing common.13*17 The true-positive
rate when the cancer is well circum
scribed and fairly large (more than
1 cm in diameter) is now in the 90%
range with good cytologic back-up.
The next logical step in further
ing this technique is to use a stereo
tactic apparatus.918 With the pa
tient lying prone on a special table
and the breast compressed and im
mobilized, two stereoradiographs
are obtained with an x-ray tube
mounted beneath the table. The
coordinate values are fed into a
calculator to produce a threedimensional setting for the needle.
After needle insertion, repeat ste
reoradiographs are obtained to con
firm proper placement. The position
of the lesion can then be marked for
subsequent surgical removal.
Since the instrument enables
highly accurate localization of the
lesion, the next step is to perform
fine-needle aspiration on these nonpalpable lesions for diagnostic and

treatment planning. Perhaps the
perfection of this next step will
eventually aid in reducing the num
ber of patients requiring open biop
sy, since it has been shown that
60% to 70% of our patients have
benign disease.
The stereotactic technique pro
vides a highly accurate localization
method. The disadvantages are
equipment cost, space requirements
and the skills necessary to operate
the equipment. Until shown in a
clinical trial that FNAC can accu
rately diagnose malignant disease in
patients with nonpalpable lesions,
with few false-negative results, the
technique cannot be used for diag
nostic purposes, but it is a useful
aid to open biopsy.

Conclusions
Of the 124 biopsies performed
using the fine-needle localization
technique, our malignancy rate was
41% (slightly better than that re
ported in the literature). We ad
dressed the concern that the pa
tients might have been “overselect
ed” in order to give this number; in
other words, only the “more suspi
cious” lesions were biopsied and
therefore malignant lesions in the
“less suspicious” candidates were
being missed. However, the higher
proportion of “early” (noninvasive)
lesions in our study group argued
against this thought.
Unfortunately no risk factor or
cluster of factors appeared to indi
cate a population more likely to
have carcinomas.
The next obvious step in the
investigation of this patient popula
tion is an attempt to use fine-needle
aspiration in conjunction with these
localization techniques.
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DIFLUCAN
(fluconazole/pfizer)

A N OPPORTUNISTIC WAY
TO TREAT FUNGAL INFECTION
PRODUCT INFORMATION
NAME OF DRUG
DIFLUCAN TABLETS
DIFLUCAN INTRAVENOUS INFUSION 2 mg/mL in 0.9% SODIUM CHLORIDE
(fluconazole)
THERAPEUTIC CLASSIFICATION Antifungal
ACTIONS: Fluconazole is a highly selective inhibitor of fungal cytochrome P-450 sterol C14-alpha-dem ethylation. Mammalian cell dem ethylation is much less sensitive to
fluconazole inhibition. The subsequent loss of norm al sterols correlates w ith the
accumulation of 14-alpha-methyl sterols in fungi and may be responsible for the fungistatic
activity of fluconazole.
INDICATIONS AND CLINICAL USE: DIFLUCAN (fluconazole) is indicated for the treatment
of: 1. Oropharyngeal and esophageal candidiasis. DIFLUCAN is also effective for the
treatm ent of serious systemic candidal infections, including urinary tract infection,
peritonitis, and pneumonia. 2. Cryptococcal meningitis. 3. Prevention of the recurrence of
cryptococcal meningitis in patients with acquired immunodeficiency syndrome (AIDS).
Specim ens fo r fungal culture and other relevant laboratory studies (serology,
histopathology) should be obtained prior to therapy to isolate and identify causative
organisms. Therapy may be instituted before the results of the cultures and other laboratory
studies are known; however, once these results become available, anti-infective therapy
should be adjusted accordingly.
CONTRAINDICATIONS: DIFLUCAN (fluconazole) is contraindicated in patients who have
shown hypersensitivity to fluconazole or to any of its excipients. There is no information
regarding cross hypersensitivity between fluconazole and other azole antifungal agents.
Caution should be used in prescribing DIFLUCAN to patients with hypersensitivity to other
azoles.
WARNINGS: Patients with baseline abnormal liver function tests and those who develop
abnormal liver function tests during DIFLUCAN (fluconazole) therapy should be monitored
for the development of more severe hepatic injury. Although serious hepatic reactions have
been rare and the causal association with DIFLUCAN uncertain, if clinical signs and
symptoms consistent with liver disease develop that may be attributable to fluconazole,
DIFLUCAN should be discontinued, (see ADVERSE REACTIONS).
Immunocompromised patients, especially those with AIDS, who develop rashes during
treatment with DIFLUCAN should be monitored closely and the drug discontinued if lesions
progress, (see ADVERSE REACTIONS).
PRECAUTIONS
Use in Pregnancy: There are no adequate and well-controlled studies in pregnant women.
DIFLUCAN (fluconazole) is not recommended in pregnant women unless the potential
benefit outweighs the potential risk to mother and fetus.
Use in Nursing Mothers: It is not known whether fluconazole is excreted in human milk.
Because many drugs are excreted in human m ilk, caution should be exercised when
DIFLUCAN is administered to a nursing woman.
Use in Children: The clinical use of DIFLUCAN in children below 13 years of age has not
been established.
Use in Elderly: DIFLUCAN was well tolerated by patients aged 65 years and over.
Drug Interactions
Cimetidine and Antacids Absorption of orally administered DIFLUCAN does not appear to
be affected by gastric pH. Cimetidine did not affect oral bioavailability of fluconazole to a
clinically meaningful extent; reduction of about 13% in AUC (area under the plasma
concentration-time curve) and 21% in peak plasma concentration (Cmax) was observed.
Administration of magnesium/aluminum hydroxide formulation, just prior to DIFLUCAN
adm inistration had no clinically relevant effects on the absorption or elimination of
fluconazole in normal volunteers.
Cyclosporine DIFLUCAN administered at 100 mg daily dose does not affect cyclosporine
pharmacokinetic levels in patients with bone marrow transplants. There have been several
reports in the literature associating concomitant administration of high doses of DIFLUCAN
with an increase in cyclosporine plasma concentrations in renal transplant patients with or
w ith o u t im paired renal function. Therefore, when DIFLUCAN and cyclosporine are
coadministered, cyclosporine levels should be monitored and cyclosporine dose accordingly
adjusted.
Warfarin DIFLUCAN increased the prothrombin time after warfarin administration in healthy
males. Though the magnitude of change was sm all (12% ), careful m onitoring of
prothrombin time in patients receiving coumarin-type anticoagulants is recommended.
Hydrochlorothiazide Concomitant administration of multiple doses of DIFLUCAN and
hydrochlorothiazide was associated with increases in fluconazole plasma levels which were
not considered to be clinically significant.
Sulfonylurea-Oral Hypoglycemics The potential fo r hypoglycemia due to decreased
elimination and increased blood levels of sulfonylurea oral hypoglycemics (glibenclamide,
glipizide and tolbutamide) has been demonstrated with concomitant administration of
DIFLUCAN. Blood glucose levels should be m onitored closely and the dose of the
hypoglycemic agent should be adjusted as necessary.
Phenytoin Concomitant administration of DIFLUCAN at steady state and phenytoin at steady
state resulted in an increase of up to 75% in AUC phenytoin. Since phenytoin has a low
therapeutic ratio, phenytoin plasma levels should be closely monitored when DIFLUCAN is
coadministered. The dose of phenytoin should be adjusted to maintain therapeutic levels.
Rifampin Concomitant adm inistration of DIFLUCAN and rifam pin resulted in a 25%
decrease in the AUC and a 20% shorter half-life of fluconazole. The dosage of fluconazole
should be increased by 25% when fluconazole is administered with rifampin.
Zidovudine (AZT) and/or Pentamidine Isethionate Though no formal interaction studies have
been completed for DIFLUCAN and concomitant zidovudine and/or pentamidine isethionate,

these drugs have been used together in patients with AIDS with no clinically important
difference in the pattern of adverse events.
Drug/Laboratory Test Interactions: None known.
ADVERSE REACTIONS: Sixteen percent of over 4000 patients treated with DIFLUCAN
(fluconazole) in clinical trials of 7 days or more experienced adverse events.
Treatment was discontinued in 1.5% of patients due to adverse clinical events and in 1.3%
of patients due to laboratory test abnormalities.
Adverse clinical events were reported more frequently in HIV infected patients (21 %) than in
non-HIV infected patients (13%). However, the patterns of adverse events in HIV infected
and non-HIV infected patients were similar. The proportions of patients discontinuing
therapy due to clinical adverse events were similar in the two groups (1.5%). The two most
serious adverse clinical events noted during clinical trials with DIFLUCAN were: 1. Exfoliative
skin disorders 2. Hepatic necrosis Because most of these patients had serious underlying
disease (predominantly AIDS or malignancy) and were receiving multiple concomitant
medications, including many known to be hepatotoxic or associated with exfoliative skin
disorders, the causal association of these reactions with fluconazole is uncertain. Two cases
of hepatic necrosis and one exfoliative skin disorder (Stevens-Johnson syndrome) were
associated with a fatal outcome.
The following treatment-related clinical adverse events occurred at an incidence of 1% or
greater in 4,048 patients receiving fluconazole for 7 or more days in clinical trials: Nausea
3.7% Headache 1.9% Skin Rash 1.8% Vomiting 1.7% Abdominal Pain 1.7% Diarrhea
1.5% Other treatment-related clinical adverse events which occurred less commonly (0.2 to
<1%) are presented by organ system below:
Skin and Appendages: pruritus.
Musculoskeletal: myalgia.
Central and Peripheral Nervous System: convulsions, dizziness, paresthesia, tremor, vertigo.
Autonomic Nervous System: dry mouth, increased sweating.
Psychiatric: insomnia, somnolence.
Gastrointestinal: anorexia, constipation, dyspepsia, flatulence.
Liver and Biliary System: cholestasis, hepatocellular damage.
Special Senses: taste perversion.
Hematopoietic: anemia
General: fatigue, malaise, asthenia, fever.
LABORATORY TEST ABNORMALITIES
Liver Function: Clinically significant increases were observed in the following proportions
of patients: AST (SGOT) 1%, ALT (SGPT) 1.2%, Alkaline Phosphatase 1.2%, Total bilirubin
0.3%. The incidence of elevated serum transaminases was independent of age or route
(p.o. or i.v.) of administration but was greater in patients taking DIFLUCAN concomitantly
with one or more of the following medications: rifampin, phenytoin, isoniazid, valproic acid,
or oral hypoglycemic agents. Clinically significant increases also were more frequent in
patients who: 1) had SGOT or SGPT elevations greater than three times the upper limit of
normal (>3xULN) at the time of entering the study (baseline), 2) had a diagnosis of hepatitis
at any time during the study and, 3) were identified as alcohol abusers. The overall rate of
serum transaminase elevations of more than 8 times the upper lim it of normal was
approximately 1% in patients treated with DIFLUCAN during clinical trials. (See table below)
Percent
Number
Percent
Number*
Percent
Drugof
Percent
Drugof
Lab
Abnormal
Related
Patients
Abnormal
Related
Patients
Parameter
Baseline < 3xULN
Baseline > 3xULN
3007
4.2
0.8
9.4
3.8
1.0
4.8
2874
0.0
3.1
Non-Hepatitis Patients
Hepatitis Patients
3.9
0.8
2900
10.6
1.9
SGOT
160
1.0
2799
4.4
2.1
11.4
140
SGPT
Non-Alcohol Abuse
Alcohol Abuse
4.2
0.9
3018
9.5
2.4
SGOT
42
1.0
4.7
2899
2.5
40
10.0
SGPT
Never Received
Received
I.V. Fluconazole
I.V. Fluconazole
4.2
0.9
2916
5.6
1.4
SGOT
144
1.0
4.7
2800
0.7
5.0
139
SGPT
< 65 Years Old
a.65 Years Old
4.3
0.9
2783
SGOT
277
4.3
1.1
1.0
4.8
2681
1.2
3.9
SGPT
258
*Note: Only patients who had measurements at baseline and during therapy were included.
Renal Function: Clinically significant increases were observed in the following proportions
of patients: blood urea nitrogen (0.4%) and creatinine (0.3%).
Hematological Function: Clinically meaningful deviations from baseline in hematologic
values which were possibly related to DIFLUCAN were observed in the following proportions
of patients: hemoglobin (0.5%), white blood cell count (0.5%), and total platelet count
( 0 . 6% ) .
SYMPTOMS AND TREATMENT OF OVERDOSAGE
Symptoms: Presently, there are no known symptoms of DIFLUCAN (fluconazole)
overdosage in man.
Treatment: In the event of overdosage, symptomatic treatment (with supportive measures
and gastric lavage if necessary) may be adequate. Fluconazole is largely excreted in urine. A
three hour hemodialysis session decreases plasma levels by approximately 50%.
Mice and rats receiving very high doses of fluconazole, whether orally or intravenously,
displayed a variety of nonspecific, agonal signs such as decreased activity, ataxia, shallow
respiration, ptosis, lacrimation, salivation, urinary incontinence and cyanosis. Death was
sometimes preceded by clonic convulsions.
DOSAGE AND ADMINISTRATION
Oral and Intravenous Treatment: Fluconazole is well absorbed and excreted predominantly
unchanged in urine follow ing oral administration in man. The oral bioavailability is
essentially complete (greater than 90%), and is independent of dose. Peak plasma
concentrations after oral administration are attained rapidly, usually within 2 hours of
dosing. Since oral absorption is rapid and almost complete, the daily dose of DIFLUCAN
(fluconazole) is the same for oral and intravenous administration. The terminal plasma
elimination half-life is approximately 30 hours (range 20-50 hours).
The daily dose of DIFLUCAN and the route of administration should be based on the
infecting organism, the patient's condition and the response to therapy. Treatment should
be continued until clinical parameters and laboratory tests indicate that an active fungal
infection has been cured or has subsided. An inadequate period of treatment may lead to
recurrence of active infection. Patients with AIDS and cryptococcal meningitis or recurrent
oropharyngeal candidiasis usually require maintenance therapy to prevent relapse.
SGOT
SGPT
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Recommended Adult Dosages
Loading Dose: Administration of a loading dose on the first day of treatment, consisting
of twice the usual daily dose, results in plasma concentrations close to steady state by
the second day. Patients with acute infections should be given a loading dose equal to
twice the daily dose, not to exceed a maximum single dose of 400 mg, on the first day of
treatment.
Oropharyngeal Candidiasis: 100 mg once daily. Treatment should be continued for at least
2 weeks to decrease the likelihood of relapse.
Esophageal Candidiasis: 100 mg to 200 mg once daily. Patients should be treated for a
minimum of 3 weeks and for at least 2 weeks following resolution of symptoms.
Systemic Candidiasis: 200 mg to 400 mg once daily. These patients should be treated for a
minimum of 4 weeks and for at least 2 weeks following resolution of symptoms.
Cryptococcal Meningitis: 200 mg to 400 mg once daily. Although the duration of therapy
for cryptococcal meningitis is unknown, it is recommended that the initial therapy should
last a minimum of 10 weeks.
Prevention o f Recurrence o f Cryptococcal Meningitis in AIDS: 200 mg once daily.
DIFLUCAN (fluconazole) may be administered either orally or by intravenous infusion. The
intravenous infusion of DIFLUCAN should be administered at a maximum rate of
approximately 200 mg/hour given as a continuous infusion. See Directions for Use .
Dosage in Patients With Impaired Renal Function
Fluconazole is cleared primarily by renal excretion as unchanged drug. In patients with
impaired renal function, an initial loading dose of 50 to 400 mg should be given. After the
loading dose, the daily dose (according to indication) should be based on the following
table:
Creatinine Clearance (mL/min)
Percent of Recommended Dose
>50
100%
21-50
50%
11-20
25%
Patients receiving
one recommended
regular hemodialysis
dose after each dialysis

Directions for Use: Inspect visually fo r particulate m atter or discoloration p rior to
administration. Do not use if cloudiness or precipitation is evident.
Reject the contents as unsterile if the metal seal is broken. NOT INTENDED FOR
MULTIDOSE USE: discard any portion not used when the seal is first broken.
Connect an intravenous giving set to the bottle of DIFLUCAN (fluconazole) intravenous
solution and also insert a venting set through the bung. Infuse DIFLUCAN intravenous
solution at a m axim um rate o f 200 m g/hour. Flush DIFLUCAN intravenous solution
remaining in the giving set with sterile normal saline.
Because fluconazole is available as a dilute saline solution, in patients requiring sodium or
fluid restriction, consideration should be given to the rate of fluid administration.
Incompatibility: It is recommended that DIFLUCAN I.V. be infused separately.
Compatibility: Administration sets ( “giving" sets).
DIFLUCAN I.V. infusion is com patible w ith (i.e. not susceptible to abso rp tio n ) sets
constructed of a delivery tube (PVC) luer lock (modified phenylene oxide), flash ball (latex)
drip chamber (polypropylene) and piercing spike (polypropylene).
DOSAGE FORMS
Availability: DIFLUCAN TABLETS are available as pink tablets containing 50 mg, 100 mg
and 200 mg of fluconazole.
Supplied in bottles (opaque polyethylene) of 50 or 100 tablets.
DIFLUCAN I.V. is available as a sterile aqueous solution fo r direct infusion. Each mL
contains 2 mg fluconazole and 9 mg sodium chloride. Supplied in clear glass bottles of 100
mL, affording doses of 200 mg fluconazole, sealed with a rubber bung.
STORAGE
DIFLUCAN TABLETS (fluconazole) 50,100, and 200 mg: Store below 30°C.
DIFLUCAN I.V. (fluconazole) 2 mg/mL: Store below 30°C. Do not freeze.
References: 1. DIFLUCAN new drug submission, Data on file, Pfizer Canada Inc.
2. Product monograph-DIFLUCAN’ .

NEW

When serum creatinine is the only measure of renal function available, the following formula
(based on sex, weight, and age of the patient) should be used to estimate the creatinine
clearance.
Males:
Weight (kg) x (140 - age)
72 x serum creatinine (mg/100 mL)
Females:
0.85 x above value

DIFLUCAN

Composition: DIFLUCAN Tablets (pink) contain 50, 100 or 200 mg fluconazole. Also
contains the following non-medicinal ingredients: microcrystalline cellulose, dibasic calcium
phosphate anhydrous, povidone, croscarmellose sodium, FD & C Red No. 40 aluminum lake
dye, and magnesium stearate.
DIFLUCAN I.V. for infusion is a sterile solution of fluconazole in saline at a concentration of
2 mg/mL which is made iso-osmotic with sodium chloride 9 mg/mL.

© Pfizer Canada Inc. 1991
Kirkland, Quebec
H9J 2M5
‘ Prepared by Pfizer Canada Inc. (R.U.)
Pfizer Inc. TM Owner

SESAP VI Critique /

(fluconazole/pfizer)

Product Monograph is
available on request.

l pl>IAel

Critique SESAP VI

Item 38
Colonoscopic polypectomy spares many patients abdominal operations. If carcinoma is found in the polyp,
however, further treatment may be required depending on the level o f invasion and the completeness o f
colonoscopic resection. If the resection is complete and the carcinoma is confined to the mucosa or is confined to
the polyp head with no evidence o f spread into the stalk (as in this patient), further treatment is unnecessary
because metastatic disease and local recurrence are unlikely. The low risk o f colectomy in this particular
72-year-old woman should be balanced against the even smaller likelihood o f extension o f the carcinoma. In a
younger patient with a longer life expectancy and lower risk o f operation, colectomy for this lesion may be
indicated.
Patients at high risk for residual disease after polypectomy include those with cancer close to the plane o f
resection, cancer in the lymphatics or veins, poorly differentiated tumor, sessile polyps, short stalked polyps, or
incomplete excision. These patients should undergo secondary resection o f the involved area o f the colon.

¥
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CLASSIFIED ADVERTISING
ANNONCES CLASSEES
The Canadian Journal o f Surgery is pleased to accept classified advertisements. The deadline is 1 month before issue date. Classified rates: $55
for the first 40 words or less, additional words 70c each (additional $21 for frame). Special Display under 100 words, 55 X 55 mm, $125. $15
charge (first insertion only) for CJS reply box numbers. Display rates available on request. VISA, MASTERCARD AND AMERICAN EXPRESS
ACCEPTED.
Copy should be mailed to: Beverley Kirkpatrick, Manager, Classified Advertising, Canadian Journal o f Surgery, PO Box 8650, Ottawa, ON
K1G 0G8. Tel: (613) 731-9331. Fax: (613) 523-0937.
Send all box number replies to: Box . . . , Canadian Journal o f Surgery, PO Box 8650, Ottawa, ON K1G 0G8.

Le Journal canadien de chirurgie accepte volontiers les annonces classees. Celles-ci doivent etre recues au Journal au plus tard 1 mois avant la
date de parution. Tarifs des annonces classees 55 $ jusqu'a 40 mots et 70 <f par mot supplem ental (21 $ pour encadrement au trait). Encadre
special jusqu'a 100 mots, 55 X 55 mm, 125 $. L ’emploi d’une boite-reponse au Journal donne lieu a la perception d’un supplement de 15 $
(pour la premiere insertion seulement). Tarifs des encadres grand format disponibles sur demande. VISA, MASTERCARD ET AMERICAN
EXPRESS ACCEPTES.
La texte des annonces doit etre adresse a : Beverley Kirkpatrick, Gestionnaire des annonces classees, Journal canadien de chirurgie, CP 8650,
Ottawa, ON K1G 0G8. T e l : (613) 731-9331. Fax : (613) 523-0937.
Veuillez faire parvenir les reponses aux numeros de boites a l'adresse suivante : Boite . . . . Journal canadien de chirurgie, CP 8650, Ottawa,
ON K1G 0G8.

TRANSPLANT SURGEON: ON - The MultiOrgan Transplantation Programme at the Uni
versity o f Toronto and the Toronto Hospital is
seeking a general surgeon with training and
experience in all aspects of Gl transplantation,
including hepatic and pancreatic transplanta
tion. The individual should have an MD and
FRCSC or its equivalent and be eligible to
practise medicine in Ontario. He/she will be
required to initiate and manage all aspects of
a clinical program in pancreatic transplanta
tion and to initiate and manage a research
program in a related area. This program will
function as an integral part of the Multi-Organ
Transplantation Programme at the University
of Toronto and at the Toronto Hospital. Re
sponsibilities will include undergraduate and
postgraduate education, advanced training in
transplantation and collaborative work with
clinicians and basic scientists involved in the
overall program. In accordance with Canadian
immigration regulations, this advertisement is
directed to Canadian citizens and permanent
residents of Canada. The University of Toron
to encourages both men and women to apply
for this position. Interested candidates should
forward their curriculum vitae to: Dr. B.R.
Taylor, Head of the Division of General Sur
gery, University of Toronto, Toronto General
Hospital, Eaton North 9-232, Toronto, ON
M5G 2C4. Deadline for receipt of applications
is Sept. 30, 1991.
-S91-60

GENERAL SURGEON: PE - A general sur
geon is required for a 30-member clinic in
Charlottetown, Prince Edward Island. The
clinic is staffed with several family physicians
and specialists. One of the two general sur
geons is appoaching retirement. The area is
served by a new, modern 350-bed hospital.
The recreational facilities in the area are excel
lent w ith numerous golf courses as well as
boating facilities. Subspecialties are well cov
ered. Apply to: Mr. Ken Heckbert, Manager,
Polyclinic, 199 Grafton St., Charlottetown, PE
C1A 1L2.
-S91-49
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CHAIRMAN, DIVISION OF ORTHOPEDIC
SURGERY: PQ - Applications are invited for
the position of Chairman, Division of Orthope
dic Surgery, McGill University Faculty of Medi
cine. MD identifiable as a clinician. Must also
have extensive knowledge in all facets of
orthopedic surgery with a strong interest in
research; must have experience in educational
design and execution of undergraduate, grad
uate and postgraduate training programs;
must have administrative experience in both
hospital and academic settings. Will be re
sponsible for the entire administration of the
University Division of Orthopedic Surgery;
also will be responsible for maintaining and
strengthening the training program at all clini
cal levels; and responsible for the mainte
nance and continuing development of strong
research components. Salary commensurate
with qualifications and experience. The suc
cessful candidate should be able to justify a
full professor position and potentially qualify
for an endowed chair. In accordance with
Canadian immigration requirements, this ad
vertisement is directed to Canadian citizens
and permanent residents. Please reply to: Dr.
Mostafa M. Elhilali, Royal Victoria Hospital,
Room S695, 687 Pine Ave. W., Montreal, PQ
H3A 1A1. Fax: (514) 843-1552.
-S91-57

CARDIAC SURGICAL FELLOWSHIP: ON Available beginning July 1, 1991 at university
medical centre doing a large volume and
diversity of adult cardiac surgical procedures;
program affiliated with the University of To
ronto, Canada. Medical licence in Ontario
necessary. Ideal for FRCS or ABTS board
eligible/certified general surgeon awaiting
thoracic residency, or board eligible/certified
individual in thoracic surgery seeking addition
al experience. Salary commensurate with ex
perience, board status and potential for billing
(Canadians only). Please respond with CM to:
Bernard S. Goldman, MD, Head, Division of
Cardiovascular Surgery, Sunnybrook Health
Science Centre, 2075 Bayview Ave., Ste.
H410, Toronto, ON Canada M4N 3M5. Tel:
(416)480-6070.
-S91-48

CLINICAL BURN FELLOWSHIP: ON - The
regional adult burn centre for Toronto, Cana
da - located at the Wellesley Hospital in
downtown Toronto - has a position available
for a 1-year clinical burn fellowship beginning
Jan. 1, 1992. This modern, self-contained,
well-staffed and well-funded unit has 10
acute beds and 100 annual admissions. The
fellow is responsible for the surgical and
critical care management of all patients. Ex
tensive well-funded research programs are in
progress in burn immunology and metabolism
and nutrition. Clinical investigations are en
couraged. Candidate should have completed a
residency in plastic surgery or general sur
gery. Foreign graduates from outside the U.S.
or Canada must have successfully completed
the Medical Council of Canada Evaluating
exam before applying. The position is fully
funded. Please reply to: Dr. Walter Peters,
The Wellesley Hospital, 160 Wellesley St. E.,
2nd Floor, Ste. 224, Turner Wing, Toronto,
ON, Canada M4Y 1J3. Tel: (416) 926-7790.
Fax: (416) 926-4997.
-S91-58

ORTHOPEDIC SURGEON: ON - Estab
lished 18-year old downtown Toronto prac
tice. Daily gross over $1300. Available imme
diately due to health and age. All offers
considered. Contact: Dr. Ed Kosinka, 360
Bloor St. W ., Ste. 405, Toronto, ON M5S
1X1, tel: (416) 266-7679, or Blake Cassidy,
tel: (416) 266-1828.
-S91-59

NON-CARDIAC THORACIC SURGEON:
US - Due to retirement, the Mary Imogene
Bassett Hospital is seeking a general thoracic
surgeon. MIBH is a multispecialty group prac
tice with a surgical residency and research
opportunities. Excellent lifestyle and recre
ation. Academic appointment at Columbia
University. Contact: Michael S. Gold, MD,
Surgeon-in-Chief, One Atwell Rd., Cooperstown, NY 13326. Tel: (607) 547-3968.
-S91-51

C L IN IC A L F E L LO W S H IP
P E D IA T R IC S U R G ER Y
NEW FOUNDLAND

GENERAL SURGEON

Applications are invited for the position of Clinical
Fellow in Pediatric Surgery, Discipline of Surgery, Memorial
University of Newfoundland. Based at the Dr. Charles A.
Janeway Child Health Centre, a 200-bed teaching hospital.
Salary $47 418.
In accordance with Canadian immigration require
ments, this advertisement is directed to Canadian citizens
and permanent residents. Closing date for this position is
June 15, 1991.
Apply with curriculum vitae and list of three referees to:
Dr. F.B. Maroun, Acting Chairman
Discipline of Surgery
Memorial University
Health Sciences Centre
St. John’s, NF
A1B 3V6

_________

S91-63

CLASSIFIED ADVERTISING
Unlike a tabloid or newspaper that is read today and discarded
tomorrow, an advertisement in the Classified Advertising section
of CJS is read today and reread tomorrow.
CJS is the only Canadian publication exclusively for surgeons.
No other Canadian surgical publication reaches over 9000
subscribers every 2 months, giving wide coverage for your
advertising dollar.
Average issue readership of CJS (81 %) is among the highest of
any medical journal in Canada, and the latest readership
studies confirm the best and most cost efficient way to reach
Canadian surgeons is through the pages of CJS.
LET CJS CLASSIFIED ADS WORK FOR YOU -CJS-1

ORDER FORM
ADVERTISEMENT:

Excellent opportunity exists in Sarnia/Lambton
County to develop a lucrative private practice
covering the full scope of general surgery. There
are two hospitals in Sarnia providing a full range of
inpatient and outpatient care normally found in
community hospitals and some services of
regional calibre. Support services are excellent
and include exceptional diagnostic and ambulatory
care departments.
The city of Sarnia and county of Lambton catchment
area has a total population of 120 000. Superior
recreation facilities for persons who enjoy sailing
and other water sports, golf and curling, etc., are
available.
For further information call or write to:
K. W. Dickie, MD, FRCSC
Chief of Surgery, Sarnia General Hospital
220 North Mitton Street
Sarnia, Ontario
N7T 6H6
Tel: (519) 332-0210 (office)
P. N. Mehta, MD, FRCSC
Chief of Surgery, St. Joseph’s Hospital
290 North Russell Street
Sarnia, Ontario
N7T 6S3
Tel: (519) 336-7860 (office)
S9i-6i
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NO. OF INSERTIONS:
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______
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SURGEON-IN-CHIEF
THE TORONTO HOSPITAL
The Toronto Hospital is seeking a Surgeon-in-Chief to be
responsible for the clinical and academic programs at The
General Division and The Western Division of that hospi
tal. The position is supported through the University of
Toronto by the James Wallace McCutcheon Chair, which
is located at the hospital.
The Surgeon-in-Chief will organize and lead strong clinical
and academic programs in all subspecialties of surgery.
These programs are supported by over 800 beds, physi
cia n o ffic e s , a m b u la to ry p ra c tic e s p a c e , and
hospital-based research laboratories. The successful
candidate will work in close collaboration with nursing and
administrative colleagues in managing the surgical pro
grams.
The successful candidate must qualify as a professor at
the University of Toronto and must have a proven track
record of academic surgery and demonstrated leadership
skills.
Date of appointment open: Closing date for receipt of
applications: July 31, 1991.
In accordance with Canadian immigration requirements,
this advertisement is directed to Canadian citizens and
permanent residents.
Interested candidates should apply to:
Chairman
Surgeon-in-Chief Search Committee
c/o President’s Office
The Toronto Hospital
585 University Ave.
Toronto, ON
M5G 2C4
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ST. CLARE’S MERCY HOSPITAL
ST. JOHN’S, NEWFOUNDLAND
is seeking a new
C H IE F O F S U R G E R Y
The successful applicant will be cross-appointed
by the hospital and Memorial University of New
foundland and will head a major teaching service
designated as the centre for future developments
in surgery. The department presently encom
passes general, thoracic, vascular and orthopedic
surgery.
Please reply to:
Chair of Search Commitee for
Chief of Surgery
Dr. F. B. Maroun
Chair of Surgery, MUN
c /o Health Sciences Centre
St. John’s, Newfoundland
A1B3V6
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THE SURGEON’S CHOICE
STERILE SINGLE USE SURGICAL BLADES & SCALPELS
SURGICAL BLADES

SCALPELS WITH BLADES - SINGLE U SE

v/
Superb sharpness, foil wrapped individually in quickdispenser boxes. Made from the highest quality materials,
for assured uniformity.
Available in all sizes:
#'s 10, 11, 12, 14, 15A, 15, 20,21,22, 23, 24 and 25.
Any size, 100 per box.
VERY SPECIAL:

$9.99/bx

REGULAR $17.95

Each scalpel is packed in a polyester and aluminum foil to
protect blade edges. Unique dispenser box of 20 scalpels.
Each scalpel in individually inspected.
Available in all sizes:
10, 11, 12, 14, 15A, 15, 20, 21, 22, 23, 24 and 25.
Any size, 20 per box.
SUPER SPECIAL:

$6.99

Box of 20

REGULAR $10.95

STAINLESS STEEL HANDLES
M ade from Rust-Free stainless steel. Arrow shaped design for assured grip. Sim ply T h e Finest. G uaranteed
____________

VERY SPECIAL:

$6.95

MICROBLADES AND MICROKNIVES
These Microblades have been developed in conjunction with leading surgeons and have achieved the aim of
developing a well balanced instrument to ensure precision and consistency in microsurgery.
•
•
•

Sterile and disposable.
Microbiade cutting edges are available in four standard angles.
Blade after blade, cutting edges are precision-ground for sharpness
and consistent cutting angles.

Microblades are color-coded to determine different blade angles.
For greater cutting edge protection, microblades are individually
encased in plastic and wrapped in a pre-sterilized "peel-off" pouch.

MAXOM
polyglyconate monofilament absorbable suture

Easier
handling
first throw
to last
-#■
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Maxon. A softer, more supple suture that offers strength,
superior handling characteristics and patient benefits.

DAVIS+GECK
MEDICAL DEVICE DIVISION
C y a n a t n id C a n a d a Inc.

A World Leader in Wound Management
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